WO2009010454A2 - Amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors - Google Patents

Amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors Download PDF

Info

Publication number
WO2009010454A2
WO2009010454A2 PCT/EP2008/059043 EP2008059043W WO2009010454A2 WO 2009010454 A2 WO2009010454 A2 WO 2009010454A2 EP 2008059043 W EP2008059043 W EP 2008059043W WO 2009010454 A2 WO2009010454 A2 WO 2009010454A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
cycloalkyl
group
alkylhalo
phenyl
Prior art date
Application number
PCT/EP2008/059043
Other languages
French (fr)
Other versions
WO2009010454A3 (en
Inventor
Christelle Bolea
Original Assignee
Addex Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Addex Pharma S.A. filed Critical Addex Pharma S.A.
Priority to US12/452,601 priority Critical patent/US20100137336A1/en
Priority to EP08775002A priority patent/EP2181091A2/en
Publication of WO2009010454A2 publication Critical patent/WO2009010454A2/en
Publication of WO2009010454A3 publication Critical patent/WO2009010454A3/en
Priority to US13/135,069 priority patent/US20110257182A1/en
Priority to US13/747,366 priority patent/US8524726B2/en
Priority to US13/747,411 priority patent/US20130137704A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/20—Synthetic spices, flavouring agents or condiments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to novel compounds of Formula (I), wherein X 1 , X 2 , X 3 , X 4 , A m and B n are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors - subtype 4 ("mGluR4") which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR4 receptors.
  • mGluR4 metabotropic glutamate receptors - subtype 4
  • the invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR4 is involved.
  • Glutamate is the major amino-acid transmitter in the mammalian central nervous system (CNS). Glutamate plays a major role in numerous physiological functions, such as learning and memory but also sensory perception, development of synaptic plasticity, motor control, respiration and regulation of cardiovascular function. Furthermore, glutamate is at the center of several different neurological and psychiatric diseases, where there is an imbalance in glutamatergic neurotransmission.
  • Glutamate mediates synaptic neurotransmission through the activation of ionotropic glutamate receptor channels (iGluRs), namely the NMDA, AMPA and kainate receptors which are responsible for fast excitatory transmission (Nakanishi et al, (1998) Brain Res Rev., 26:230-235).
  • iGluRs ionotropic glutamate receptor channels
  • mGluRs metabotropic glutamate receptors
  • the mGluRs are G protein-coupled receptors (GPCRs) with seven-transmembrane spanning domains and belong to GPCR family 3 along with the calcium-sensing, GABAb and pheromone receptors.
  • GPCRs G protein-coupled receptors
  • the mGluR family is composed of eight members. They are classified into three groups (group I comprising mGluRl and mGluR5; group II comprising mGluR2 and mGluR3; group III comprising mGluR4, mGluR ⁇ , mGluR7 and mGluR8) according to sequence homology, pharmacological profile and nature of intracellular signalling cascades activated (Schoepp et al. (1999) Neuropharmacology, 38:1431-76).
  • Glutamate activates the mGluRs through binding to the large extracellular amino- terminal domain of the receptor, herein called the orthosteric binding site. This activation induces a conformational change of the receptor which results in the activation of the G-protein and intracellular signalling pathways.
  • mGluR4 receptors are expressed most intensely in the cerebellar cortex, basal ganglia, sensory relay nuclei of the thalamus and hippocampus (Bradley et al. (1999) Journal of Comparative Neurology, 407:33-46; Corti et al. (2002) Neuroscience, 110:403-420).
  • the mGluR4 subtype is negatively coupled to adenylate cyclase via activation of the Gc ⁇ /o protein, is expressed primarily on presynaptic terminals, functioning as an autoreceptor or heteroceptor and activation of mGluR4 leads to decreases in transmitter release from presynaptic terminals (Corti et al. (2002) Neuroscience, 110:403-420; Millan et al. (2002) Journal of Biological Chemistry 277:47796-47803; Valenti et al. (2003) Journal of Neuroscience 23:72218-7226).
  • Orthosteric agonists of mGluR4 are not selective and activate the other Group III mGluRs (Schoepp et al. (1999) Neuropharmacology 38:1431-1476).
  • the Group III orthosteric agonist L-AP4 was able to reduce motor deficits in animal models of
  • Parkinson's disease valenti et al. (2003) J. Neurosci. 23:7218-7226
  • decrease excitotoxicity Bruno et al. (2000) J. Neurosci. 20;6413-6420
  • mGluR4 Marino et al. (2005) Curr. Topics Med. Chem. 5:885- 895
  • ACPT-I another selective group III mGluR agonist has been shown to caused a dose-and-structure dependant decrease in haloperidol-induced catalepsy and attenuated haloperidol- increased Proenkephalin mRNA expression in the striatum (Konieczny et al.
  • mGluR4 is believed to be the most interesting novel drug target for the treatment of Parkinson's disease (for a review see Conn et al. Nature Review Neuroscience 2005).
  • Symptoms of Parkinson's disease appear to be due to an imbalance in the direct and indirect output pathways of the basal ganglia and reduction of transmission at the inhibitory GABAergic striato-pallidal synapse in the indirect pathway may result in alleviation of these symptoms (Marino et al. (2002) Amino Acids, 23:185-191).
  • mGluR4 is more abundant in striato-pallidal synapses than in striato-nigral synapses, and its localization suggests function as a presynaptic heteroceptor on GABAergic neurons (Bradley et al. (1999) Journal of Comparative Neurology, 407:33-46) suggesting that selective activation or positive modulation of mGluR4 would decrease GABA release in this synapse thereby decreasing output of the indirect pathway and reducing or eliminating the Parkinson's disease symptoms.
  • a new avenue for developing selective compounds acting at mGluRs is to identify molecules that act through allosteric mechanisms, modulating the receptor by binding to a site different from the highly conserved orthosteric binding site.
  • PHCCC a positive allosteric modulator of mGluR4 not active on others mGluRs
  • mGluR4 receptors which are expressed in ⁇ - and F cells in the islets of Langerhans inhibits glucagon secretion.
  • Molecules which activate or potentiate agonist activity of these receptors may be an effective treatment for hyperglycemia, one of the symptoms of type 2 diabetes (Uehara et al. (2004) Diabetes 53:998-1006).
  • ⁇ -chemokine RANTES is importantly involved in neuronal inflammation and has been implicated in the pathophysiology of multiple sclerosis.
  • Activation of Group III mGluRs with L-AP4 reduced the synthesis and release RANTES in wild-type cultured astrocytes, whereas the ability of L-AP4 to inhibit RANTES was greatly decreased in astrocyte cultures from mGluR4 knockout mice (Besong et al. (2002) Journal of Neuroscience, 22:5403-5411).
  • positive allosteric modulators of mGluR4 may be an effective treatment for neuroinflammatory disorders of the central nervous system, including multiple sclerosis and related disorders.
  • mGluR4 receptors Two different variants of the mGluR4 receptor are expressed in taste tissues and may function as receptors for the umami taste sensation (Monastyrskaia et al. (1999) Br. J Pharmacol. 128:1027-1034; Toyono et al. (2002) Arch. Histol. Cytol. 65:91-96).
  • positive allosteric modulators of mGluR4 may be useful as taste agents, flavour agents, flavour enhancing agents or food additives.
  • vagal afferents innervating gastric muscle express group III mGluRs (mGluR4, mGluR ⁇ , mGluR7 and mGluR8) and actively transport receptors to their peripheral endings (Page et al (2005) 128:402-10). Recently, it was shown that the activation of peripheral group III mGluRs inhibited vagal afferents mechanosensitivity in vitro which translates into reduced triggering of transient lower oesophagal sphincter relaxations and gastroesophageal reflux in vivo (Young et al (2008) Neuropharmacol 54:965-975).
  • the compounds of general formula I show potent activity and selectivity on mGluR4 receptor.
  • the compounds of the invention demonstrate advantageous properties over compounds of the prior art. Improvements have been observed in one or more of the following characteristics of the compounds of the invention: the potency on the target, the selectivity for the target, the bioavailability, the brain penetration, and the activity in behavioural models.
  • the present invention relates to a method of treating or preventing a condition in a mammal, including a human, the treatment or prevention of which is affected or facilitated by the neuromodulatory effect of mGluR4 modulators.
  • the invention relates to compounds having metabotropic glutamate receptor 4 modulator activity.
  • the present invention provides a compound according to Formula (I),
  • a m radicals are each independently selected from the group of hydrogen, halogen, -CN, -OH, -NO 2 , -CF3, -SH, -NH 2 and an optionally substituted radical selected from the group of -(Ci-C 6 )alkyl, -(d-C 6 )alkylhalo, -(C 3 -C 7 )cycloalkyl, -(Ci-C 6 )alkylcyano, -(Ci- Ce)alkylheteroaryl, -(Ci-C6)alkylaryl, aryl, heteroaryl, heterocycle, -(Co-Ce)alkyl-OR 1 , - O-(C 2 -C 6 )alkyl-OR 1 , -NR 1 (C 2 -C 6 )alkyl-OR 2 , -(C 3 -C 7 )cycloalkyl-(Ci-C 6 )alkyl, -0-(C 3
  • Any two radicals of A m may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
  • R 1 , R 2 , R 3 and R 4 are each independently hydrogen or an optionally substituted radical selected from the group of -(Ci-C 6 )alkylhalo, -(Ci-Ce)alkyl, -(Ci-Ce)alkylcyano, -(C 3 - d)cycloalkyl, -(C 4 -C io)alkylcycloalkyl, heteroaryl, -(Ci-C 6 )alkylheteroaryl, aryl, heterocycle and -(Ci-Ce)alkylaryl; Any two radicals of R (R 1 , R 2 , R 3 or R 4 ) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring; n is an integer ranging from 1 to 3;
  • B n radicals are each independently selected from the group of hydrogen, halogen, -CN, - OH, -NO 2 , -CF3, -SH, -NH 2 and an optionally substituted radical selected from the group of -(Ci-C 6 )alkyl, -(d-C 6 )alkylhalo, -(C 3 -C 7 )cycloalkyl, -(Ci-C 6 )alkylcyano, -(Ci- Ce)alkylheteroaryl, -(Ci-C6)alkylaryl, aryl, heteroaryl, heterocycle, -(Co-Ce)alkyl-OR 5 , - O-(C 2 -C 6 )alkyl-OR 5 , -NR 5 (C 2 -C 6 )alkyl-OR 6 , -(C 3 -C 7 )cycloalkyl-(Ci-C 6 )alkyl, -0-(C 3
  • Any two radicals of B n may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
  • R 5 , R 6 , R 7 and R 8 are each independently hydrogen or an optionally substituted radical selected from the group of -(Ci-C 6 )alkylhalo, -(Ci-Ce)alkyl, -(Ci-Ce)alkylcyano, -(C 3 - d)cycloalkyl, -(C 4 -C io)alkylcycloalkyl, heteroaryl, -(Ci-C 6 )alkylheteroaryl, aryl, heterocycle and -(Ci-Ce)alkylaryl; Any two radicals of R (R 5 , R 6 , R 7 or R 8 ) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring; provided that: (i) Formula (I) can not be and provided that:
  • the compounds heterocyclic carboxamides known as such from international patent publication WO2007/001975 and benzamides known as such from international patent publication WO2004/087048 are excluded from the present invention by virtue of proviso (ii).
  • the compounds thiazole-4-carboxamides known as such from international patent publication WO2006/074884 are excluded from the present invention by virtue of proviso (iii).
  • the invention concerns a compound according to Formula (I-a),
  • n is an integer ranging from 1 to 3;
  • a m radicals are each independently selected from the group of hydrogen, halogen, -CN, -OH, -NO 2 , -CF 3 , -SH, -NH 2 and an optionally substituted radical selected from the group of -(Ci-C 6 )alkyl, -(Ci-C 6 )alkylhalo, -(C 3 -C 7 )cycloalkyl, -(Ci-C 6 )alkylcyano, -(Ci- C 6 )alkylheteroaryl, -(Ci-C 6 )alkylaryl, aryl, heteroaryl, heterocycle, -(C 0 -C 6 )alkyl-OR 1 , - O-(C 2 -C 6 )alkyl-OR 1 , -NR 1 (C 2 -C 6 )alkyl-OR 2 , -(C 3 -C 7 )cycloalkyl-(Ci-C 6 )
  • Any two radicals of A m may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
  • R 1 , R 2 , R 3 and R 4 are each independently hydrogen or an optionally substituted radical selected from the group of -(Ci-C 6 )alkylhalo, -(Ci-Ce)alkyl, -(Ci-Ce)alkylcyano, -(C 3 - C 7 )CyC loalkyl, -(C 4 -C io)alkylcycloalkyl, heteroaryl, -(Ci-C 6 )alkylheteroaryl, aryl, heterocycle and -(Ci-Ce)alkylaryl;
  • R Any two radicals of R (R 1 , R 2 , R 3 or R 4 ) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
  • B 1 and B 2 are each independently selected from the group of hydrogen, halogen, -CN, - OH, -NO 2 , -CF3, -SH, -NH 2 and an optionally substituted radical selected from the group of -(Ci-C 6 )alkyl, -(d-C 6 )alkylhalo, -(C 3 -C 7 )cycloalkyl, -(d-C 6 )alkylcyano, -(Ci- Ce)alkylheteroaryl, -(Ci-Ce)alkylaryl, aryl, heteroaryl, heterocycle, -(Co-Ce)alkyl-OR 5 , - O-(C 2 -C 6 )alkyl-OR 5 , -NR 5 (C 2 -C 6 )alkyl-OR 6 , -(C 3 -C 7 )cycloalkyl-(d-C 6 )alkyl, -0-(C 3
  • Any two radicals of B n may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
  • R 5 , R 6 , R 7 and R 8 are each independently hydrogen or an optionally substituted radical selected from the group of -(C 1 -C6)alkylhalo, -(Ci-Ce)alkyl, -(Ci-Ce)alkylcyano, -(d- C 7 )CyC loalkyl, -(C 4 -C io)alkylcycloalkyl, heteroaryl, -(Ci-C 6 )alkylheteroaryl, aryl, heterocycle and -(Ci-C6)alkylaryl; Any two radicals of R (R 5 , R 6 , R 7 or R 8 ) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring; provided that according to proviso (i):
  • Formula (I) Am x 2" ⁇ 1 can not be and provided that according to proviso (iv): Formula (I) Am x 2' ⁇ 1 can not be ; and provided that according to proviso (v):
  • the invention concerns a compound according to Formula (I-b),
  • n is an integer ranging from 1 to 3;
  • a m radicals are each independently selected from the group of hydrogen, halogen, -CN, -OH, -NO 2 , -CF3, -SH, -NH 2 and an optionally substituted radical selected from the group of -(Ci-C 6 )alkyl, -(d-C 6 )alkylhalo, -(C 3 -C 7 )cycloalkyl, -(Ci-C 6 )alkylcyano, -(Ci- C 6 )alkylheteroaryl, -(Ci-C 6 )alkylaryl, aryl, heteroaryl, heterocycle, -(C 0 -C 6 )alkyl-OR 1 , - O-(C 2 -C 6 )alkyl-OR 1 , -NR 1 (C 2 -C 6 )alkyl-OR 2 , -(C 3 -C 7 )cycloalkyl-(Ci-C 6 )alkyl
  • R 1 , R 2 , R 3 and R 4 are each independently hydrogen or an optionally substituted radical selected from the group of -(Ci-C 6 )alkylhalo, -(Ci-Ce)alkyl, -(Ci-Ce)alkylcyano, -(C 3 - C 7 )CyC loalkyl, -(C 4 -C io)alkylcycloalkyl, heteroaryl, -(Ci-C 6 )alkylheteroaryl, aryl, heterocycle and -(Ci-Ce)alkylaryl;
  • R Any two radicals of R (R 1 , R 2 , R 3 or R 4 ) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
  • B 1 and B 2 are each independently selected from the group of hydrogen, halogen, -CN, - OH, -NO 2 , -CF3, -SH, -NH 2 and an optionally substituted radical selected from the group of -(Ci-C 6 )alkyl, -(d-C 6 )alkylhalo, -(C 3 -C 7 )cycloalkyl, -(d-C 6 )alkylcyano, -(Ci-
  • R 5 , R 6 , R 7 and R 8 are each independently hydrogen or an optionally substituted radical selected from the group of -(C 1 -C6)alkylhalo, -(Ci-Ce)alkyl, -(Ci-Ce)alkylcyano, -(C 3 - C 7 )cycloalkyl, -(C 4 -C 10 )alkylcycloalkyl, heteroaryl, -(C 1 -C6)alkylheteroaryl, aryl, heterocycle and -(C 1 -C6)alkylaryl;
  • R 5 , R 6 , R 7 or R 8 Any two radicals of R (R 5 , R 6 , R 7 or R 8 ) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring; provided that according to proviso (i):
  • Formula (I) Am x 2' * 1 can not be A 1 ; and provided that according to proviso (iv): Formula (I) Am x 2' ⁇ 1 can not be .
  • the invention concerns a compound according to Formula (I-c),
  • n is an integer ranging from 1 to 3;
  • a m radicals are each independently selected from the group of hydrogen, halogen, -CN, -OH, -NO 2 , -CF3, -SH, -NH 2 and an optionally substituted radical selected from the group of -(Ci-C 6 )alkyl, -(d-C 6 )alkylhalo, -(C 3 -C 7 )cycloalkyl, -(Ci-C 6 )alkylcyano, -(Ci-
  • R 1 , R 2 , R 3 and R 4 are each independently hydrogen or an optionally substituted radical selected from the group of -(Ci-C 6 )alkylhalo, -(Ci-C 6 )alkyl, -(Ci-C 6 )alkylcyano, -(C 3 - C 7 )cycloalkyl, -(C 4 -C 10 )alkylcycloalkyl, heteroaryl, -(C 1 -C6)alkylheteroaryl, aryl, heterocycle and -(C 1 -C6)alkylaryl;
  • R Any two radicals of R (R 1 , R 2 , R 3 or R 4 ) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
  • B 1 is selected from the group of hydrogen, halogen, -CN, -OH, -NO 2 , -CF 3 , -SH, -NH 2 and an optionally substituted radical selected from the group of -(Ci-Ce)alkyl, -(C 1 - C 6 )alkylhalo, -(C 3 -C 7 )cycloalkyl, -(Ci-C 6 )alkylcyano, -(Ci-C 6 )alkylheteroaryl, -(Ci- C 6 )alkylaryl, aryl, heteroaryl, heterocycle, -(C 0 -C 6 )alkyl-OR 5 , -O-(C 2 -C 6 )alkyl-OR 5 , - NR 5 (C 2 -C 6 )alkyl-OR 6 , -(C 3 -C 7 )cycloalkyl-(Ci-C 6 )alkyl,
  • R 5 , R 6 , R 7 and R 8 are each independently hydrogen or an optionally substituted radical selected from the group of -(Ci-C6)alkylhalo, -(Ci-C6)alkyl, -(Ci-C6)alkylcyano, -(C 3 - C 7 )CyC loalkyl, -(C 4 -C io)alkylcycloalkyl, heteroaryl, -(Ci-C 6 )alkylheteroaryl, aryl, heterocycle and -(Ci-C 6 )alkylaryl;
  • R 5 , R 6 , R 7 or R 8 Any two radicals of R (R 5 , R 6 , R 7 or R 8 ) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
  • Particular preferred compounds of the invention are compounds as mentioned in the following list (List of Particular Preferred Compounds), as well as a pharmaceutically acceptable acid or base addition salt thereof, a stereochemical ⁇ isomeric form thereof and an JV-oxide form thereof.
  • (C 1 -C 6 ) means a carbon radical having 1, 2, 3, 4, 5 or 6 carbon atoms.
  • (C 0 -C 6 ) means a carbon radical having 0, 1, 2, 3, 4, 5 or 6 carbon atoms.
  • C means a carbon atom
  • N means a nitrogen atom
  • O means an oxygen atom
  • S means a sulphur atom.
  • a subscript is the integer 0 (zero) the radical to which the subscript refers, indicates that the radical is absent, i.e. there is a direct bond between the radicals.
  • bonds refers to a saturated covalent bond.
  • bonds When two or more bonds are adjacent to one another, they are assumed to be equal to one bond.
  • alkyl includes both straight and branched chain alkyl radicals and may be methyl, ethyl, n-propyl, i-propyl, n-butyl, i- butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, t-pentyl, neo-pentyl, n-hexyl, i-hexyl or t- hexyl.
  • (Co-C 3 )alkyl refers to an alkyl radical having 0, 1, 2 or 3 carbon atoms and may be methyl, ethyl, n-propyl and i-propyl.
  • cycloalkyl refers to an optionally substituted carbocycle containing no heteroatoms, including mono-, bi-, and tricyclic saturated carbocycles, as well as fused ring systems.
  • fused ring systems can include one ring that is partially or fully unsaturated such as a benzene ring to form fused ring systems such as benzo- fused carbocycles.
  • Cycloalkyl includes such fused ring systems as spirofused ring systems.
  • cycloalkyl examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, decahydronaphthalene, adamantane, indanyl, fluorenyl and 1,2,3,4-tetrahydronaphthalene and the like.
  • (C3-Cv)cycloalkyl may be cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
  • aryl refers to an optionally substituted monocyclic or bicyclic hydrocarbon ring system containing at least one unsaturated aromatic ring. Examples and suitable values of the term “aryl” are phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, indyl, indenyl and the like.
  • heteroaryl refers to an optionally substituted monocyclic or bicyclic unsaturated, aromatic ring system containing at least one heteroatom selected independently from N, O or S.
  • heteroaryl may be, but are not limited to thienyl, pyridyl, thiazolyl, isothiazolyl, furyl, pyrrolyl, triazolyl, imidazolyl, oxadiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolonyl, oxazolonyl, thiazolonyl, tetrazolyl, thiadiazolyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl, tetrahydrotriazolopyridyl, tetrahydrotriazolopyrimidinyl, benzofuryl, benzothiophenyl,
  • alkylaryl refers respectively to a substituent that is attached via the alkyl radical to an aryl, heteroaryl or cycloalkyl radical, respectively.
  • (Ci-C 6 )alkylaryl includes aryl-Ci-C ⁇ -alkyl radicals such as benzyl, 1-phenylethyl, 2-phenylethyl, 1- phenylpropyl, 2-phenylpropyl, 3-phenylpropyl, 1-naphthylmethyl and 2- naphthylmethyl.
  • (Ci-C 6 )alkyheteroaryl includes heteroaryl-Ci-C ⁇ -alkyl radicals, wherein examples of heteroaryl are the same as those illustrated in the above definition, such as 2-furylmethyl, 3-furylmethyl, 2-thienylmethyl, 3-thienylmethyl, 1- imidazolylmethyl, 2-imidazolylmethyl, 3-imidazolylmethyl, 2-oxazolylmethyl, 3- oxazolylmethyl, 2-thiazolylmethyl, 3-thiazolylmethyl, 2-pyridylmethyl, 3- pyridylmethyl, 4-pyridylmethyl, 1-quinolylmethyl or the like.
  • heterocycle refers to an optionally substituted, monocyclic or bicyclic saturated, partially saturated or unsaturated ring system containing at least one heteroatom selected independently from N, O and S.
  • a 5- or 6-membered ring containing one or more atoms independently selected from C, N, O and S includes aromatic and heteroaromatic rings as well as carbocyclic and heterocyclic rings which may be saturated or unsaturated.
  • rings may be, but are not limited to, furyl, isoxazolyl, isothiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, thiazolyl, thienyl, imidazolyl, imidazolidinyl, imidazolinyl, triazolyl, morpholinyl, piperazinyl, piperidyl, piperidonyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl, tetrahydrothiopyranyl, oxazolidinonyl, thiomorpholinyl, oxadiazolyl, thiadiazolyl, tetrazolyl, phenyl, cyclohexyl, cyclopentyl,
  • a 3- to 10-membered ring containing one or more atoms independently selected from C, N, O and S includes aromatic and heteroaromatic rings as well as carbocyclic and heterocyclic rings which may be saturated or unsaturated.
  • rings may be, but are not limited to imidazolidinyl, imidazolinyl, morpholinyl, piperazinyl, piperidyl, piperidonyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl, thiomorpholinyl, tetrahydrothiopyranyl, furyl, pyrrolyl, isoxazolyl, isothiazolyl, oxazolyl, oxazolidinonyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, thiazolyl, thienyl, imidazolyl, triazolyl, phenyl, cyclopropyl, aziridinyl, cyclobutyl, azetidinyl, oxadia
  • alkylhalo means an alkyl radical as defined above, substituted with one or more halo radicals.
  • (Ci- C 6 )alkylhalo may include, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl and difluoroethyl.
  • the term "O-Ci-C ⁇ -alkylhalo” may include, but is not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy and fluoroethoxy.
  • alkylcyano means an alkyl radical as defined above, substituted with one or more cyano.
  • the term “optionally substituted” refers to radicals further bearing one or more substituents which may be, but are not limited to, (Ci-C6)alkyl, hydroxy, (Ci-C6)alkyloxy, mercapto, aryl, heterocycle, halogen, trifluoromethyl, pentafluoroethyl, cyano, cyanomethyl, nitro, amino, amido, amidinyl, carboxyl, carboxamide, carbamate, sulfonamide, ester and sulfonyl.
  • solvate refers to a complex of variable stoichiometry formed by a solute (e.g. a compound of Formula (I)) and a solvent.
  • the solvent is a pharmaceutically acceptable solvent as preferably water; such solvent may not interfere with the biological activity of the solute.
  • positive allosteric modulator of mGluR4" or “allosteric modulator of mGluR4" refers also to a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof and an JV-oxide form thereof.
  • Allosteric modulators of mGluR4 described herein, and the pharmaceutically acceptable salts, solvates and hydrates thereof can be used in pharmaceutical preparations in combination with a pharmaceutically acceptable carrier or diluent.
  • Suitable pharmaceutically acceptable carriers include inert solid fillers or diluents and sterile aqueous or organic solutions.
  • the allosteric modulators of mGluR4 will be present in such pharmaceutical compositions in amounts sufficient to provide the desired dosage amount in the range described herein. Techniques for formulation and administration of the compounds of the instant invention can be found in Remington: the Science and Practice of Pharmacy, 19 th edition, Mack Publishing Co., Easton, PA (1995).
  • the amount of allosteric modulators of mGluR4, administered to the subject will depend on the type and severity of the disease or condition and on the characteristics of the subject, such as general health, age, sex, body weight and tolerance to drugs. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. Effective dosages for commonly used CNS drugs are well known to the skilled person.
  • the total daily dose usually ranges from about 0.05 - 2000 mg.
  • the present invention relates to pharmaceutical compositions which provide from about 0.01 to 1000 mg of the active ingredient per unit dose.
  • the compositions may be administered by any suitable route.
  • parenterally in the form of solutions for injection topically in the form of onguents or lotions, ocularly in the form of eye-drops, rectally in the form of suppositories, intranasally or transcutaneously in the form of delivery system like patches.
  • the allosteric modulators of mGluR4 thereof can be combined with a suitable solid or liquid carrier or diluent to form capsules, tablets, pills, powders, syrups, solutions, suspensions and the like.
  • the tablets, pills, capsules, and the like contain from about 0.01 to about 99 weight percent of the active ingredient and a binder such as gum tragacanth, acacias, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid, a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin.
  • a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.
  • tablets may be coated with shellac, sugar or both.
  • a syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.
  • the disclosed allosteric modulators of mGluR4 can be combined with sterile aqueous or organic media to form injectable solutions or suspensions.
  • injectable solutions or suspensions for example, solutions in sesame or peanut oil, aqueous propylene glycol and the like can be used, as well as aqueous solutions of water-soluble pharmaceutically-acceptable salts of the compounds.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the compounds may also be formulated as a depot preparation.
  • Such long acting formulations may be administered by implantation, for example, subcutaneously or intramuscularly or by intramuscular injection.
  • implantation for example, subcutaneously or intramuscularly or by intramuscular injection.
  • sparingly soluble derivatives for example, as sparingly soluble salts.
  • Preferably disclosed allosteric modulators of mGluR4 or pharmaceutical formulations containing these compounds are in unit dosage form for administration to a mammal.
  • the unit dosage form can be any unit dosage form known in the art including, for example, a capsule, an IV bag, a tablet, or a vial.
  • the quantity of active ingredient in a unit dose of composition is an effective amount and may be varied according to the particular treatment involved. It may be appreciated that it may be necessary to make routine variations to the dosage depending on the age and condition of the patient.
  • the dosage will also depend on the route of administration which may be by a variety of routes including oral, aerosol, rectal, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal and intranasal.
  • the compounds according to the invention may be prepared by methods known in the art of organic synthesis as set forth in part by the following synthesis schemes. In all of the schemes described below, it is well understood that protecting groups for sensitive or reactive groups are employed where necessary in accordance with general principles of chemistry. Protecting groups are manipulated according to standard methods of organic synthesis (Green T. W. and Wuts P.G.M. (1991) Protecting Groups in Organic Synthesis, John Wiley & Sons). These groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art. The selection of process as well as the reaction conditions and order of their execution shall be consistent with the preparation of compounds of Formula (I), (I-a), (I-b), (I-c) and (I-d).
  • the compounds according to the invention may be represented as a mixture of enantiomers, which may be resolved into the individual pure R- or S-enantiomers. If for instance, a particular enantiomer is required, it may be prepared by asymmetric synthesis or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers.
  • a basic functional group such as an amino or an acidic functional group such as carboxyl
  • this resolution may be conveniently performed by fractional crystallization from various solvents as the salts of an optical active acid or by other methods known in the literature (e.g. chiral column chromatography).
  • Resolution of the final product, an intermediate or a starting material may be performed by any suitable method known in the art (Eliel EX., Wilen S.H. and Mander L.N. (1984) Stereochemistry of Organic Compounds, Wiley-Interscience).
  • heterocyclic compounds of the invention can be prepared using synthetic routes well known in the art (Katrizky A.R. and. Rees CW. (1984) Comprehensive Heterocyclic Chemistry, Pergamon Press).
  • the product from the reaction can be isolated and purified employing standard techniques, such as extraction, chromatography, crystallization and distillation.
  • the compounds of the invention may be prepared by general route of synthesis as disclosed in the following methods.
  • compounds of Formula (I) may be prepared according to the synthetic sequences illustrated in Scheme 1.
  • Acid chloride gl can be generated from carboxylic acid g3 in the presence of a reagent such as thionyl chloride or oxalyl chloride. Then gl may be coupled with the primary amine g2 in the presence of a base such as Et 3 N or DIEA in a suitable solvent.
  • Amide g4 can also be obtained from the reaction of carboxylic acid g3 and the primary amine g2 (Scheme 1).
  • the reaction may be promoted by a coupling agent known in the art of organic synthesis such as EDCI (l-(3-dimethylaminopropyl)-3- ethylcarbodiimide), in a suitable solvent (e.g. THF, DCM, DMF).
  • a co- catalyst such as HOBT (hydroxybenzotriazole) will also be present in the reaction mixture.
  • the reaction typically proceeds at ambient temperature for a time in the range of about 4 up to 12 hours.
  • amide g5 can be alkylated using either B 2 X (where X is Cl, Br or I) in the presence of a base such as K2CO3, Cs 2 CO 3 or NaH in a suitable solvent such as acetone, DMF or THF to yield g6 (Scheme 2).
  • compounds of Formula (I-b) may be prepared according to the synthetic sequences illustrated in Scheme 3.
  • p-Nitro-phenoxy gll can be obtained from substitution on fluorophenyl g7 by hydroxyl compounds like g8 or by/?-nitrophenol g9 on bromide compounds glO in the presence of a base such as CS2CO3.
  • compound gll can be reduced in the presence of iron or zinc in acetic acid to yield the primary amine gl2.
  • gl2 can then be coupled to acid chloride as exemplified earlier in Scheme 1.
  • compounds of Formula (I-c) may be prepared according to the synthetic sequences illustrated in Scheme 4.
  • Piperazine gl4 can be acylated under standard conditions in the presence of acid chloride.
  • compound gl6 can be reduced under standard hydrogenation conditions with Pt/C in primary amine gl7.
  • gl7 can then be coupled to acid chloride as exemplified earlier in Scheme 1.
  • compounds of Formula (I-c) may be prepared according to the synthetic sequences illustrated in Scheme 5.
  • Piperazine gl4 can be protected by (BoC) 2 O, then reduced with Pt/C and coupled with acid chloride under conditions well known for a person skilled in the art.
  • the secondary amine g22 can finally be acylated either by acid chloride or carboxylic acid as exemplified earlier in Scheme 1.
  • Step 1 Thiophene-2-carboxylic acid (31.2 mmol, 4.00 g) was slowly added to a solution of thionyl chloride (56.2 mmol, 4.08 mL). The reaction mixture was stirred at room temperature for 1 hour. After evaporation of the thionyl chloride, the crude product was purified by bulb-to-bulb distillation (85 0 C, 14 Torr) to yield thiophene-2-carbonyl chloride (23.7 mmol, 3.48 g, 76%) as a colorless liquid.
  • Example 2 The title compound was prepared from 3-aminophenol (18.0 mmol, 2.00 g). Reaction conditions: 12 hours at 50 0 C. 1.7 g (7.9 mmol, 43%) of iV-(3- hydroxyphenyl)picolinamide were obtained.
  • Step 2 A suspension of iron (5.07 mmol, 283 mg), acetic acid (1.22 mmol, 70 ⁇ L) and of 2-chloro-l-(3-chlorophenoxy)-4-nitrobenzene (1.02 mmol, 288 mg) in water/EtOH (1 :1, 8 mL) was stirred at 80 0 C for 30 minutes. After evaporation of EtOH, the aqueous phase was basified with a saturated solution of NaHCOs and was extracted with AcOEt.
  • Step 1 2-Bromopyrimidine (1.26 mmol, 211 mg) was added to a suspension of 2-methoxy-4-nitrophenol (1.15 mmol, 200 mg), CS2CO3
  • Step 2 A suspension of iron (4.45 mmol, 248 mg), acetic acid (1.07 mmol, 61 ⁇ L) and of 2-(2-methoxy-4-nitrophenoxy)pyrimidine (0.89 mmol, 220 mg) in water/EtOH (1 :1, 7 mL) was stirred at 8O 0 C for 30 minutes. After evaporation of EtOH, the aqueous phase was basified with a saturated solution of NaHCO 3 and was extracted with AcOEt.
  • Step 3 Pico lino yl chloride hydrochloride (1.33 mmol, 256 mg) and Et 3 N (2.67 mmol, 0.37 mL) were added sequentially to a solution of 3-methoxy-4- (pyrimidin-2-yloxy)aniline (0.89 mmol, 193 mg) in DCM (3 mL) at 0 0 C. The reaction mixture was stirred at room temperature for 2 hours. The organic phase was washed with a saturated solution Of NaHCO 3 . The aqueous phase was extracted with AcOEt. The organic phase was washed with brine, was dried over MgSO 4 , was filtered and was concentrated under reduced pressure.
  • EXAMPLE 6 7V-(3-Chloro-4-(4-isobutyrylpiperazin-l-yl)phenyl)picolinamide (Final Compound 4-2) l-(4-(2-Chloro-4-nitrophenyl)piperazin-l-yl)-2-methylpropan-l-one
  • Step 1 Isobutyryl chloride (1.24 mmol, 0.13 mL) and EtsN (2.48 mmol, 0.35 mL) were added to a solution of l-(2-chloro-4-nitrophenyl)piperazine (0.83 mmol, 200 mg) in DCM (5 mL) at 0 0 C. The reaction mixture was stirred at room temperature for 2 hours. The organic phase was washed with a saturated solution of NaHCOs. The aqueous phase was extracted with AcOEt.
  • Step 2 A solution of l-(4-(2-chloro-4-nitrophenyl)piperazin-l- yl)-2-methylpropan-l-one (0.62 mmol, 195 mg) in EtOH (120 mL) was passed through a Pt/C 5% column in an H-Cube equipment (mode: Full). Then the solution was concentrated under reduced pressure to yield l-(4-(4-amino-2-chlorophenyl)piperazin-l- yl)-2-methylpropan-l-one (0.62 mmol, 175 mg, 99%). The product was used without further purification.
  • Step 3 Pico lino yl chloride hydrochloride (0.93 mmol, 178 mg) and Et 3 N (1.86 mmol, 0.26 mL) were added to a solution of l-(4-(4-amino-2- chlorophenyl)piperazin-l-yl)-2-methylpropan-l-one (0.62 mmol, 175 mg) in DCM (3 mL) at 0 0 C. The reaction mixture was stirred at room temperature for 2 hours. The organic phase was washed with a saturated solution Of NaHCO 3 . The aqueous phase was extracted with AcOEt.
  • Step 1 A solution of l-(2-chloro-4-nitrophenyl)piperazine (2.90 mmol, 700 mg), BoC 2 O (3.19 mmol, 0.96 mL), Et 3 N (3.48 mmol, 0.49 mL) and of DMAP (0.29 mmol, 35 mg) in DCM (5 mL) was stirred at room temperature overnight. The organic phase was washed once with HCl 0.1 M, once with water, once with brine, was dried over Na 2 SO 4 , was filtered and was concentrated under reduced pressure to afford tert-butyl 4-(2-chloro-4-nitrophenyl)piperazine-l-carboxylate (2.50 mmol, 854 mg, 86%). The product was used without further purification.
  • Step 2 A solution of tert-butyl 4-(2-chloro-4- nitrophenyl)piperazine-l-carboxylate (2.50 mmol, 854 mg) in EtOH (450 mL) was passed through a Pt/C 5% column in an H-Cube equipment (mode: Full). Then the solution was concentrated under reduced pressure to yield tert-butyl 4-(4-amino-2- chlorophenyl)piperazine-l-carboxylate (2.46 mmol, 766 mg, 98%). The product was used without further purification.
  • Step 3 Pico lino yl chloride hydrochloride (3.68 mmol, 656 mg) and Et 3 N (7.37 mmol, 1.03 mL) were added to a solution of tert-bvXy ⁇ 4-(4-amino-2- chlorophenyl)piperazine-l-carboxylate (2.46 mmol, 766 mg) in DCM (40 mL) at 0 0 C. The reaction mixture was stirred at room temperature for 1 hour. The organic phase was washed with a saturated solution Of NaHCO 3 . The aqueous phase was extracted with AcOEt.
  • Step 4 HCl 4 M in dioxane (12.3 mmol, 3.07 mL) was added to a solution of tert-hvXy ⁇ 4-(2-chloro-4-(picolinamido)phenyl)piperazine-l-carboxylate (2.46 mmol, 1.02 g) in DCM (10 mL). The reaction mixture was stirred at room temperature overnight. After evaporation, DCM was added and then a NaOH 1 M solution. The aqueous phase was extracted with DCM. The organic phase was washed with brine, was dried over MgSO 4 , was filtered and was concentrated under reduced pressure.
  • Step 5 A solution of JV-(3-chloro-4-(piperazin-l- yl)phenyl)picolinamide (0.19 mmol, 60 mg), propionic acid (0.19 mmol, 14 ⁇ L),
  • Step 5 A suspension of (bromomethyl)benzene (0.61 mmol, 74 ⁇ L), ⁇ /-(3-chloro-4-(piperazin-l-yl)phenyl)picolinamide (0.51 mmol, 161 mg) and Of K 2 CO 3 (0.51 mmol, 70 mg) in ACN (3 mL) was stirred at 80 0 C for 30 minutes. After evaporation of the solvent, water and AcOEt were added. The aqueous phase was extracted with AcOEt. The organic phase was washed with brine, was dried over Na 2 SO 4 , was filtered and was concentrated under reduced pressure.
  • Table 2 Compounds prepared according to the Examples.
  • Table 3 Compounds prepared according to the Examples.
  • LCMS were recorded on a Waters Micromass ZQ 2996 system by the following conditions: Reversed phase HPLC was carried out on an Zorbax SB-C 18 cartridge (1.8 ⁇ m, 4.6 x 30 mm) from Agilent, with a flow rate of 1.5 ml/min. The gradient conditions used are: 90 % A (water + 0.05 % of formic acid), 10% B (acetonitrile + 0.05 % of formic acid) to 100 % B at 3.5 minutes, kept till 3.7 minutes and equilibrated to initial conditions at 3.8 minutes until 4.5 minutes. Injection volume 5-20 ⁇ L. ES MS detector was used, acquiring both in positive and negative ionization modes. Cone voltage was 30 V for both positive and negative ionization modes.
  • the compounds provided in the present invention are positive allosteric modulators of mGluR4. As such, these compounds do not appear to bind to the orthosteric glutamate recognition site, and do not activate the mGluR4 by themselves. Instead, the response of mGluR4 to a concentration of glutamate or mGluR4 agonist is increased when compounds of Formula I, I-a-d are present. Compounds of Formula I, I-a-d are expected to have their effect at mGluR4 by virtue of their ability to enhance the function of the receptor.
  • the compounds of the present invention are positive allosteric modulators of mGluR4 receptor. Their activity was examined on recombinant human mGluR4a receptors by detecting changes in intracellular Ca 2+ concentration, using the fluorescent Ca 2+ -sensitive dye Fluo4-(AM) and a Fluorometric Imaging Plate Reader (FLIPR, Molecular Devices, Sunnyvale, CA)
  • the cDNA encoding the human metabotropic glutamate receptor (hmGluR4) was subcloned into an expression vector containing also the hygromycin resistance gene.
  • the cDNA encoding a G protein allowing redirection of the activation signal to intracellular calcium flux was subcloned into a different expression vector containing also the puromycin resistance gene. Transfection of both these vectors into HEK293 cells with PolyFect reagent (Qiagen) according to supplier's protocol, and hygromycin and puromycin treatment allowed selection of antibiotic resistant cells which had integrated stably one or more copies of the plasmids.
  • Positive cellular clones expressing hmGluR4 were identified in a functional assay measuring changes in calcium fluxes in in response to glutamate or selective known mGluR4 orthosteric agonists and antagonists HEK-293 cells expressing hmGluR4 were maintained in media containing DMEM, dialyzed Fetal Calf Serum (10 %), GlutamaxTM (2 mM), Penicillin (100 units/ml), Streptomycin (100 ⁇ g/ml), Geneticin (100 ⁇ g/ml) and Hygromycin-B (40 ⁇ g/ml) and puromycin (1 ⁇ g/ml ) at 37°C/5%CO 2 .
  • Human mGluR4 HEK-293 cells were plated out 24 hours prior to FLIPR 384 assay in black-walled, clear-bottomed, poly-L-ornithine-coated 384-well plates at a density of 25,000 cells/well in a glutamine/glutamate free DMEM medium containing foetal bovine serum (10 %), penicillin (100 units/ml) and streptomycin (100 ⁇ g/ml) at 37 0 C / 5 % CO 2 .
  • the medium was aspirated and the cells were loaded with a 3 ⁇ M solution of Fluo4-AM (LuBio Science, Lucerne, Switzerland) in 0.03 % pluronic acid. After 1 hour at 37°C/5% CO 2 , the non incorporated dye was removed by washing cell plate with the assay buffer and the cells were left in the dark at room temperature for six hours before testing. All assays were performed in a pH 7.4 buffered- solution containing 20 mM HEPES, 143 mM NaCl, 6 mM KCl, 1 mM MgSO 4 , 1 mM CaCl 2 , 0.125 mM sulfapyrazone, 0.1 % glucose.
  • EC 25 glutamate concentration is the concentration giving 25 % of the maximal glutamate response.
  • the Table 6 below represents the mean EC50 obtained from at least three independent experiments of selected molecules performed in duplicate.
  • the positive allosteric modulators provided in the present invention are expected to increase the effectiveness of glutamate or mGluR4 agonists at mGluR4 receptor. Therefore, these positive allosteric modulators are expected to be useful for treatment of various neurological and psychiatric disorders associated with glutamate dysfunction described to be treated herein and others that can be treated by such positive allosteric modulators.
  • active ingredient can be replaced by the same amount of any of the compounds according to the present invention, in particular by the same amount of any of the exemplified compounds.
  • An aqueous suspension is prepared for oral administration so that each 1 milliliter contains 1 to 5 mg of one of the active compounds, 50 mg of sodium carboxymethyl cellulose, 1 mg of sodium benzoate, 500 mg of sorbitol and water ad 1 ml. 3. Injectable
  • a parenteral composition is prepared by stirring 1.5 % by weight of active ingredient of the invention in 10% by volume propylene glycol and water.
  • active ingredient can be replaced with the same amount of any of the compounds according to the present invention, in particular by the same amount of any of the exemplified compounds.

Abstract

The present invention relates to novel compounds of Formula (I), wherein X1, X2, X3, X4, Am and Bn are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors - subtype 4 ('mGluR4') which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR4 is involved.

Description

NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE
RECEPTORS
SUMMARY OF THE INVENTION
Figure imgf000002_0001
The present invention relates to novel compounds of Formula (I), wherein X1, X2, X3, X4, Am and Bn are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors - subtype 4 ("mGluR4") which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR4 is involved.
BACKGROUND OF THE INVENTION
Glutamate is the major amino-acid transmitter in the mammalian central nervous system (CNS). Glutamate plays a major role in numerous physiological functions, such as learning and memory but also sensory perception, development of synaptic plasticity, motor control, respiration and regulation of cardiovascular function. Furthermore, glutamate is at the center of several different neurological and psychiatric diseases, where there is an imbalance in glutamatergic neurotransmission.
Glutamate mediates synaptic neurotransmission through the activation of ionotropic glutamate receptor channels (iGluRs), namely the NMDA, AMPA and kainate receptors which are responsible for fast excitatory transmission (Nakanishi et al, (1998) Brain Res Rev., 26:230-235). In addition, glutamate activates metabotropic glutamate receptors (mGluRs) which have a more modulatory role that contributes to the fine-tuning of synaptic efficacy.
The mGluRs are G protein-coupled receptors (GPCRs) with seven-transmembrane spanning domains and belong to GPCR family 3 along with the calcium-sensing, GABAb and pheromone receptors.
The mGluR family is composed of eight members. They are classified into three groups (group I comprising mGluRl and mGluR5; group II comprising mGluR2 and mGluR3; group III comprising mGluR4, mGluRβ, mGluR7 and mGluR8) according to sequence homology, pharmacological profile and nature of intracellular signalling cascades activated (Schoepp et al. (1999) Neuropharmacology, 38:1431-76).
Glutamate activates the mGluRs through binding to the large extracellular amino- terminal domain of the receptor, herein called the orthosteric binding site. This activation induces a conformational change of the receptor which results in the activation of the G-protein and intracellular signalling pathways.
In the central nervous system, mGluR4 receptors are expressed most intensely in the cerebellar cortex, basal ganglia, sensory relay nuclei of the thalamus and hippocampus (Bradley et al. (1999) Journal of Comparative Neurology, 407:33-46; Corti et al. (2002) Neuroscience, 110:403-420). The mGluR4 subtype is negatively coupled to adenylate cyclase via activation of the Gcά/o protein, is expressed primarily on presynaptic terminals, functioning as an autoreceptor or heteroceptor and activation of mGluR4 leads to decreases in transmitter release from presynaptic terminals (Corti et al. (2002) Neuroscience, 110:403-420; Millan et al. (2002) Journal of Biological Chemistry 277:47796-47803; Valenti et al. (2003) Journal of Neuroscience 23:72218-7226).
Orthosteric agonists of mGluR4 are not selective and activate the other Group III mGluRs (Schoepp et al. (1999) Neuropharmacology 38:1431-1476). The Group III orthosteric agonist L-AP4 was able to reduce motor deficits in animal models of
Parkinson's disease (Valenti et al. (2003) J. Neurosci. 23:7218-7226) and decrease excitotoxicity (Bruno et al. (2000) J. Neurosci. 20;6413-6420) and these effects appear to be mediated through mGluR4 (Marino et al. (2005) Curr. Topics Med. Chem. 5:885- 895). In addition to LAP-4, ACPT-I, another selective group III mGluR agonist has been shown to caused a dose-and-structure dependant decrease in haloperidol-induced catalepsy and attenuated haloperidol- increased Proenkephalin mRNA expression in the striatum (Konieczny et al. 2007). Furthemore, Lopez et al. (2007, J Neuroscience) have shown that bilateral infusions of ACPT-I or LAP-4 into the globus pallidus fully reversed the severe akinetic deficits produced by 6-hydroxydopamine lesions of nigrostriatal dopamine neurons in a reaction-time task without affecting the performance of controls. In addition, the reversal of haloperidol-induced catalepsy by intrapallidal ACPT-I was prevented by concomitant administration of a selective group III receptor antagonist (RS)-alpha-cyclopropyl-4-phosphonophenylglycine. The opposite effects produced by group III mGluR activation in the SNr strongly suggest a role of mGluR4 rather than others mGluR receptor sub-types in normalizing basal ganglia activity (Lopez et al. 2007).
These results suggest that, among mGluRs subtypes, mGluR4 is believed to be the most interesting novel drug target for the treatment of Parkinson's disease (for a review see Conn et al. Nature Review Neuroscience 2005).
Symptoms of Parkinson's disease appear to be due to an imbalance in the direct and indirect output pathways of the basal ganglia and reduction of transmission at the inhibitory GABAergic striato-pallidal synapse in the indirect pathway may result in alleviation of these symptoms (Marino et al. (2002) Amino Acids, 23:185-191).
mGluR4 is more abundant in striato-pallidal synapses than in striato-nigral synapses, and its localization suggests function as a presynaptic heteroceptor on GABAergic neurons (Bradley et al. (1999) Journal of Comparative Neurology, 407:33-46) suggesting that selective activation or positive modulation of mGluR4 would decrease GABA release in this synapse thereby decreasing output of the indirect pathway and reducing or eliminating the Parkinson's disease symptoms. A new avenue for developing selective compounds acting at mGluRs is to identify molecules that act through allosteric mechanisms, modulating the receptor by binding to a site different from the highly conserved orthosteric binding site.
Positive allosteric modulators of mGluRs have emerged recently as novel pharmacological entities offering this attractive alternative. This type of molecule has been discovered for mGluRl, mGluR2, mGluR4, mGluR5, mGluR7 and mGluR8 (Knofiach F. et al. (2001) Proc. Natl. Acad. Sci. U S A., 98:13402-13407; Johnson K et al. (2002) Neuropharmacology, 43:291; O'Brien J.A. et al. (2003) MoI. Pharmacol, 64:731-40 ; Johnson M.P. et al. (2003) J. Med. Chem., 46:3189-92; Marino M.J. et al.
(2003) Proc. Natl. Acad. Sci. U S A., 100:13668-73; Mitsukawa K. et al. (2005) Proc Natl Acad Sci U S A 102(51): 18712-7; Wilson J. et al. (2005) Neuropharmacology 49:278; for a review see Mutel V. (2002) Expert Opin. Ther. Patents, 12:1-8; Kew J.N.
(2004) Pharmacol. Ther., 104(3):233-44; Johnson M.P. et al. (2004) Biochem. Soc. Trans., 32:881-7; recently Ritzen A., Mathiesen, J.M., and Thomsen C. (2005) Basic
Clin. Pharmacol. Toxicol. 97:202-13).
In particular molecules have been described as mGluR4 positive allosteric modulators
(Maj et al. (2003) Neuropharmacology 45:895-906; Mathiesen et al. (2003) British Journal of Pharmacology 138: 1026-1030). It has been demonstrated that such molecules have been characterized in in vitro systems as well as in rat brain slices where they potentiated the effect of LAP-4 in inhibiting transmission at the striatopallidal synapse.
These compounds do not activate the receptor by themselves (Marino et al. (2003) Proc.
Nat. Acad. Sci. USA 100:13668-13673). Rather, they enable the receptor to produce a maximal response to a concentration of glutamate or the Group III orthosteric agonist L-
AP4 which by itself induces a minimal response.
PHCCC, a positive allosteric modulator of mGluR4 not active on others mGluRs (Maj et al. (2003) Neuropharmacology 45:895-906), has been shown to be efficacious in animal models of Parkinson's disease thus representing a potential novel therapeutic approach for Parkinson's disease as well as for other motor disorders and disturbances (Marino et al. (2003) Proc. Nat. Acad. Sci. USA 100:13668-13673), neurodegeneration in Parkinson's disease (Marino et al. (2005) Curr. Topics Med. Chem. 5:885-895; Valenti et al. (2005) J Pharmacol. Exp. Ther. 313:1296-1304; Vernon et al. (2005) Eur. J Neurosci. 22:1799-1806, Battaglia et al. (2006) J. Neurosci. 26:7222-7229), and neurodegeneration in Alzheimer's disease or due to ischemic or traumatic insult (Maj et al. (2003) Neuropharmacology 45:895-906).
PHCCC also has been shown to be active in animal model of anxiety (Stachowicz et al. (2004) Eur J Pharmacol 498:153-156). Previously, ACPT-I has been showed to produce a dose-dependent anti-conflict effect after intrahippocampal administration and anti- depressant-like effects in rats after intracerebroventricular administration (Tatarczynska et al., 2002)
Activation of mGluR4 receptors which are expressed in α- and F cells in the islets of Langerhans inhibits glucagon secretion. Molecules which activate or potentiate agonist activity of these receptors may be an effective treatment for hyperglycemia, one of the symptoms of type 2 diabetes (Uehara et al. (2004) Diabetes 53:998-1006).
The β-chemokine RANTES is importantly involved in neuronal inflammation and has been implicated in the pathophysiology of multiple sclerosis. Activation of Group III mGluRs with L-AP4 reduced the synthesis and release RANTES in wild-type cultured astrocytes, whereas the ability of L-AP4 to inhibit RANTES was greatly decreased in astrocyte cultures from mGluR4 knockout mice (Besong et al. (2002) Journal of Neuroscience, 22:5403-5411). These data suggest that positive allosteric modulators of mGluR4 may be an effective treatment for neuroinflammatory disorders of the central nervous system, including multiple sclerosis and related disorders.
Two different variants of the mGluR4 receptor are expressed in taste tissues and may function as receptors for the umami taste sensation (Monastyrskaia et al. (1999) Br. J Pharmacol. 128:1027-1034; Toyono et al. (2002) Arch. Histol. Cytol. 65:91-96). Thus positive allosteric modulators of mGluR4 may be useful as taste agents, flavour agents, flavour enhancing agents or food additives. There are anatomical evidence that the majority of vagal afferents innervating gastric muscle express group III mGluRs (mGluR4, mGluRβ, mGluR7 and mGluR8) and actively transport receptors to their peripheral endings (Page et al (2005) 128:402-10). Recently, it was shown that the activation of peripheral group III mGluRs inhibited vagal afferents mechanosensitivity in vitro which translates into reduced triggering of transient lower oesophagal sphincter relaxations and gastroesophageal reflux in vivo (Young et al (2008) Neuropharmacol 54:965-975). Labelling for mGluR4 and mGluR8 was abundant in gastric vagal afferents in the nodose ganglion, at their termination sites in the nucleus tractus solitarius and in gastric vagal motoneurons. These data suggest that positive allosteric modulators of mGluR4 may be an effective treatment for gastroesophageal reflux disease (GERD) and lower esophageal disorders and gastro -intestinal disorders.
International patent publication WO2005/007096 describes mGluR4 receptor positive allosteric modulator useful, alone or in combination with a neuroleptic agent, for treating or preventing movement disorders. However, none of the specifically disclosed compounds are structurally related to the compounds of the invention.
(i) International patent publications WO2007/072090 and WO2006/167029 describe respectively thienopyridines as modulators of mGluRl and mGluR5 and tricyclic compounds as mGluRl antagonists.
(ii) International patent publication WO2007/001975 describes heterocyclic carboxamides as histamine H3 antagonists. International patent publication WO2004/087048 describes benzamides as modulators of metabotropic glutamate receptors.
(iii) International patent publication WO2006/074884 describes thiazole-4- carboxamides as mGluR5 receptor antagonists.
(iv) US patent publications US2006199960 and US2006199828 describe 3- aminopyridine-2-carboxamides and 3-aminopyrazine-2-carboxamides respectively as metabotropic glutamate receptor antagonists. (v) International patent publication WO99/36416 describes furan-2-carboxamides and thiophen-2-carboxamides as modulators of metabotropic glutamate receptors.
It has now surprisingly been found that the compounds of general formula I show potent activity and selectivity on mGluR4 receptor. The compounds of the invention demonstrate advantageous properties over compounds of the prior art. Improvements have been observed in one or more of the following characteristics of the compounds of the invention: the potency on the target, the selectivity for the target, the bioavailability, the brain penetration, and the activity in behavioural models.
The present invention relates to a method of treating or preventing a condition in a mammal, including a human, the treatment or prevention of which is affected or facilitated by the neuromodulatory effect of mGluR4 modulators.
DETAILED DESCRIPTION OF THE INVENTION
The invention relates to compounds having metabotropic glutamate receptor 4 modulator activity. In its most general compound aspect, the present invention provides a compound according to Formula (I),
Figure imgf000008_0001
a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof and an TV-oxide form thereof, wherein:
X1 is selected from the group of N, O and S and X2, X3 and X4 are each independently selected from the group of C, N, O, S and C=C representing a 5 or 6 membered heteroaryl ring which may further be substituted by 1 to 3 radicals Am; m is an integer ranging from 1 to 3;
Am radicals are each independently selected from the group of hydrogen, halogen, -CN, -OH, -NO2, -CF3, -SH, -NH2 and an optionally substituted radical selected from the group of -(Ci-C6)alkyl, -(d-C6)alkylhalo, -(C3-C7)cycloalkyl, -(Ci-C6)alkylcyano, -(Ci- Ce)alkylheteroaryl, -(Ci-C6)alkylaryl, aryl, heteroaryl, heterocycle, -(Co-Ce)alkyl-OR1, - O-(C2-C6)alkyl-OR1, -NR1(C2-C6)alkyl-OR2, -(C3-C7)cycloalkyl-(Ci-C6)alkyl, -0-(C3- C7)cycloalkyl-(Ci-C6)alkyl, -NR1-(C3-C7)cycloalkyl-(Ci-C6)alkyl, -(d-C6)alkylhalo- OR1, -(Ci-C6)alkylhalo-NR1R2, -(C0-C6)alkyl-S-R1, -O-(C2-C6)alkyl-S-R1, -NR1^C2- C6)alkyl-S-R2, -(C0-C6)alkyl-S(=O)-R1, -O-(d-C6)alkyl-S(=O)-R1, -NR1-(d-C6)alkyl- S(=O)-R2, -(Co-C6)alkyl-S(=0)2-R1, -O-(Ci-C6)alkyl-S(=O)2-R1, -NR1-(d-C6)alkyl- S(=O)2-R2, -(C0-C6)alkyl-NR1R2, -O-(C2-C6)alkyl-NR1R2, -NR1-(C2-C6)alkyl-NR2R3, - (C0-C6)alkyl-S(=O)2NR1R2, -O-(d-C6)alkyl-S(=O)2NR1R2, -NR1-(d-C6)alkyl- S(=O)2NR2R3, -(C0-C6)alkyl-NR1-S(=O)2R2, -O-(C2-C6)alkyl-NR1-S(=O)2R2, -NR1^C2- C6)alkyl-NR2-S(=O)2R3, -(C0-C6)alkyl-C(=O)-NR1R2, -O-(d-C6)alkyl-C(=O)-NR1R2, - NR1-(Ci-C6)alkyl-C(=O)-NR2R3, -(C0-C6)alkyl-NR1C(=O)-R2, -O-(C2-C6)alkyl- NR1C(=0)-R2, -NR1-(C2-C6)alkyl-NR2C(=O)-R3, -(C0-C6)alkyl-OC(=O)-R1, -0-(C2- C6)alkyl-OC(=O)-R1, -NR1-(C2-C6)alkyl-OC(=O)-R2, -(C0-C6)alkyl-C(=O)-OR1, -O- (Ci-C6)alkyl-C(=O)-OR1, -NR1-(d-C6)alkyl-C(=O)-OR2, -(C0-C6)alkyl-C(=O)-R1, -O- (Ci-C6)alkyl-C(=O)-R1, -NR1-(d-C6)alkyl-C(=O)-R2, -(C0-C6)alkyl-NR1-C(=O)-OR2, - (C0-C6)alkyl-O-C(=O)-NR1R2, -(C0-C6)alkyl-NR1-C(=NR2)-NR3R4, -(C0-C6)alkyl-NR1- C(=O)-NR2R3, -O-(C2-C6)alkyl-NR1-C(=O)-NR2R3, -NR1-(C2-C6)alkyl-NR2-C(=O)- NR3R4 and -(C0-C6)alkyl-NR1-C(=S)-NR2R3;
Any two radicals of Am (A1 and A2) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
R1, R2, R3 and R4 are each independently hydrogen or an optionally substituted radical selected from the group of -(Ci-C6)alkylhalo, -(Ci-Ce)alkyl, -(Ci-Ce)alkylcyano, -(C3- d)cycloalkyl, -(C4-C io)alkylcycloalkyl, heteroaryl, -(Ci-C6)alkylheteroaryl, aryl, heterocycle and -(Ci-Ce)alkylaryl; Any two radicals of R (R1, R2, R3 or R4) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring; n is an integer ranging from 1 to 3;
Bn radicals are each independently selected from the group of hydrogen, halogen, -CN, - OH, -NO2, -CF3, -SH, -NH2 and an optionally substituted radical selected from the group of -(Ci-C6)alkyl, -(d-C6)alkylhalo, -(C3-C7)cycloalkyl, -(Ci-C6)alkylcyano, -(Ci- Ce)alkylheteroaryl, -(Ci-C6)alkylaryl, aryl, heteroaryl, heterocycle, -(Co-Ce)alkyl-OR5, - O-(C2-C6)alkyl-OR5, -NR5(C2-C6)alkyl-OR6, -(C3-C7)cycloalkyl-(Ci-C6)alkyl, -0-(C3- C7)cycloalkyl-(Ci-C6)alkyl, -NR5-(C3-C7)cycloalkyl-(Ci-C6)alkyl, -(d-C6)alkylhalo- OR5, -(Ci-C6)alkylhalo-NR5R6, -(C0-C6)alkyl-S-R5, -O-(C2-C6)alkyl-S-R5, -NR5-(C2- C6)alkyl-S-R6, -(C0-C6)alkyl-S(=O)-R5, -O-(d-C6)alkyl-S(=O)-R5, -NR5-(d-C6)alkyl- S(=O)-R6, -(Co-C6)alkyl-S(=0)2-R5, -O-(Ci-C6)alkyl-S(=O)2-R5, -NR5-(d-C6)alkyl- S(=O)2-R6, -(C0-C6)alkyl-NR5R6, -O-(C2-C6)alkyl-NR5R6, -NR5-(C2-C6)alkyl-NR6R7, - (C0-C6)alkyl-S(=O)2NR5R6, -O-(d-C6)alkyl-S(=O)2NR5R6, -NR5-(d-C6)alkyl- S(=O)2NR6R7, -(C0-C6)alkyl-NR5-S(=O)2R6, -O-(C2-C6)alkyl-NR5-S(=O)2R6, -NR5-(C2- C6)alkyl-NR6-S(=O)2R7, -(C0-C6)alkyl-C(=O)-NR5R6, -O-(d-C6)alkyl-C(=O)-NR5R6, - NR5-(Ci-C6)alkyl-C(=O)-NR6R7, -(C0-C6)alkyl-NR5C(=O)-R6, -O-(C2-C6)alkyl- NR5C(=O)-R6, -NR5-(C2-C6)alkyl-NR6C(=O)-R7, -(C0-C6)alkyl-OC(=O)-R5, -0-(C2- C6)alkyl-OC(=O)-R5, -NR5-(C2-C6)alkyl-OC(=O)-R6, -(C0-C6)alkyl-C(=O)-OR5, -O- (Ci-C6)alkyl-C(=O)-OR5, -NR5-(d-C6)alkyl-C(=O)-OR6, -(C0-C6)alkyl-C(=O)-R5, -O- (Ci-C6)alkyl-C(=O)-R5, -NR5-(d-C6)alkyl-C(=O)-R6, -(C0-C6)alkyl-NR5-C(=O)-OR6, - (C0-C6)alkyl-O-C(=O)-NR5R6, -(C0-C6)alkyl-NR5-C(=NR6)-NR7R8, -(C0-C6)alkyl-NR5- C(=O)-NR6R7, -O-(C2-C6)alkyl-NR5-C(=O)-NR6R7, -NR5-(C2-C6)alkyl-NR6-C(=O)- NR7R8 and -(C0-C6)alkyl-NR5-C(=S)-NR6R7;
Any two radicals of Bn (B1 and B2) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
R5, R6, R7 and R8 are each independently hydrogen or an optionally substituted radical selected from the group of -(Ci-C6)alkylhalo, -(Ci-Ce)alkyl, -(Ci-Ce)alkylcyano, -(C3- d)cycloalkyl, -(C4-C io)alkylcycloalkyl, heteroaryl, -(Ci-C6)alkylheteroaryl, aryl, heterocycle and -(Ci-Ce)alkylaryl; Any two radicals of R (R5, R6, R7 or R8) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring; provided that: (i) Formula (I)
Figure imgf000011_0001
can not be and provided that:
(ii) Formula (I)
Figure imgf000011_0002
when B1 is NR5R6 and
CH2NR5R6; and provided that:
R1HN
(iii) Formula (I) Am x2"x can not be A1 ; and provided that:
(iv) Formula (I) Am x2'χ1 can not be
Figure imgf000011_0003
; and provided that:
(v) when X1 is O or S and X2,X3 and X4 are C then in Formula (I) HN ^B" can not
be HN^ ^B" ;
The compounds thienopyridines known as such from international patent publications WO2007/072090 and WO2006/167029 are excluded from the present invention by virtue of proviso (i).
The compounds heterocyclic carboxamides known as such from international patent publication WO2007/001975 and benzamides known as such from international patent publication WO2004/087048 are excluded from the present invention by virtue of proviso (ii). The compounds thiazole-4-carboxamides known as such from international patent publication WO2006/074884 are excluded from the present invention by virtue of proviso (iii).
The compounds 3-aminopyridine-2-carboxamides and 3-aminopyrazine-2- carboxamides known respectively as such from US patent publications US2006199960 and US2006199828 are excluded from the present invention by virtue of proviso (iv).
The compounds furan-2-carboxamides and thiophen-2-carboxamides known as such from international patent publication WO99/36416 are excluded from the present invention by virtue of proviso (v).
In one aspect of Formula (I), the invention concerns a compound according to Formula (I-a),
Figure imgf000012_0001
a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof and an JV-oxide form thereof, wherein:
X1 is selected from the group of N, O and S and X2, X3 and X4 are each independently selected from the group of C, N, O, S and C=C representing a 5 or 6 membered heteroaryl ring which may further be substituted by 1 to 3 radicals Am;
m is an integer ranging from 1 to 3;
Am radicals are each independently selected from the group of hydrogen, halogen, -CN, -OH, -NO2, -CF3, -SH, -NH2 and an optionally substituted radical selected from the group of -(Ci-C6)alkyl, -(Ci-C6)alkylhalo, -(C3-C7)cycloalkyl, -(Ci-C6)alkylcyano, -(Ci- C6)alkylheteroaryl, -(Ci-C6)alkylaryl, aryl, heteroaryl, heterocycle, -(C0-C6)alkyl-OR1, - O-(C2-C6)alkyl-OR1, -NR1(C2-C6)alkyl-OR2, -(C3-C7)cycloalkyl-(Ci-C6)alkyl, -0-(C3- C7)cycloalkyl-(Ci-C6)alkyl, -NR1-(C3-C7)cycloalkyl-(Ci-C6)alkyl, -(Ci-C6)alkylhalo- OR1, -(Ci-C6)alkylhalo-NR1R2, -(C0-C6)alkyl-S-R1, -O-(C2-C6)alkyl-S-R1, -NR^(C2- C6)alkyl-S-R2, -(C0-C6)alkyl-S(=O)-R1, -O-(d-C6)alkyl-S(=O)-R1, -NR1-(d-C6)alkyl- S(=O)-R2, -(Co-C6)alkyl-S(=0)2-R1, -O-(Ci-C6)alkyl-S(=O)2-R1, -NR1-(d-C6)alkyl- S(=O)2-R2, -(C0-C6)alkyl-NR1R2, -O-(C2-C6)alkyl-NR1R2, -NR1-(C2-C6)alkyl-NR2R3, - (C0-C6)alkyl-S(=O)2NR1R2, -O-(Ci-C6)alkyl-S(=O)2NR1R2, -NR1-(d-C6)alkyl- S(=O)2NR2R3, -(C0-C6)alkyl-NR1-S(=O)2R2, -O-(C2-C6)alkyl-NR1-S(=O)2R2, -NR^(C2- C6)alkyl-NR2-S(=O)2R3, -(C0-C6)alkyl-C(=O)-NR1R2, -O-(d-C6)alkyl-C(=O)-NR1R2, - NR1-(Ci-C6)alkyl-C(=O)-NR2R3, -(C0-C6)alkyl-NR1C(=O)-R2, -O-(C2-C6)alkyl- NR1CC=O)-R2, -NR1-(C2-C6)alkyl-NR2C(=O)-R3, -(C0-C6)alkyl-OC(=O)-R1, -0-(C2- C6)alkyl-OC(=O)-R1, -NR1-(C2-C6)alkyl-OC(=O)-R2, -(C0-C6)alkyl-C(=O)-OR1, -O- (Ci-C6)alkyl-C(=O)-OR1, -NR1-(d-C6)alkyl-C(=O)-OR2, -(C0-C6)alkyl-C(=O)-R1, -O- (Ci-C6)alkyl-C(=O)-R1, -NR1-(d-C6)alkyl-C(=O)-R2, -(C0-C6)alkyl-NR1-C(=O)-OR2, - (C0-C6)alkyl-O-C(=O)-NR1R2, -(C0-C6)alkyl-NR1-C(=NR2)-NR3R4, -(C0-C6)alkyl-NR1- C(=O)-NR2R3, -O-(C2-C6)alkyl-NR1-C(=O)-NR2R3, -NR1-(C2-C6)alkyl-NR2-C(=O)- NR3R4 and -(C0-C6)alkyl-NR1-C(=S)-NR2R3;
Any two radicals of Am (A1 and A2) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
R1, R2, R3 and R4 are each independently hydrogen or an optionally substituted radical selected from the group of -(Ci-C6)alkylhalo, -(Ci-Ce)alkyl, -(Ci-Ce)alkylcyano, -(C3- C7)CyC loalkyl, -(C4-C io)alkylcycloalkyl, heteroaryl, -(Ci-C6)alkylheteroaryl, aryl, heterocycle and -(Ci-Ce)alkylaryl;
Any two radicals of R (R1, R2, R3 or R4) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
B1 and B2 are each independently selected from the group of hydrogen, halogen, -CN, - OH, -NO2, -CF3, -SH, -NH2 and an optionally substituted radical selected from the group of -(Ci-C6)alkyl, -(d-C6)alkylhalo, -(C3-C7)cycloalkyl, -(d-C6)alkylcyano, -(Ci- Ce)alkylheteroaryl, -(Ci-Ce)alkylaryl, aryl, heteroaryl, heterocycle, -(Co-Ce)alkyl-OR5, - O-(C2-C6)alkyl-OR5, -NR5(C2-C6)alkyl-OR6, -(C3-C7)cycloalkyl-(d-C6)alkyl, -0-(C3- C7)cycloalkyl-(Ci-C6)alkyl, -NR5-(C3-C7)cycloalkyl-(d-C6)alkyl, -(d-C6)alkylhalo- OR5, -(Ci-C6)alkylhalo-NR5R6, -(C0-C6)alkyl-S-R5, -O-(C2-C6)alkyl-S-R5, -NR5-(C2- C6)alkyl-S-R6, -(C0-C6)alkyl-S(=O)-R5, -O-(d-C6)alkyl-S(=O)-R5, -NR5-(d-C6)alkyl- S(=O)-R6, -(Co-C6)alkyl-S(=0)2-R5, -O-(Ci-C6)alkyl-S(=O)2-R5, -NR5-(d-C6)alkyl- S(=O)2-R6, -(C0-C6)alkyl-NR5R6, -O-(C2-C6)alkyl-NR5R6, -NR5-(C2-C6)alkyl-NR6R7, - (C0-C6)alkyl-S(=O)2NR5R6, -O-(Ci-C6)alkyl-S(=O)2NR5R6, -NR5-(d-C6)alkyl- S(=O)2NR6R7, -(C0-C6)alkyl-NR5-S(=O)2R6, -O-(C2-C6)alkyl-NR5-S(=O)2R6, -NR5-(C2- C6)alkyl-NR6-S(=O)2R7, -(C0-C6)alkyl-C(=O)-NR5R6, -O-(d-C6)alkyl-C(=O)-NR5R6, - NR5-(Ci-C6)alkyl-C(=O)-NR6R7, -(C0-C6)alkyl-NR5C(=O)-R6, -O-(C2-C6)alkyl- NR5C(=O)-R6, -NR5-(C2-C6)alkyl-NR6C(=O)-R7, -(C0-C6)alkyl-OC(=O)-R5, -0-(C2- C6)alkyl-OC(=O)-R5, -NR5-(C2-C6)alkyl-OC(=O)-R6, -(C0-C6)alkyl-C(=O)-OR5, -O- (Ci-C6)alkyl-C(=O)-OR5, -NR5-(d-C6)alkyl-C(=O)-OR6, -(C0-C6)alkyl-C(=O)-R5, -O- (Ci-C6)alkyl-C(=O)-R5, -NR5-(d-C6)alkyl-C(=O)-R6, -(C0-C6)alkyl-NR5-C(=O)-OR6, - (C0-C6)alkyl-O-C(=O)-NR5R6, -(C0-C6)alkyl-NR5-C(=NR6)-NR7R8, -(C0-C6)alkyl-NR5- C(=O)-NR6R7, -O-(d-C6)alkyl-NR5-C(=O)-NR6R7, -NR5-(C2-C6)alkyl-NR6-C(=O)- NR7R8 and -(C0-C6)alkyl-NR5-C(=S)-NR6R7;
Any two radicals of Bn (B1 and B2) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
R5, R6, R7 and R8 are each independently hydrogen or an optionally substituted radical selected from the group of -(C1-C6)alkylhalo, -(Ci-Ce)alkyl, -(Ci-Ce)alkylcyano, -(d- C7)CyC loalkyl, -(C4-C io)alkylcycloalkyl, heteroaryl, -(Ci-C6)alkylheteroaryl, aryl, heterocycle and -(Ci-C6)alkylaryl; Any two radicals of R (R5, R6, R7 or R8) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring; provided that according to proviso (i):
Formula (I) Am *2~χ1 can not be
Figure imgf000014_0001
and provided that according to proviso (iii):
Formula (I) Am x2"χ1 can not be
Figure imgf000014_0002
and provided that according to proviso (iv): Formula (I) Am x2'χ1 can not be
Figure imgf000015_0001
; and provided that according to proviso (v):
when X1 is O or S and X2,X3 and X4 are C then in Formula (I) HN Bn Can not be
4QC-
In a second aspect of Formula (I), the invention concerns a compound according to Formula (I-b),
Figure imgf000015_0002
a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof and an TV-oxide form thereof, wherein:
X1 is selected from the group of N, O and S and X2, X3 and X4 are each independently selected from the group of C, N, O, S and C=C representing a 5 or 6 membered heteroaryl ring which may further be substituted by 1 to 3 radicals Am;
m is an integer ranging from 1 to 3;
Am radicals are each independently selected from the group of hydrogen, halogen, -CN, -OH, -NO2, -CF3, -SH, -NH2 and an optionally substituted radical selected from the group of -(Ci-C6)alkyl, -(d-C6)alkylhalo, -(C3-C7)cycloalkyl, -(Ci-C6)alkylcyano, -(Ci- C6)alkylheteroaryl, -(Ci-C6)alkylaryl, aryl, heteroaryl, heterocycle, -(C0-C6)alkyl-OR1, - O-(C2-C6)alkyl-OR1, -NR1(C2-C6)alkyl-OR2, -(C3-C7)cycloalkyl-(Ci-C6)alkyl, -0-(C3- C7)cycloalkyl-(Ci-C6)alkyl, -NR1-(C3-C7)cycloalkyl-(Ci-C6)alkyl, -(Ci-C6)alkylhalo- OR1, -(Ci-C6)alkylhalo-NR1R2, -(C0-C6)alkyl-S-R1, -O-(C2-C6)alkyl-S-R1, -NR1^C2- C6)alkyl-S-R2, -(C0-C6)alkyl-S(=O)-R1, -O-(d-C6)alkyl-S(=O)-R1, -NR1-(d-C6)alkyl- S(=O)-R2, -(Co-C6)alkyl-S(=0)2-R1, -O-(Ci-C6)alkyl-S(=O)2-R1, -NR1-(d-C6)alkyl- S(=O)2-R2, -(C0-C6)alkyl-NR1R2, -O-(C2-C6)alkyl-NR1R2, -NR1-(C2-C6)alkyl-NR2R3, - (C0-C6)alkyl-S(=O)2NR1R2, -O-(Ci-C6)alkyl-S(=O)2NR1R2, -NR1-(d-C6)alkyl- S(=O)2NR2R3, -(C0-C6)alkyl-NR1-S(=O)2R2, -O-(C2-C6)alkyl-NR1-S(=O)2R2, -NR^(C2- C6)alkyl-NR2-S(=O)2R3, -(C0-C6)alkyl-C(=O)-NR1R2, -O-(d-C6)alkyl-C(=O)-NR1R2, - NR1-(Ci-C6)alkyl-C(=O)-NR2R3, -(C0-C6)alkyl-NR1C(=O)-R2, -O-(C2-C6)alkyl- NR1CC=O)-R2, -NR1-(C2-C6)alkyl-NR2C(=O)-R3, -(C0-C6)alkyl-OC(=O)-R1, -0-(C2- C6)alkyl-OC(=O)-R1, -NR1-(C2-C6)alkyl-OC(=O)-R2, -(C0-C6)alkyl-C(=O)-OR1, -O- (Ci-C6)alkyl-C(=O)-OR1, -NR1-(d-C6)alkyl-C(=O)-OR2, -(C0-C6)alkyl-C(=O)-R1, -O- (Ci-C6)alkyl-C(=O)-R1, -NR1-(d-C6)alkyl-C(=O)-R2, -(C0-C6)alkyl-NR1-C(=O)-OR2, - (C0-C6)alkyl-O-C(=O)-NR1R2, -(C0-C6)alkyl-NR1-C(=NR2)-NR3R4, -(C0-C6)alkyl-NR1- C(=O)-NR2R3, -O-(C2-C6)alkyl-NR1-C(=O)-NR2R3, -NR1-(C2-C6)alkyl-NR2-C(=O)- NR3R4 and -(C0-C6)alkyl-NR1-C(=S)-NR2R3; Any two radicals of Am (A1 and A2) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
R1, R2, R3 and R4 are each independently hydrogen or an optionally substituted radical selected from the group of -(Ci-C6)alkylhalo, -(Ci-Ce)alkyl, -(Ci-Ce)alkylcyano, -(C3- C7)CyC loalkyl, -(C4-C io)alkylcycloalkyl, heteroaryl, -(Ci-C6)alkylheteroaryl, aryl, heterocycle and -(Ci-Ce)alkylaryl;
Any two radicals of R (R1, R2, R3 or R4) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
B1 and B2 are each independently selected from the group of hydrogen, halogen, -CN, - OH, -NO2, -CF3, -SH, -NH2 and an optionally substituted radical selected from the group of -(Ci-C6)alkyl, -(d-C6)alkylhalo, -(C3-C7)cycloalkyl, -(d-C6)alkylcyano, -(Ci-
Ce)alkylheteroaryl, -(Ci-Ce)alkylaryl, aryl, heteroaryl, heterocycle, -(Co-Ce)alkyl-OR5, -
O-(C2-C6)alkyl-OR5, -NR5(C2-C6)alkyl-OR6, -(C3-C7)cycloalkyl-(d-C6)alkyl, -0-(C3-
C7)cycloalkyl-(Ci-C6)alkyl, -NR5-(C3-C7)cycloalkyl-(d-C6)alkyl, -(d-C6)alkylhalo- OR5, -(Ci-C6)alkylhalo-NR5R6, -(C0-C6)alkyl-S-R5, -O-(C2-C6)alkyl-S-R5, -NR5-(C2-
C6)alkyl-S-R6, -(C0-C6)alkyl-S(=O)-R5, -O-(d-C6)alkyl-S(=O)-R5, -NR5-(d-C6)alkyl-
S(=O)-R6, -(Co-C6)alkyl-S(=0)2-R5, -O-(d-C6)alkyl-S(=O)2-R5, -NR5-(d-C6)alkyl- S(=O)2-R6, -(C0-C6)alkyl-NR5R6, -O-(C2-C6)alkyl-NR5R6, -NR5-(C2-C6)alkyl-NR6R7, - (C0-C6)alkyl-S(=O)2NR5R6, -O-(Ci-C6)alkyl-S(=O)2NR5R6, -NR5-(d-C6)alkyl- S(=O)2NR6R7, -(C0-C6)alkyl-NR5-S(=O)2R6, -O-(C2-C6)alkyl-NR5-S(=O)2R6, -NR5-(C2- C6)alkyl-NR6-S(=O)2R7, -(C0-C6)alkyl-C(=O)-NR5R6, -O-(d-C6)alkyl-C(=O)-NR5R6, - NR5-(Ci-C6)alkyl-C(=O)-NR6R7, -(C0-C6)alkyl-NR5C(=O)-R6, -O-(C2-C6)alkyl- NR5C(=O)-R6, -NR5-(C2-C6)alkyl-NR6C(=O)-R7, -(C0-C6)alkyl-OC(=O)-R5, -0-(C2- C6)alkyl-OC(=O)-R5, -NR5-(C2-C6)alkyl-OC(=O)-R6, -(C0-C6)alkyl-C(=O)-OR5, -O- (Ci-C6)alkyl-C(=O)-OR5, -NR5-(d-C6)alkyl-C(=O)-OR6, -(C0-C6)alkyl-C(=O)-R5, -O- (Ci-C6)alkyl-C(=O)-R5, -NR5-(Ci-C6)alkyl-C(=O)-R6, -(C0-C6)alkyl-NR5-C(=O)-OR6, - (C0-C6)alkyl-O-C(=O)-NR5R6, -(C0-C6)alkyl-NR5-C(=NR6)-NR7R8, -(C0-C6)alkyl-NR5- C(=O)-NR6R7, -O-(C2-C6)alkyl-NR5-C(=O)-NR6R7, -NR5-(C2-C6)alkyl-NR6-C(=O)- NR7R8 and -(C0-C6)alkyl-NR5-C(=S)-NR6R7;
Any two radicals of Bn (B1 and B2) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring; R5, R6, R7 and R8 are each independently hydrogen or an optionally substituted radical selected from the group of -(C1-C6)alkylhalo, -(Ci-Ce)alkyl, -(Ci-Ce)alkylcyano, -(C3- C7)cycloalkyl, -(C4-C 10)alkylcycloalkyl, heteroaryl, -(C1-C6)alkylheteroaryl, aryl, heterocycle and -(C1-C6)alkylaryl;
Any two radicals of R (R5, R6, R7 or R8) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring; provided that according to proviso (i):
Formula (I) Am *2~χ1 can not be
Figure imgf000017_0001
and provided that according to proviso (iii):
R1HN
Formula (I) Am x2'*1 can not be A1 ; and provided that according to proviso (iv): Formula (I) Am x2'χ1 can not be
Figure imgf000018_0001
.
In a third aspect of Formula (I), the invention concerns a compound according to Formula (I-c),
Figure imgf000018_0002
a pharmaceutically acceptable acid or base addition salt thereof, a stereochemical^ isomeric form thereof and an TV-oxide form thereof, wherein:
X1 is selected from the group of N, O and S and X2, X3 and X4 are each independently selected from the group of C, N, O, S and C=C representing a 5 or 6 membered heteroaryl ring which may further be substituted by 1 to 3 radicals Am;
m is an integer ranging from 1 to 3;
Am radicals are each independently selected from the group of hydrogen, halogen, -CN, -OH, -NO2, -CF3, -SH, -NH2 and an optionally substituted radical selected from the group of -(Ci-C6)alkyl, -(d-C6)alkylhalo, -(C3-C7)cycloalkyl, -(Ci-C6)alkylcyano, -(Ci-
Ce)alkylheteroaryl, -(Ci-Ce)alkylaryl, aryl, heteroaryl, heterocycle, -(Co-Ce)alkyl-OR1, -
O-(C2-C6)alkyl-OR1, -NR1(C2-C6)alkyl-OR2, -(C3-C7)cycloalkyl-(Ci-C6)alkyl, -0-(C3-
C7)cycloalkyl-(Ci-C6)alkyl, -NR1-(C3-C7)cycloalkyl-(Ci-C6)alkyl, -(d-C6)alkylhalo- OR1, -(Ci-C6)alkylhalo-NR1R2, -(C0-C6)alkyl-S-R1, -O-(C2-C6)alkyl-S-R1, -NR1^C2-
C6)alkyl-S-R2, -(C0-C6)alkyl-S(=O)-R1, -O-(d-C6)alkyl-S(=O)-R1, -NR1-(d-C6)alkyl-
S(=O)-R2, -(Co-C6)alkyl-S(=0)2-R1, -O-(Ci-C6)alkyl-S(=O)2-R1, -NR1-(d-C6)alkyl-
S(=O)2-R2, -(C0-C6)alkyl-NR1R2, -O-(C2-C6)alkyl-NR1R2, -NR1-(C2-C6)alkyl-NR2R3, -
(C0-C6)alkyl-S(=O)2NR1R2, -O-(d-C6)alkyl-S(=O)2NR1R2, -NR1-(d-C6)alkyl- S(=O)2NR2R3, -(C0-C6)alkyl-NR1-S(=O)2R2, -O-(C2-C6)alkyl-NR1-S(=O)2R2, -NR^(C2- C6)alkyl-NR2-S(=O)2R3, -(C0-C6)alkyl-C(=O)-NR1R2, -O-(d-C6)alkyl-C(=O)-NR1R2, - NR1-(Ci-C6)alkyl-C(=O)-NR2R3, -(C0-C6)alkyl-NR1C(=O)-R2, -O-(C2-C6)alkyl- NR1CC=O)-R2, -NR1-(C2-C6)alkyl-NR2C(=O)-R3, -(C0-C6)alkyl-OC(=O)-R1, -0-(C2- C6)alkyl-OC(=O)-R1, -NR1-(C2-C6)alkyl-OC(=O)-R2, -(C0-C6)alkyl-C(=O)-OR1, -O- (Ci-C6)alkyl-C(=O)-OR1, -NR1-(d-C6)alkyl-C(=O)-OR2, -(C0-C6)alkyl-C(=O)-R1, -O- (Ci-C6)alkyl-C(=O)-R1, -NR1-(Ci-C6)alkyl-C(=O)-R2, -(C0-C6)alkyl-NR1-C(=O)-OR2, - (C0-C6)alkyl-O-C(=O)-NR1R2, -(C0-C6)alkyl-NR1-C(=NR2)-NR3R4, -(C0-C6)alkyl-NR1- C(=O)-NR2R3, -O-(C2-C6)alkyl-NR1-C(=O)-NR2R3, -NR1-(C2-C6)alkyl-NR2-C(=O)- NR3R4 and -(C0-C6)alkyl-NR1-C(=S)-NR2R3; Any two radicals of Am (A1 and A2) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
R1, R2, R3 and R4 are each independently hydrogen or an optionally substituted radical selected from the group of -(Ci-C6)alkylhalo, -(Ci-C6)alkyl, -(Ci-C6)alkylcyano, -(C3- C7)cycloalkyl, -(C4-C 10)alkylcycloalkyl, heteroaryl, -(C1-C6)alkylheteroaryl, aryl, heterocycle and -(C1-C6)alkylaryl;
Any two radicals of R (R1, R2, R3 or R4) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
B1 is selected from the group of hydrogen, halogen, -CN, -OH, -NO2, -CF3, -SH, -NH2 and an optionally substituted radical selected from the group of -(Ci-Ce)alkyl, -(C1- C6)alkylhalo, -(C3-C7)cycloalkyl, -(Ci-C6)alkylcyano, -(Ci-C6)alkylheteroaryl, -(Ci- C6)alkylaryl, aryl, heteroaryl, heterocycle, -(C0-C6)alkyl-OR5, -O-(C2-C6)alkyl-OR5, - NR5(C2-C6)alkyl-OR6, -(C3-C7)cycloalkyl-(Ci-C6)alkyl, -O-(C3-C7)cycloalkyl-(Ci- C6)alkyl, -NR5-(C3-C7)cycloalkyl-(Ci-C6)alkyl, -(Ci-C6)alkylhalo-OR5, -(Ci- C6)alkylhalo-NR5R6, -(C0-C6)alkyl-S-R5, -O-(C2-C6)alkyl-S-R5, -NR5-(C2-C6)alkyl-S- R6, -(C0-C6)alkyl-S(=O)-R5, -O-(d-C6)alkyl-S(=O)-R5, -NR5-(d-C6)alkyl-S(=O)-R6, - (Co-C6)alkyl-S(=0)2-R5, -O-(d-C6)alkyl-S(=O)2-R5, -NR5-(d-C6)alkyl-S(=O)2-R6, - (C0-C6)alkyl-NR5R6, -O-(C2-C6)alkyl-NR5R6, -NR5-(C2-C6)alkyl-NR6R7, -(C0-C6)alkyl- S(=O)2NR5R6, -O-(Ci-C6)alkyl-S(=O)2NR5R6, -NR5-(d-C6)alkyl-S(=O)2NR6R7, -(C0- C6)alkyl-NR5-S(=O)2R6, -O-(C2-C6)alkyl-NR5-S(=O)2R6, -NR5-(C2-C6)alkyl-NR6- S(=O)2R7, -(C0-C6)alkyl-C(=O)-NR5R6, -O-(d-C6)alkyl-C(=O)-NR5R6, -NR5-(Ci- C6)alkyl-C(=O)-NR6R7, -(C0-C6)alkyl-NR5C(=O)-R6, -O-(C2-C6)alkyl-NR5C(=O)-R6, - NR5-(C2-C6)alkyl-NR6C(=O)-R7, -(C0-C6)alkyl-OC(=O)-R5, -O-(C2-C6)alkyl-OC(=O)- R5, -NR5-(C2-C6)alkyl-OC(=O)-R6, -(C0-C6)alkyl-C(=O)-OR5, -O-(d-C6)alkyl-C(=O)- OR5, -NR5-(Ci-C6)alkyl-C(=O)-OR6, -(C0-C6)alkyl-C(=O)-R5, -O-(d-C6)alkyl-C(=O)- R5, -NR5-(Ci-C6)alkyl-C(=O)-R6, -(C0-C6)alkyl-NR5-C(=O)-OR6, -(C0-C6)alkyl-O- C(=O)-NR5R6, -(C0-C6)alkyl-NR5-C(=NR6)-NR7R8, -(C0-C6)alkyl-NR5-C(=O)-NR6R7, - O-(C2-C6)alkyl-NR5-C(=O)-NR6R7, -NR5-(C2-C6)alkyl-NR6-C(=O)-NR7R8 and -(C0- C6)alkyl-NR5-C(=S)-NR6R7;
R5, R6, R7 and R8 are each independently hydrogen or an optionally substituted radical selected from the group of -(Ci-C6)alkylhalo, -(Ci-C6)alkyl, -(Ci-C6)alkylcyano, -(C3- C7)CyC loalkyl, -(C4-C io)alkylcycloalkyl, heteroaryl, -(Ci-C6)alkylheteroaryl, aryl, heterocycle and -(Ci-C6)alkylaryl;
Any two radicals of R (R5, R6, R7 or R8) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
Z is selected from the group of O and NR9; and R9 is hydrogen or an optionally substituted radical selected from the group of -(C1- C6)alkylhalo, -(Ci-C6)alkyl, -(Ci-C6)alkylcyano, -(C3-C7)cycloalkyl, -(C4- Cio)alkylcycloalkyl, heteroaryl, -(Ci-C6)alkylheteroaryl, aryl, heterocycle, -C(=O)alkyl, -C(=O)-(C3-C7)cycloalkyl -C(=O)aryl, -C(=O)heteroaryl, -C(=O)heterocycle, -C(=O)- (Ci-C6)alkylcycloalkyl, -C(=O)-(Ci-C6)alkylheteroaryl and -(Ci-C6)alkylaryl.
Particular preferred compounds of the invention are compounds as mentioned in the following list (List of Particular Preferred Compounds), as well as a pharmaceutically acceptable acid or base addition salt thereof, a stereochemical^ isomeric form thereof and an JV-oxide form thereof.
N-(3 ,4-dichlorophenyl)- lH-pyrrole-2-carboxamide
Λ/-(3-Chlorophenyl)-lH-imidazole-2-carboxamide
Λ/-(3-Methoxyphenyl)thiophene-2-carboxamide
5-Methyl-Λ/-(4-phenoxyphenyl)furan-2-carboxamide
Furan-2-carboxylic acid {3-[2-(4-fluoro-phenyl)-2-oxo-ethoxy]-phenyl} -amide
N-(3 -Methoxyphenyl)picolinamide
N-(3 -Methoxyphenyl)-2-methylthiazo le-4-carboxamide
Λ/-(3-Chlorophenyl)thiophene-2-carboxamide
5-Bromo-Λ/-(3-methoxyphenyl)furan-2-carboxamide N-(3 -Chlorophenyl)pico linamide
Λ/-(3-Methoxyphenyl)thiazole-2-carboxamide
Λ/-(3-(2-(3-Methoxyphenyl)-2-oxoethoxy)phenyl)furan-2-carboxamide
Λ/-(3-(2-Oxo-2-/?-tolylethoxy)phenyl)furan-2-carboxamide
Λ/-(3-(2-(4-Methoxyphenyl)-2-oxoethoxy)phenyl)furan-2-carboxamide
Λ/-(3-(l-Oxo-l-/?-tolylpropan-2-yloxy)phenyl)furan-2-carboxamide
N-(3 -(Trifluoromethoxy)phenyl)pico linamide
Λ/-(3-(2-(3-Chlorophenyl)-2-oxoethoxy)phenyl)picolinamide
N-(3 -(3 -Phenylpropoxy)phenyl)pico linamide
N-(3-(2-(2-Methoxyphenyl)-2-oxoethoxy)phenyl)picolinamide
N-(3 -(2-(3 -Methoxyphenyl)-2-oxoethoxy)phenyl)pico linamide
Λ/-(3-(2-(3-Fluorophenyl)-2-oxoethoxy)phenyl)pico linamide
Λ/-(3-(2-(2-Chlorophenyl)-2-oxoethoxy)phenyl)picolinamide
N-(3 -Fluorophenyl)pico linamide
N-(3 -Methoxyphenyl)-5 -methylisoxazo le-3 -carboxamide
JV-(4-Fluoro-3 -methoxyphenyl)pico linamide
Λ/-(3-Chlorophenyl)-lH-pyrrole-2-carboxamide
Λ/-(3-(2-(2-Fluorophenyl)-2-oxoethoxy)phenyl)picolinamide
Λ/-(3-Methoxyphenyl)pyrimidine-4-carboxamide
6-Fluoro-Λ/-(4-fluoro-3-methoxyphenyl)pico linamide
Λ/-(3-Chloro-4-(pyrimidin-2-yloxy)phenyl)pico linamide
N-(4-Fluoro-3 -methoxyphenyl)thiazo le-2-carboxamide
Λ/-(3-Chloro-4-(pyrimidin-2-yloxy)phenyl)-2-methylthiazole-4-carboxamide
Λ/-(3-Chloro-4-(pyrimidin-2-yloxy)phenyl)thiazo le-2-carboxamide
N-(3 -Chloro-4-morpho linophenyl)pico linamide
Λ/-(3-Chloro-4-(pyridin-2-yloxy)phenyl)pico linamide
Λ/-(3-Chloro-4-(2,5-difluorophenoxy)phenyl)pico linamide
Λ/-(3-Chloro-4-(2-chlorophenoxy)phenyl)pico linamide
Λ/-(3-Chloro-4-(5-(trifluoromethyl)pyridin-2-yloxy)phenyl)pico linamide jV-(3-Chloro-4-(4-isobutyrylpiperazin- 1 -yl)phenyl)pico linamide
Λ/-(3-Methoxy-4-(pyrimidin-2-yloxy)phenyl)pico linamide
Λ/-(4-(Trifluoromethoxy)phenyl)pico linamide
N-(3 -Chloro-4-(3 -chlorophenoxy)phenyl)pico linamide
N-(3 -Chloro-4-(3 -fluorophenoxy)phenyl)pico linamide
Λ/-(3-Chloro-4-(4-fluorophenoxy)phenyl)pico linamide
Λ/-(3-Chloro-4-(4-chlorophenoxy)phenyl)pico linamide
Λ/-(3-Chloro-4-(4-propionylpiperazin- 1 -yl)phenyl)pico linamide
N-(4-(4-Benzoylpiperazin- 1 -yl)-3-chlorophenyl)pico linamide
JV-(3-Chloro-4-(4-cyanophenoxy)phenyl)pico linamide
Λ/-(3-Chloro-4-(3-cyanopyridin-2-yloxy)phenyl)picolinamide iV-(4-(4-Benzylpiperazin- 1 -yl)-3-chlorophenyl)pico linamide DEFINITION OF TERMS
Listed below are definitions of various terms used in the specification and claims to describe the present invention. For the avoidance of doubt it is to be understood that in this specification "(C1-C6)" means a carbon radical having 1, 2, 3, 4, 5 or 6 carbon atoms. "(C0-C6)" means a carbon radical having 0, 1, 2, 3, 4, 5 or 6 carbon atoms. In this specification "C" means a carbon atom, "N" means a nitrogen atom, "O" means an oxygen atom and "S" means a sulphur atom. In the case where a subscript is the integer 0 (zero) the radical to which the subscript refers, indicates that the radical is absent, i.e. there is a direct bond between the radicals.
In this specification, unless stated otherwise, the term "bond" refers to a saturated covalent bond. When two or more bonds are adjacent to one another, they are assumed to be equal to one bond. For example, a radical -A-B-, wherein both A and B may be a bond, the radical is depicting a single bond.
In this specification, unless stated otherwise, the term "alkyl" includes both straight and branched chain alkyl radicals and may be methyl, ethyl, n-propyl, i-propyl, n-butyl, i- butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, t-pentyl, neo-pentyl, n-hexyl, i-hexyl or t- hexyl. The term "(Co-C3)alkyl" refers to an alkyl radical having 0, 1, 2 or 3 carbon atoms and may be methyl, ethyl, n-propyl and i-propyl.
In this specification, unless stated otherwise, the term "cycloalkyl" refers to an optionally substituted carbocycle containing no heteroatoms, including mono-, bi-, and tricyclic saturated carbocycles, as well as fused ring systems. Such fused ring systems can include one ring that is partially or fully unsaturated such as a benzene ring to form fused ring systems such as benzo- fused carbocycles. Cycloalkyl includes such fused ring systems as spirofused ring systems. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, decahydronaphthalene, adamantane, indanyl, fluorenyl and 1,2,3,4-tetrahydronaphthalene and the like. The term "(C3-Cv)cycloalkyl" may be cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. The term "aryl" refers to an optionally substituted monocyclic or bicyclic hydrocarbon ring system containing at least one unsaturated aromatic ring. Examples and suitable values of the term "aryl" are phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, indyl, indenyl and the like.
In this specification, unless stated otherwise, the term "heteroaryl" refers to an optionally substituted monocyclic or bicyclic unsaturated, aromatic ring system containing at least one heteroatom selected independently from N, O or S. Examples of "heteroaryl" may be, but are not limited to thienyl, pyridyl, thiazolyl, isothiazolyl, furyl, pyrrolyl, triazolyl, imidazolyl, oxadiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolonyl, oxazolonyl, thiazolonyl, tetrazolyl, thiadiazolyl, benzoimidazolyl, benzooxazolyl, benzothiazolyl, tetrahydrotriazolopyridyl, tetrahydrotriazolopyrimidinyl, benzofuryl, benzothiophenyl, thionaphthyl, indolyl, isoindolyl, pyridonyl, pyridazinyl, pyrazinyl, pyrimidinyl, quinolyl, phtalazinyl, naphthyridinyl, quinoxalinyl, quinazolyl, imidazopyridyl, oxazolopyridyl, thiazolopyridyl, imidazopyridazinyl, oxazolopyridazinyl, thiazolopyridazinyl, cynnolyl, pteridinyl, furazanyl, benzotriazolyl, pyrazolopyridinyl and purinyl.
In this specification, unless stated otherwise, the term "alkylaryl", "alkylheteroaryl" and "alky lcyclo alky 1" refers respectively to a substituent that is attached via the alkyl radical to an aryl, heteroaryl or cycloalkyl radical, respectively. The term "(Ci-C6)alkylaryl" includes aryl-Ci-Cβ-alkyl radicals such as benzyl, 1-phenylethyl, 2-phenylethyl, 1- phenylpropyl, 2-phenylpropyl, 3-phenylpropyl, 1-naphthylmethyl and 2- naphthylmethyl. The term "(Ci-C6)alkyheteroaryl" includes heteroaryl-Ci-Cβ-alkyl radicals, wherein examples of heteroaryl are the same as those illustrated in the above definition, such as 2-furylmethyl, 3-furylmethyl, 2-thienylmethyl, 3-thienylmethyl, 1- imidazolylmethyl, 2-imidazolylmethyl, 3-imidazolylmethyl, 2-oxazolylmethyl, 3- oxazolylmethyl, 2-thiazolylmethyl, 3-thiazolylmethyl, 2-pyridylmethyl, 3- pyridylmethyl, 4-pyridylmethyl, 1-quinolylmethyl or the like.
In this specification, unless stated otherwise, the term "heterocycle" refers to an optionally substituted, monocyclic or bicyclic saturated, partially saturated or unsaturated ring system containing at least one heteroatom selected independently from N, O and S.
In this specification, unless stated otherwise, a 5- or 6-membered ring containing one or more atoms independently selected from C, N, O and S, includes aromatic and heteroaromatic rings as well as carbocyclic and heterocyclic rings which may be saturated or unsaturated. Examples of such rings may be, but are not limited to, furyl, isoxazolyl, isothiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, thiazolyl, thienyl, imidazolyl, imidazolidinyl, imidazolinyl, triazolyl, morpholinyl, piperazinyl, piperidyl, piperidonyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl, tetrahydrothiopyranyl, oxazolidinonyl, thiomorpholinyl, oxadiazolyl, thiadiazolyl, tetrazolyl, phenyl, cyclohexyl, cyclopentyl, cyclohexenyl and cyclopentenyl.
In this specification, unless stated otherwise, a 3- to 10-membered ring containing one or more atoms independently selected from C, N, O and S, includes aromatic and heteroaromatic rings as well as carbocyclic and heterocyclic rings which may be saturated or unsaturated. Examples of such rings may be, but are not limited to imidazolidinyl, imidazolinyl, morpholinyl, piperazinyl, piperidyl, piperidonyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl, thiomorpholinyl, tetrahydrothiopyranyl, furyl, pyrrolyl, isoxazolyl, isothiazolyl, oxazolyl, oxazolidinonyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, thiazolyl, thienyl, imidazolyl, triazolyl, phenyl, cyclopropyl, aziridinyl, cyclobutyl, azetidinyl, oxadiazolyl, thiadiazolyl, tetrazolyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl and cyclooctenyl.
In this specification, unless stated otherwise, the term "halo" or "halogen" may be fluoro, chloro, bromo or iodo.
In this specification, unless stated otherwise, the term "alkylhalo" means an alkyl radical as defined above, substituted with one or more halo radicals. The term "(Ci- C6)alkylhalo" may include, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl and difluoroethyl. The term "O-Ci-Cβ-alkylhalo" may include, but is not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy and fluoroethoxy.
In this specification, unless stated otherwise, the term "alkylcyano" means an alkyl radical as defined above, substituted with one or more cyano.
In this specification, unless stated otherwise, the term "optionally substituted" refers to radicals further bearing one or more substituents which may be, but are not limited to, (Ci-C6)alkyl, hydroxy, (Ci-C6)alkyloxy, mercapto, aryl, heterocycle, halogen, trifluoromethyl, pentafluoroethyl, cyano, cyanomethyl, nitro, amino, amido, amidinyl, carboxyl, carboxamide,
Figure imgf000025_0001
carbamate, sulfonamide, ester and sulfonyl.
In this specification, unless stated otherwise, the term "solvate" refers to a complex of variable stoichiometry formed by a solute (e.g. a compound of Formula (I)) and a solvent. The solvent is a pharmaceutically acceptable solvent as preferably water; such solvent may not interfere with the biological activity of the solute.
In this specification, unless stated otherwise, the term "positive allosteric modulator of mGluR4" or "allosteric modulator of mGluR4" refers also to a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof and an JV-oxide form thereof.
PHARMACEUTICAL COMPOSITIONS
Allosteric modulators of mGluR4 described herein, and the pharmaceutically acceptable salts, solvates and hydrates thereof can be used in pharmaceutical preparations in combination with a pharmaceutically acceptable carrier or diluent. Suitable pharmaceutically acceptable carriers include inert solid fillers or diluents and sterile aqueous or organic solutions. The allosteric modulators of mGluR4 will be present in such pharmaceutical compositions in amounts sufficient to provide the desired dosage amount in the range described herein. Techniques for formulation and administration of the compounds of the instant invention can be found in Remington: the Science and Practice of Pharmacy, 19th edition, Mack Publishing Co., Easton, PA (1995).
The amount of allosteric modulators of mGluR4, administered to the subject will depend on the type and severity of the disease or condition and on the characteristics of the subject, such as general health, age, sex, body weight and tolerance to drugs. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. Effective dosages for commonly used CNS drugs are well known to the skilled person. The total daily dose usually ranges from about 0.05 - 2000 mg.
The present invention relates to pharmaceutical compositions which provide from about 0.01 to 1000 mg of the active ingredient per unit dose. The compositions may be administered by any suitable route. For example orally in the form of capsules, etc ., parenterally in the form of solutions for injection, topically in the form of onguents or lotions, ocularly in the form of eye-drops, rectally in the form of suppositories, intranasally or transcutaneously in the form of delivery system like patches.
For oral administration, the allosteric modulators of mGluR4 thereof can be combined with a suitable solid or liquid carrier or diluent to form capsules, tablets, pills, powders, syrups, solutions, suspensions and the like.
The tablets, pills, capsules, and the like contain from about 0.01 to about 99 weight percent of the active ingredient and a binder such as gum tragacanth, acacias, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid, a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin. When a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.
Various other materials may be present as coatings or to modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.
For parenteral administration the disclosed allosteric modulators of mGluR4 can be combined with sterile aqueous or organic media to form injectable solutions or suspensions. For example, solutions in sesame or peanut oil, aqueous propylene glycol and the like can be used, as well as aqueous solutions of water-soluble pharmaceutically-acceptable salts of the compounds. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
In addition, to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation, for example, subcutaneously or intramuscularly or by intramuscular injection. Thus, for example, as an emulsion in an acceptable oil, or ion exchange resins, or as sparingly soluble derivatives, for example, as sparingly soluble salts.
Preferably disclosed allosteric modulators of mGluR4 or pharmaceutical formulations containing these compounds are in unit dosage form for administration to a mammal. The unit dosage form can be any unit dosage form known in the art including, for example, a capsule, an IV bag, a tablet, or a vial. The quantity of active ingredient in a unit dose of composition is an effective amount and may be varied according to the particular treatment involved. It may be appreciated that it may be necessary to make routine variations to the dosage depending on the age and condition of the patient. The dosage will also depend on the route of administration which may be by a variety of routes including oral, aerosol, rectal, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal and intranasal.
METHODS OF SYNTHESIS
The compounds according to the invention, in particular the compounds according to the Formula (I), (I-a), (I-b), (I-c) and (I-d), may be prepared by methods known in the art of organic synthesis as set forth in part by the following synthesis schemes. In all of the schemes described below, it is well understood that protecting groups for sensitive or reactive groups are employed where necessary in accordance with general principles of chemistry. Protecting groups are manipulated according to standard methods of organic synthesis (Green T. W. and Wuts P.G.M. (1991) Protecting Groups in Organic Synthesis, John Wiley & Sons). These groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art. The selection of process as well as the reaction conditions and order of their execution shall be consistent with the preparation of compounds of Formula (I), (I-a), (I-b), (I-c) and (I-d).
The compounds according to the invention may be represented as a mixture of enantiomers, which may be resolved into the individual pure R- or S-enantiomers. If for instance, a particular enantiomer is required, it may be prepared by asymmetric synthesis or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers. Alternatively, where the molecule contains a basic functional group such as an amino or an acidic functional group such as carboxyl, this resolution may be conveniently performed by fractional crystallization from various solvents as the salts of an optical active acid or by other methods known in the literature (e.g. chiral column chromatography).
Resolution of the final product, an intermediate or a starting material may be performed by any suitable method known in the art (Eliel EX., Wilen S.H. and Mander L.N. (1984) Stereochemistry of Organic Compounds, Wiley-Interscience).
Many of the heterocyclic compounds of the invention can be prepared using synthetic routes well known in the art (Katrizky A.R. and. Rees CW. (1984) Comprehensive Heterocyclic Chemistry, Pergamon Press).
The product from the reaction can be isolated and purified employing standard techniques, such as extraction, chromatography, crystallization and distillation.
The compounds of the invention may be prepared by general route of synthesis as disclosed in the following methods. In one embodiment of the present invention compounds of Formula (I) may be prepared according to the synthetic sequences illustrated in Scheme 1. Acid chloride gl can be generated from carboxylic acid g3 in the presence of a reagent such as thionyl chloride or oxalyl chloride. Then gl may be coupled with the primary amine g2 in the presence of a base such as Et3N or DIEA in a suitable solvent.
Figure imgf000029_0001
Scheme 1
Amide g4 can also be obtained from the reaction of carboxylic acid g3 and the primary amine g2 (Scheme 1). The reaction may be promoted by a coupling agent known in the art of organic synthesis such as EDCI (l-(3-dimethylaminopropyl)-3- ethylcarbodiimide), in a suitable solvent (e.g. THF, DCM, DMF). Typically, a co- catalyst such as HOBT (hydroxybenzotriazole) will also be present in the reaction mixture. The reaction typically proceeds at ambient temperature for a time in the range of about 4 up to 12 hours. For a person skilled in the art of organic chemistry it is well understood that amide g5 can be alkylated using either B2X (where X is Cl, Br or I) in the presence of a base such as K2CO3, Cs2CO3 or NaH in a suitable solvent such as acetone, DMF or THF to yield g6 (Scheme 2).
Alkylatlon,
Figure imgf000029_0002
Figure imgf000029_0003
Scheme 2
In another embodiment of the present invention compounds of Formula (I-b) may be prepared according to the synthetic sequences illustrated in Scheme 3. p-Nitro-phenoxy gll can be obtained from substitution on fluorophenyl g7 by hydroxyl compounds like g8 or by/?-nitrophenol g9 on bromide compounds glO in the presence of a base such as CS2CO3. Then compound gll can be reduced in the presence of iron or zinc in acetic acid to yield the primary amine gl2. Finally, gl2 can then be coupled to acid chloride as exemplified earlier in Scheme 1.
Reduction Step 2
Figure imgf000030_0001
Figure imgf000030_0002
Scheme 3
In another embodiment of the present invention compounds of Formula (I-c) may be prepared according to the synthetic sequences illustrated in Scheme 4. Piperazine gl4 can be acylated under standard conditions in the presence of acid chloride. Then compound gl6 can be reduced under standard hydrogenation conditions with Pt/C in primary amine gl7. Finally, gl7 can then be coupled to acid chloride as exemplified earlier in Scheme 1.
steP 1 1 Reduction R5 Coupling Step 2
Figure imgf000030_0004
Figure imgf000030_0003
Figure imgf000030_0005
Scheme 4
In another embodiment of the present invention compounds of Formula (I-c) may be prepared according to the synthetic sequences illustrated in Scheme 5. Piperazine gl4 can be protected by (BoC)2O, then reduced with Pt/C and coupled with acid chloride under conditions well known for a person skilled in the art. After deprotection under acidic conditions, the secondary amine g22 can finally be acylated either by acid chloride or carboxylic acid as exemplified earlier in Scheme 1.
Figure imgf000031_0001
Scheme 5
EXPERIMENTAL
Unless otherwise noted, all starting materials were obtained from commercial suppliers and used without further purification.
Specifically, the following abbreviations may be used in the examples and throughout the specification.
Figure imgf000031_0002
All references to brine refer to a saturated aqueous solution of NaCl. Unless otherwise indicated, all temperatures are expressed in 0C (degrees Centigrade). All reactions are conducted not under an inert atmosphere at room temperature unless otherwise noted.
Most of the reaction were monitored by thin-layer chromatography on 0.25mm Merck silica gel plates (60F-254), visualized with UV light. Flash column chromatography was performed on prepacked silica gel cartridges (15-40 μM, Merck). Melting point determination was performed on a Buchi B-540 apparatus.
EXAMPLES
EXAMPLE 1: 7V-(3-Methoxyphenyl)thiophene-2-carboxamide (Final Compound 2-
1)
Thiophene-2-carbonyl chloride
According to Scheme 1 Step 1 : Thiophene-2-carboxylic acid (31.2 mmol, 4.00 g) was slowly added to a solution of thionyl chloride (56.2 mmol, 4.08 mL). The reaction mixture was stirred at room temperature for 1 hour. After evaporation of the thionyl chloride, the crude product was purified by bulb-to-bulb distillation (850C, 14 Torr) to yield thiophene-2-carbonyl chloride (23.7 mmol, 3.48 g, 76%) as a colorless liquid.
N-(3-methoxyphenyl)thiophene-2-carboxamide According to Scheme 1 Method A: A solution of thiophene-2-carbonyl chloride (2.92 mmol, 0.31 mL) in DCM (1 mL) was added to solution of 3 -methoxy aniline (2.44 mmol, 0.27 mL) and DIEA (4.87 mmol, 0.87 mL) in DCM (4 mL) at 00C. The reaction mixture was stirred at room temperature for 1 hour. The organic phase was washed with HCl 1 M solution, then with a saturated solution of NaHCCh, was dried over MgSO4, was filtered and was concentrated under reduced pressure to yield N-(3- methoxyphenyl)thiophene-2-carboxamide (1.71 mmol, 0.40 g, 70%) as a white solid. Mp.: 139-145°C;
LC (Zorbax SB-Ci8, 3.5μm, 4.6x30mm Column): RT = 3.80 min; MS m/z ES+= 234.
EXAMPLE 2: 7V-(3-Methoxyphenyl)picolinamide (Final Compound 2-3)
According to Scheme 1 Method B: 3-Methoxyaniline (1.62 mmol, 0.18 mL) was added to a solution of picolinic acid (1.62 mmol, 0.20 g), EDCLHCl (2.44 mmol, 0.47 g), Et3N (3.25 mmol, 0.45 mL), hydroxybenzotriazole (1.95 mmol, 0.30 g) in DCM (6 mL) at room temperature. The reaction mixture was stirred at 500C for 12 hours. The organic phase was washed with a saturated solution OfNaHCO3 and with brine, was dried over MgSO4, was filtered and was concentrated under reduced pressure. The crude product was purified by flash chromatography over silica gel using cyclohexane/ AcOEt (90:10) as eluent to afford JV-(3-methoxyphenyl)picolinamide (1.46 mmol, 0.33 g, 90%) as an orange liquid.
LC (Zorbax SB-Ci8, 3.5μm, 4.6x30mm Column): RT = 3.94 min; MS m/z ES+= 229.
EXAMPLE 3: 7V-(3-(2-(2-Methoxyphenyl)-2-oxoethoxy)phenyl)picolinamide (Final Compound 2-9)
N-(3-Hydroxyphenyl)picolinamide
According to Example 2: The title compound was prepared from 3-aminophenol (18.0 mmol, 2.00 g). Reaction conditions: 12 hours at 500C. 1.7 g (7.9 mmol, 43%) of iV-(3- hydroxyphenyl)picolinamide were obtained.
LC (Zorbax SB-Ci8, 3.5μm, 4.6x30mm Column): RT = 1.74 min; MS m/z ES+= 215.
N- (3- (2- (2-Methoxyphenyl)-2-oxoethoxy)phenyl)picolinamide
According to Scheme 2: K2CO3 (2.33 mmol, 323 mg) and 2-bromo-l-(2- methoxyphenyl)ethanone (0.47 mmol, 107 mg) were added sequentially to a solution of N-(3-hydroxyphenyl)picolinamide (0.47 mmol, 100 mg) in acetone (3 mL). The reaction mixture was stirred at 500C for 14 hours. After filtration and evaporation, the crude product was diluted with water and with DCM. The organic phase was washed with brine, was dried over MgSO4, was filtered and was concentrated under reduced pressure. The crude product was triturated with Et2O to obtain N-(3-(2-(2- methoxyphenyl)-2-oxoethoxy)phenyl)picolinamide (0.26 mmol, 94 mg, 55%) as a yellow solid. Mp.: 136-137°C;
LC (Zorbax SB-Ci8, 3.5μm, 4.6x30mm Column): RT = 2.67 min; MS m/z ES+= 363.
EXAMPLE 4: 7V-(3-Chloro-4-(3-chlorophenoxy)phenyl)picolinamide (Final Compound 3-11)
2-Chloro-l-(3-chlorophenoxy)-4-nitrobenzene
According to Scheme 3 Step 1, Method A: 2-Chloro-l-fluoro-4-nitrobenzene (1.12 mmol, 0.20 g) was added to a suspension of 3-chlorophenol (1.02 mmol, 0.10 mL),
Cs2CO3 (1.25 mmol, 407 mg) in DMF/ACN (40:60, 3.6 mL). The reaction mixture was stirred at room temperature overnight. The reaction mixture was quenched with water. The aqueous phase was extracted with AcOEt. The organic phase was washed with brine, was dried over MgSO4, was filtered and was concentrated under reduced pressure. The crude product was used without further purification to obtain 2-chloro-l- (3-chlorophenoxy)-4-nitrobenzene (1.02 mmol, 288 mg, 100%) as an orange solid.
LC (Zorbax SB-Ci8, 3.5μm, 4.6x30mm Column): RT = 3.22 min.
3-Chloro-4-(3-chlorophenoxy)aniline
According to Scheme 3 Step 2: A suspension of iron (5.07 mmol, 283 mg), acetic acid (1.22 mmol, 70 μL) and of 2-chloro-l-(3-chlorophenoxy)-4-nitrobenzene (1.02 mmol, 288 mg) in water/EtOH (1 :1, 8 mL) was stirred at 800C for 30 minutes. After evaporation of EtOH, the aqueous phase was basified with a saturated solution of NaHCOs and was extracted with AcOEt. The organic phase was washed with brine, was dried over MgSO4, was filtered and was concentrated under reduced pressure to yield 3- chloro-4-(3-chlorophenoxy)aniline (1.02 mmol, 258 mg, 100%) as a solid. The product was used without further purification.
LC (Zorbax SB-Ci8, 3.5μm, 4.6x30mm Column): RT = 2.77 min; MS m/z ES+= 254.
N-(3-Chloro-4-(3-chlorophenoxy)phenyl)picolinamide According to Scheme 3 Step 3: Pico lino yl chloride hydrochloride (1.52 mmol, 271 mg) and Et3N (3.05 mmol, 0.42 mL) were added sequentially to a solution of 3-chloro-4-(3- chlorophenoxy)aniline (1.02 mmol, 258 mg) in DCM (6 mL) at 00C. The reaction mixture was stirred at room temperature for 2 hours. The organic phase was washed with a saturated solution of NaHCO3 and with brine, was dried over MgSO4, was filtered and was concentrated under reduced pressure. The crude product was purified by flash chromatography over silica gel using cyclohexane/ AcOEt (90:10) as eluent to afford Λ/-(3-chloro-4-(3-chlorophenoxy)phenyl)picolinamide (0.52 mmol, 187 mg, 51%) as a white solid. M.p.: 91.5-93.5°C; LC (Zorbax SB-Ci8, 3.5μm, 4.6x30mm Column): RT = 2.45 min; MS m/z ES+= 357. EXAMPLE 5: 7V-(3-Methoxy-4-(pyrimidin-2-yloxy)phenyl)picolinamide (Final Compound 3-9)
2-(2-Methoxy-4-nitrophenoxy)pyrimidine
According to Scheme 3 Step 1 Method B: 2-Bromopyrimidine (1.26 mmol, 211 mg) was added to a suspension of 2-methoxy-4-nitrophenol (1.15 mmol, 200 mg), CS2CO3
(1.41 mmol, 460 mg) in DMF (3 mL). The reaction mixture was stirred at 8O0C for 3 days. The reaction mixture was quenched with water. The aqueous phase was extracted with AcOEt. The organic phase was washed with brine, was dried over MgSO4, was filtered and was concentrated under reduced pressure. The crude product was washed with a solution of NaOH 3M and dried to obtain 2-(2-methoxy-4- nitrophenoxy)pyrimidine (0.89 mmol, 220 mg, 78%) as a solid. The product was used without further purifcation.
LC (Zorbax SB-Ci8, 3.5μm, 4.6x30mm Column): RT = 1.89 min; MS m/z ES+= 248.
3-Methoxy-4-(pyrimidin-2-yloxy)aniline
According to Scheme 3 Step 2: A suspension of iron (4.45 mmol, 248 mg), acetic acid (1.07 mmol, 61 μL) and of 2-(2-methoxy-4-nitrophenoxy)pyrimidine (0.89 mmol, 220 mg) in water/EtOH (1 :1, 7 mL) was stirred at 8O0C for 30 minutes. After evaporation of EtOH, the aqueous phase was basified with a saturated solution of NaHCO3 and was extracted with AcOEt. The organic phase was washed with brine, was dried over MgSO4, was filtered and was concentrated under reduced pressure to yield 3-methoxy- 4-(pyrimidin-2-yloxy)aniline (0.89 mmol, 193 mg, 100%) as an oil. The product was used without further purification.
LC (Zorbax SB-Ci8, 3.5μm, 4.6x30mm Column): RT = 0.56 min; MS m/z ES+= 218.
N- (3-Methoxy-4- (pyrimidin-2-yloxy)phenyl)picolinamide
According to Scheme 3 Step 3: Pico lino yl chloride hydrochloride (1.33 mmol, 256 mg) and Et3N (2.67 mmol, 0.37 mL) were added sequentially to a solution of 3-methoxy-4- (pyrimidin-2-yloxy)aniline (0.89 mmol, 193 mg) in DCM (3 mL) at 00C. The reaction mixture was stirred at room temperature for 2 hours. The organic phase was washed with a saturated solution Of NaHCO3. The aqueous phase was extracted with AcOEt. The organic phase was washed with brine, was dried over MgSO4, was filtered and was concentrated under reduced pressure. The crude product was purified by flash chromatography over Ci 8 column using water/ ACN (70:30) as eluent to afford N-(3- methoxy-4-(pyrimidin-2-yloxy)phenyl)picolinamide (0.17 mmol, 55 mg, 19%) as a white solid. Mp.: 203-2050C;
LC (Zorbax SB-Ci8, 3.5μm, 4.6x30mm Column): RT = 1.87 min; MS m/z ES+= 323.
EXAMPLE 6: 7V-(3-Chloro-4-(4-isobutyrylpiperazin-l-yl)phenyl)picolinamide (Final Compound 4-2) l-(4-(2-Chloro-4-nitrophenyl)piperazin-l-yl)-2-methylpropan-l-one
According to Scheme 4 Step 1 : Isobutyryl chloride (1.24 mmol, 0.13 mL) and EtsN (2.48 mmol, 0.35 mL) were added to a solution of l-(2-chloro-4-nitrophenyl)piperazine (0.83 mmol, 200 mg) in DCM (5 mL) at 00C. The reaction mixture was stirred at room temperature for 2 hours. The organic phase was washed with a saturated solution of NaHCOs. The aqueous phase was extracted with AcOEt. The organic phase was washed with brine, was dried over Na2SO4, was filtered and was concentrated under reduced pressure to afford l-(4-(2-chloro-4-nitrophenyl)piperazin-l-yl)-2-methylpropan-l-one (0.83 mmol, 261 mg, 100%). The product was used without further purification.
LC (Zorbax SB-Ci8, 3.5μm, 4.6x30mm Column): RT = 2.48 min; MS m/z ES+= 312.
l-(4-(4-Amino-2-chlorophenyl)piperazin-l-yl)-2-methylpropan-l-one
According to Scheme 4 Step 2: A solution of l-(4-(2-chloro-4-nitrophenyl)piperazin-l- yl)-2-methylpropan-l-one (0.62 mmol, 195 mg) in EtOH (120 mL) was passed through a Pt/C 5% column in an H-Cube equipment (mode: Full). Then the solution was concentrated under reduced pressure to yield l-(4-(4-amino-2-chlorophenyl)piperazin-l- yl)-2-methylpropan-l-one (0.62 mmol, 175 mg, 99%). The product was used without further purification.
LC (Zorbax SB-Ci8, 3.5μm, 4.6x30mm Column): RT = 1.56 min; MS m/z ES+= 282. N-(3-Chloro-4-(4-isobutyrylpiperazin-l-yl)phenyl)picolinamide
According to Scheme 4 Step 3: Pico lino yl chloride hydrochloride (0.93 mmol, 178 mg) and Et3N (1.86 mmol, 0.26 mL) were added to a solution of l-(4-(4-amino-2- chlorophenyl)piperazin-l-yl)-2-methylpropan-l-one (0.62 mmol, 175 mg) in DCM (3 mL) at 00C. The reaction mixture was stirred at room temperature for 2 hours. The organic phase was washed with a saturated solution Of NaHCO3. The aqueous phase was extracted with AcOEt. The organic phase was washed with brine, was dried over Na2SO4, was filtered and was concentrated under reduced pressure. The crude product was purified by flash chromatography over C18 column using water/ACN (60:40) as eluent to afford Λ/-(3-chloro-4-(4-isobutyrylpiperazin-l-yl)phenyl)picolinamide (0.11 mmol, 42 mg, 18%) as a white solid.
Mp.: 156-158°C;
LC (Zorbax SB-Ci8, 3.5μm, 4.6x30mm Column): RT = 2.50 min; MS m/z ES+= 387.
EXAMPLE 7: 7V-(3-Chloro-4-(4-propionylpiperazin-l-yl)phenyl)picolinamide (Final Compound 4-3) tert-Butyl 4-(2-chloro-4-nitrophenyl)piperazine-l-carboxylate
According to Scheme 5 Step 1 : A solution of l-(2-chloro-4-nitrophenyl)piperazine (2.90 mmol, 700 mg), BoC2O (3.19 mmol, 0.96 mL), Et3N (3.48 mmol, 0.49 mL) and of DMAP (0.29 mmol, 35 mg) in DCM (5 mL) was stirred at room temperature overnight. The organic phase was washed once with HCl 0.1 M, once with water, once with brine, was dried over Na2SO4, was filtered and was concentrated under reduced pressure to afford tert-butyl 4-(2-chloro-4-nitrophenyl)piperazine-l-carboxylate (2.50 mmol, 854 mg, 86%). The product was used without further purification. LC (Zorbax SB-Ci8, 3.5μm, 4.6x30mm Column): RT = 3.19 min; MS m/z ES+= 342.
tert-Butyl 4-(4-amino-2-chlorophenyl)piperazine-l-carboxylate
According to Scheme 5 Step 2: A solution of tert-butyl 4-(2-chloro-4- nitrophenyl)piperazine-l-carboxylate (2.50 mmol, 854 mg) in EtOH (450 mL) was passed through a Pt/C 5% column in an H-Cube equipment (mode: Full). Then the solution was concentrated under reduced pressure to yield tert-butyl 4-(4-amino-2- chlorophenyl)piperazine-l-carboxylate (2.46 mmol, 766 mg, 98%). The product was used without further purification.
LC (Zorbax SB-Ci8, 3.5μm, 4.6x30mm Column): RT = 2.37 min; MS m/z ES+= 312.
tert-Butyl 4-(2-chloro-4-(picolinamido)phenyl)piperazine-l-carboxylate
According to Scheme 5 Step 3: Pico lino yl chloride hydrochloride (3.68 mmol, 656 mg) and Et3N (7.37 mmol, 1.03 mL) were added to a solution of tert-bvXy\ 4-(4-amino-2- chlorophenyl)piperazine-l-carboxylate (2.46 mmol, 766 mg) in DCM (40 mL) at 00C. The reaction mixture was stirred at room temperature for 1 hour. The organic phase was washed with a saturated solution Of NaHCO3. The aqueous phase was extracted with AcOEt. The organic phase was washed with brine, was dried over Na2SO4, was filtered and was concentrated under reduced pressure to afford tert-bvXy\ 4-(2-chloro-4- (picolinamido)phenyl)piperazine-l-carboxylate (2.46 mmol, 1.02 g, 100%).
LC (Zorbax SB-Ci8, 3.5μm, 4.6x30mm Column): RT = 3.19 min; MS m/z ES+= 417.
N-(3Chloro-4-(piperazin-l-yl)phenyl)picolinamide
According to Scheme 5 Step 4: HCl 4 M in dioxane (12.3 mmol, 3.07 mL) was added to a solution of tert-hvXy\ 4-(2-chloro-4-(picolinamido)phenyl)piperazine-l-carboxylate (2.46 mmol, 1.02 g) in DCM (10 mL). The reaction mixture was stirred at room temperature overnight. After evaporation, DCM was added and then a NaOH 1 M solution. The aqueous phase was extracted with DCM. The organic phase was washed with brine, was dried over MgSO4, was filtered and was concentrated under reduced pressure. The crude product was purified by flash chromatography over silica gel using cyclohexane/AcOEt (60:40) as eluent to afford 7V-(3-chloro-4-(piperazin-l- yl)phenyl)picolinamide (0.97 mmol, 308 mg, 40%) as an orange solid.
LC (Zorbax SB-Ci8, 3.5μm, 4.6x30mm Column): RT = 1.41 min; MS m/z ES+= 317.
N-(3-Chloro-4-(4-propionylpiperazin-l-yl)phenyl)picolinamide
According to Scheme 5 Step 5 Method A: A solution of JV-(3-chloro-4-(piperazin-l- yl)phenyl)picolinamide (0.19 mmol, 60 mg), propionic acid (0.19 mmol, 14 μL),
EDCLHCl (0.28 mmol, 54 mg), Et3N (0.38 mmol, 53 μL) and of hydroxybenzotriazole (0.21 mmol, 32 mg) in DCM (5 niL) was stirred at room temperature for 1 day. The solution was quenched with water. The aqueous phase was extracted with DCM. The organic phase was washed with brine, was dried over Na2SO4, was filtered and was concentrated under reduced pressure. The solid was triturated with water and finally with iPr2O to afford Λ/-(3-chloro-4-(4-propionylpiperazin-l-yl)phenyl)picolinamide (0.14 mmol, 51 mg, 72%) as a yellow solid.
Mp.: 176-179°C;
LC (Zorbax SB-Ci8, 3.5μm, 4.6x30mm Column): RT = 2.35 min; MS m/z ES+= 373.
EXAMPLE 8: 7V-(4-(4-Benzylpiperazin-l-yl)-3-chlorophenyl)picolinamide (Final Compound 4-5)
According to Scheme 5 Step 5 Method B: A suspension of (bromomethyl)benzene (0.61 mmol, 74 μL), Λ/-(3-chloro-4-(piperazin-l-yl)phenyl)picolinamide (0.51 mmol, 161 mg) and Of K2CO3 (0.51 mmol, 70 mg) in ACN (3 mL) was stirred at 800C for 30 minutes. After evaporation of the solvent, water and AcOEt were added. The aqueous phase was extracted with AcOEt. The organic phase was washed with brine, was dried over Na2SO4, was filtered and was concentrated under reduced pressure. The crude product was purified by flash chromatography over silica gel using DCM/ AcOEt (80:20) as eluent and finally crystallized in pentane to obtain 7V-(4-(4-benzylpiperazin-l-yl)-3- chlorophenyl)picolinamide (0.98 mmol, 40 mg, 20%) as a white solid.
Mp.: 92-94°C;
LC (Zorbax SB-Ci8, 3.5μm, 4.6x30mm Column): RT = 1.99 min; MS m/z ES+= 407.
The compounds in the following Tables have been synthezised according to the same method as previous examples 1 to 5, as denoted in the column denoted as "Exp. nr". The compounds denoted with the asterisk have been exemplified in the Examples. Table 1: Compounds prepared according to the Examples.
Figure imgf000040_0001
Figure imgf000040_0003
Table 2: Compounds prepared according to the Examples.
Figure imgf000040_0004
Figure imgf000040_0002
Figure imgf000041_0001
Table 3: Compounds prepared according to the Examples.
Figure imgf000042_0001
Figure imgf000043_0001
Figure imgf000043_0003
Table 4: Compounds prepared according to the Examples.
Figure imgf000043_0002
Figure imgf000043_0004
Physico-Chemical Data LCMS-methods:
LCMS were recorded on a Waters Micromass ZQ 2996 system by the following conditions: Reversed phase HPLC was carried out on an Zorbax SB-C 18 cartridge (1.8 μm, 4.6 x 30 mm) from Agilent, with a flow rate of 1.5 ml/min. The gradient conditions used are: 90 % A (water + 0.05 % of formic acid), 10% B (acetonitrile + 0.05 % of formic acid) to 100 % B at 3.5 minutes, kept till 3.7 minutes and equilibrated to initial conditions at 3.8 minutes until 4.5 minutes. Injection volume 5-20 μL. ES MS detector was used, acquiring both in positive and negative ionization modes. Cone voltage was 30 V for both positive and negative ionization modes.
All mass spectra were taken under electrospray ionisation (ESI) methods.
Table 5: Physico-chemical data for some compounds (nd = not determined).
Figure imgf000044_0001
Figure imgf000045_0001
PHARMACOLOGY
The compounds provided in the present invention are positive allosteric modulators of mGluR4. As such, these compounds do not appear to bind to the orthosteric glutamate recognition site, and do not activate the mGluR4 by themselves. Instead, the response of mGluR4 to a concentration of glutamate or mGluR4 agonist is increased when compounds of Formula I, I-a-d are present. Compounds of Formula I, I-a-d are expected to have their effect at mGluR4 by virtue of their ability to enhance the function of the receptor.
mGluR4 assay on HEK-expressing human mGluR4
The compounds of the present invention are positive allosteric modulators of mGluR4 receptor. Their activity was examined on recombinant human mGluR4a receptors by detecting changes in intracellular Ca2+ concentration, using the fluorescent Ca2+-sensitive dye Fluo4-(AM) and a Fluorometric Imaging Plate Reader (FLIPR, Molecular Devices, Sunnyvale, CA)
Transfection and Cell culture
The cDNA encoding the human metabotropic glutamate receptor (hmGluR4), (accession number NM_000841.1, NCBI Nucleotide database browser), was subcloned into an expression vector containing also the hygromycin resistance gene. In parallel, the cDNA encoding a G protein allowing redirection of the activation signal to intracellular calcium flux was subcloned into a different expression vector containing also the puromycin resistance gene. Transfection of both these vectors into HEK293 cells with PolyFect reagent (Qiagen) according to supplier's protocol, and hygromycin and puromycin treatment allowed selection of antibiotic resistant cells which had integrated stably one or more copies of the plasmids. Positive cellular clones expressing hmGluR4 were identified in a functional assay measuring changes in calcium fluxes in in response to glutamate or selective known mGluR4 orthosteric agonists and antagonists HEK-293 cells expressing hmGluR4 were maintained in media containing DMEM, dialyzed Fetal Calf Serum (10 %), Glutamax™ (2 mM), Penicillin (100 units/ml), Streptomycin (100 μg/ml), Geneticin (100 μg/ml) and Hygromycin-B (40 μg/ml) and puromycin (1 μg/ml ) at 37°C/5%CO2.
Fluorescent cell based- Ca2+ mobilization assay
Human mGluR4 HEK-293 cells were plated out 24 hours prior to FLIPR384 assay in black-walled, clear-bottomed, poly-L-ornithine-coated 384-well plates at a density of 25,000 cells/well in a glutamine/glutamate free DMEM medium containing foetal bovine serum (10 %), penicillin (100 units/ml) and streptomycin (100 μg/ml) at 37 0C / 5 % CO2.
On the day of the assay, the medium was aspirated and the cells were loaded with a 3 μM solution of Fluo4-AM (LuBio Science, Lucerne, Switzerland) in 0.03 % pluronic acid. After 1 hour at 37°C/5% CO2, the non incorporated dye was removed by washing cell plate with the assay buffer and the cells were left in the dark at room temperature for six hours before testing. All assays were performed in a pH 7.4 buffered- solution containing 20 mM HEPES, 143 mM NaCl, 6 mM KCl, 1 mM MgSO4, 1 mM CaCl2, 0.125 mM sulfapyrazone, 0.1 % glucose. After 10 s of basal fluorescence recording, various concentrations of the compounds of the invention were added to the cells. Changes in fluorescence levels were first monitored for 180 s in order to detect any agonist activity of the compounds. Then the cells were stimulated by an EC25 glutamate concentration for an additional 110 s in order to measure enhancing activities of the compounds of the invention. EC25 glutamate concentration is the concentration giving 25 % of the maximal glutamate response.
The concentration-response curves of representative compounds of the present invention were generated using the Prism GraphPad software (Graph Pad Inc, San Diego, USA). The curves were fitted to a four-parameter logistic equation: (Y=Bottom + (Top-Bottom)/(l+10Λ((LogEC5o-X)*Hill Slope) allowing determination of EC50 values. The Table 6 below represents the mean EC50 obtained from at least three independent experiments of selected molecules performed in duplicate.
Table 6: Activity data for selected compounds
Figure imgf000048_0001
*Table legend:
(+): EC50 > 10 μM
(++): 1 μM < EC50 <10 μM
(+++): EC50 < 1 μM The results in Table 6 demonstrate that the compounds described in the present invention are positive allosteric modulators of human mGluR4 receptors. These compounds don't have activity by themselves but they rather increase the functional activity and/or maximal efficacy of glutamate or mGluR4 agonist.
Thus, the positive allosteric modulators provided in the present invention are expected to increase the effectiveness of glutamate or mGluR4 agonists at mGluR4 receptor. Therefore, these positive allosteric modulators are expected to be useful for treatment of various neurological and psychiatric disorders associated with glutamate dysfunction described to be treated herein and others that can be treated by such positive allosteric modulators.
FORMULATION EXAMPLES
Typical examples of recipes for the formulation of the invention are as follows:
1. Tablets
Active ingredient 5 to 50 mg
Di-calcium phosphate 20 mg
Lactose 30 mg Talcum 10 mg
Magnesium stearate 5 mg
Potato starch ad 200 mg
In this Example, active ingredient can be replaced by the same amount of any of the compounds according to the present invention, in particular by the same amount of any of the exemplified compounds.
2. Suspension
An aqueous suspension is prepared for oral administration so that each 1 milliliter contains 1 to 5 mg of one of the active compounds, 50 mg of sodium carboxymethyl cellulose, 1 mg of sodium benzoate, 500 mg of sorbitol and water ad 1 ml. 3. Injectable
A parenteral composition is prepared by stirring 1.5 % by weight of active ingredient of the invention in 10% by volume propylene glycol and water.
4. Ointment
Active ingredient 5 to 1000 mg Stearyl alcohol 3 g
Lanoline 5 g
White petroleum 15 g Water ad 100 g
In this Example, active ingredient can be replaced with the same amount of any of the compounds according to the present invention, in particular by the same amount of any of the exemplified compounds.
Reasonable variations are not to be regarded as a departure from the scope of the invention. It will be obvious that the thus described invention may be varied in many ways by those skilled in the art.

Claims

1. A compound according to the general Formula (I),
Figure imgf000051_0001
a pharmaceutically acceptable acid or base addition salt thereof, a stereochemical^ isomeric form thereof and an JV-oxide form thereof, wherein:
X1 is selected from the group of N, O and S and X2, X3 and X4 are each independently selected from the group of C, N, O, S and C=C representing a 5 or 6 membered heteroaryl ring which may further be substituted by 1 to 3 radicals Am;
m is an integer ranging from 1 to 3;
Am radicals are each independently selected from the group of hydrogen, halogen, -CN, -OH, -NO2, -CF3, -SH, -NH2 and an optionally substituted radical selected from the group of -(Ci-C6)alkyl, -(Ci-C6)alkylhalo, -(C3-C7)cycloalkyl, -(Ci-
Ce)alkylcyano, -(Ci-C6)alkylheteroaryl, -(Ci-C6)alkylaryl, aryl, heteroaryl, heterocycle, -(C0-C6)alkyl-OR1, -O-(C2-C6)alkyl-OR1, -NR1(C2-C6)alkyl-OR2, -
(C3-C7)cycloalkyl-(Ci-C6)alkyl, -O-(C3-C7)cycloalkyl-(Ci-C6)alkyl, -NR!-(C3- C7)cycloalkyl-(Ci-C6)alkyl, -(Ci-C6)alkylhalo-OR1, -(d-C6)alkylhalo-NR1R2, -
(Co-C6)alkyl-S-R1, -O-(C2-C6)alkyl-S-R1, -NR1-(C2-C6)alkyl-S-R2, -(C0-C6)alkyl-
S(O)-R1, -O-(Ci-C6)alkyl-S(=O)-R1, -NR1-(d-C6)alkyl-S(=O)-R2, -(C0-
C6)alkyl-S(=O)2-R1, -O-(Ci-C6)alkyl-S(=O)2-R1, -NR1-(Ci-C6)alkyl-S(=O)2-R2, -
(C0-C6)alkyl-NR1R2, -O-(C2-C6)alkyl-NR1R2, -NR1-(C2-C6)alkyl-NR2R3, -(C0- C6)alkyl-S(=O)2NR1R2, -O-(Ci-C6)alkyl-S(=O)2NR1R2, -NR1-(d-C6)alkyl-
S(=O)2NR2R3, -(Co-C6)alkyl-NR1-S(=0)2R2, -O-(C2-C6)alkyl-NR1-S(=O)2R2, -
NR1-(C2-C6)alkyl-NR2-S(=O)2R3, -(C0-C6)alkyl-C(=O)-NR1R2, -O-(d-C6)alkyl- CC=O)-NR1R2, -NR1-(Ci-C6)alkyl-C(=O)-NR2R3, -(C0-C6)alkyl-NR1C(=O)-R2, - O-(C2-C6)alkyl-NR1C(=O)-R2, -NR1-(C2-C6)alkyl-NR2C(=O)-R3, -(C0-C6)alkyl- OCC=O)-R1 , -O-(C2-C6)alkyl-OC(=O)-R1, -NR1-(C2-C6)alkyl-OC(=O)-R2, -(C0- C6)alkyl-C(=O)-OR1, -O-(d-C6)alkyl-C(=O)-OR1, -NR1-(d-C6)alkyl-C(=O)- OR2, -(Co-C6)alkyl-C(=0)-R1, -O-(d-C6)alkyl-C(=O)-R1, -NR1-(d-C6)alkyl-
C(=O)-R2, -(C0-C6)alkyl-NR1-C(=O)-OR2, -(C0-C6)alkyl-O-C(=O)-NR1R2, -(C0- C6)alkyl-NR1-C(=NR2)-NR3R4, -(C0-C6)alkyl-NR1-C(=O)-NR2R3, -0-(C2- C6)alkyl-NR1-C(=O)-NR2R3, -NR1-(C2-C6)alkyl-NR2-C(=O)-NR3R4 and -(C0- C6)alkyl-NR1-C(=S)-NR2R3; Any two radicals of Am (A1 and A2) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
R1, R2, R3 and R4 are each independently hydrogen or an optionally substituted radical selected from the group of -(Ci-Ce)alkylhalo, -(Ci-Ce)alkyl, -(C1- Ce)alkylcyano, -(C3-C7)cycloalkyl, -(C4-C io)alkylcycloalkyl, heteroaryl, -(C1- Ce)alkylheteroaryl, aryl, heterocycle and -(Ci-Ce)alkylaryl;
Any two radicals of R (R1, R2, R3 or R4) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
n is an integer ranging from 1 to 3;
Bn radicals are each independently selected from the group of hydrogen, halogen, -CN, -OH, -NO2, -CF3, -SH, -NH2 and an optionally substituted radical selected from the group of -(d-C6)alkyl, -(d-C6)alkylhalo, -(C3-C7)cycloalkyl, -(Ci- Ce)alkylcyano, -(Ci-C6)alkylheteroaryl, -(Ci-Ce)alkylaryl, aryl, heteroaryl, heterocycle, -(C0-C6)alkyl-OR5, -O-(C2-C6)alkyl-OR5, -NR5(C2-C6)alkyl-OR6, -
(C3-C7)cycloalkyl-(Ci-C6)alkyl, -O-(C3-C7)cycloalkyl-(d-C6)alkyl, -NR5-(C3- C7)cycloalkyl-(Ci-C6)alkyl, -(d-C6)alkylhalo-OR5, -(d-C6)alkylhalo-NR5R6, - (C0-C6)alkyl-S-R5, -O-(C2-C6)alkyl-S-R5, -NR5-(C2-C6)alkyl-S-R6, -(C0-C6)alkyl- S(=O)-R5, -O-(Ci-C6)alkyl-S(=O)-R5, -NR5-(d-C6)alkyl-S(=O)-R6, -(C0- C6)alkyl-S(=O)2-R5, -O-(d-C6)alkyl-S(=O)2-R5, -NR5-(d-C6)alkyl-S(=O)2-R6, -
(C0-C6)alkyl-NR5R6, -O-(C2-C6)alkyl-NR5R6, -NR5-(C2-C6)alkyl-NR6R7, -(C0- C6)alkyl-S(=O)2NR5R6, -O-(d-C6)alkyl-S(=O)2NR5R6, -NR5-(d-C6)alkyl- S(=O)2NR6R7, -(Co-C6)alkyl-NR5-S(=0)2R6, -O-(C2-C6)alkyl-NR5-S(=O)2R6, - NR5-(C2-C6)alkyl-NR6-S(=O)2R7, -(C0-C6)alkyl-C(=O)-NR5R6, -O-(d-C6)alkyl- C(=O)-NR5R6, -NR5-(Ci-C6)alkyl-C(=O)-NR6R7, -(C0-C6)alkyl-NR5C(=O)-R6, - O-(C2-C6)alkyl-NR5C(=O)-R6, -NR5-(C2-C6)alkyl-NR6C(=O)-R7, -(C0-C6)alkyl- OC(=O)-R5, -O-(C2-C6)alkyl-OC(=O)-R5, -NR5-(C2-C6)alkyl-OC(=O)-R6, -(C0-
C6)alkyl-C(=O)-OR5, -O-(d-C6)alkyl-C(=O)-OR5, -NR5-(d-C6)alkyl-C(=O)- OR6, -(C0-C6)alkyl-C(=O)-R5, -O-(d-C6)alkyl-C(=O)-R5, -NR5-(d-C6)alkyl- C(=O)-R6, -(C0-C6)alkyl-NR5-C(=O)-OR6, -(C0-C6)alkyl-O-C(=O)-NR5R6, -(C0- C6)alkyl-NR5-C(=NR6)-NR7R8, -(C0-C6)alkyl-NR5-C(=O)-NR6R7, -0-(C2- C6)alkyl-NR5-C(=O)-NR6R7, -NR5-(C2-C6)alkyl-NR6-C(=O)-NR7R8 and -(C0-
C6)alkyl-NR5-C(=S)-NR6R7;
Any two radicals of Bn (B1 and B2) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
R5, R6, R7 and R8 are each independently hydrogen or an optionally substituted radical selected from the group of -(Ci-Ce)alkylhalo, -(Ci-Ce)alkyl, -(C1-
Ce)alkylcyano, -(C3-C7)cycloalkyl, -(C4-C io)alkylcycloalkyl, heteroaryl, -(C1- Ce)alkylheteroaryl, aryl, heterocycle and -(Ci-C6)alkylaryl;
Any two radicals of R (R5, R6, R7 or R8) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring; provided that:
(i) Formula (I) Am x2'*1 can not be ; and provided that:
(ii) Formula (I) HHNN
Figure imgf000053_0002
"^L ^ ^B Rn" c „a„n„ n „o„t+ w „4h-.e™n-. B D1' i ;s„ N Λ.TRD 55RD 66 and
Figure imgf000053_0003
and provided that:
(iii) Formula (I)
Figure imgf000053_0005
not be
Figure imgf000053_0004
and provided that:
(iv) Formula (I) Am x2"χ1 can not be
Figure imgf000054_0001
; and provided that:
(v) when X1 is O or S and X2,X3 and X4 are C then in Formula (I)
HN v^©L ^B- can not be HN 4^Q^<B" R
2. A compound according to claim 1 having the Formula (I-a),
Figure imgf000054_0002
a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof and an TV-oxide form thereof, wherein:
X1 is selected from the group of N, O and S and X2, X3 and X4 are each independently selected from the group of C, N, O, S and C=C representing a 5 or 6 membered heteroaryl ring which may further be substituted by 1 to 3 radicals Am;
m is an integer ranging from 1 to 3;
Am radicals are each independently selected from the group of hydrogen, halogen, -CN, -OH, -NO2, -CF3, -SH, -NH2 and an optionally substituted radical selected from the group of -(Ci-C6)alkyl, -(Ci-C6)alkylhalo, -(C3-C7)cycloalkyl, -(Ci- Ce)alkylcyano, -(C1-C6)alkylheteroaryl, -(Ci-Ce)alkylaryl, aryl, heteroaryl, heterocycle, -(C0-C6)alkyl-OR1, -O-(C2-C6)alkyl-OR1, -NR1(C2-C6)alkyl-OR2, - (C3-C7)cycloalkyl-(Ci-C6)alkyl, -O-(C3-C7)cycloalkyl-(Ci-C6)alkyl, -NR!-(C3- C7)cycloalkyl-(Ci-C6)alkyl, -(Ci-C6)alkylhalo-OR1, -(Ci-C6)alkylhalo-NR1R2, - (Co-C6)alkyl-S-R1, -O-(C2-C6)alkyl-S-R1, -NR1-(C2-C6)alkyl-S-R2, -(C0-C6)alkyl- SC=O)-R1, -O-(Ci-C6)alkyl-S(=O)-R1, -NR1-(d-C6)alkyl-S(=O)-R2, -(C0- C6)alkyl-S(=O)2-R1, -O-(Ci-C6)alkyl-S(=O)2-R1, -NR1-(Ci-C6)alkyl-S(=O)2-R2, - (C0-C6)alkyl-NR1R2, -O-(C2-C6)alkyl-NR1R2, -NR1-(C2-C6)alkyl-NR2R3, -(C0-
C6)alkyl-S(=O)2NR1R2, -O-(Ci-C6)alkyl-S(=O)2NR1R2, -NR1-(d-C6)alkyl- SC=O)2NR2R3, -(Co-C6)alkyl-NR1 -SC=O)2R2, -O-(C2-C6)alkyl-NR1-S(=O)2R2, - NR1-(C2-C6)alkyl-NR2-S(=O)2R3, -(C0-C6)alkyl-C(=O)-NR1R2, -O-(d-C6)alkyl- CC=O)-NR1R2, -NR1-(Ci-C6)alkyl-C(=O)-NR2R3, -(C0-C6)alkyl-NR1C(=O)-R2, - O-(C2-C6)alkyl-NR1C(=O)-R2, -NR1-(C2-C6)alkyl-NR2C(=O)-R3, -(C0-C6)alkyl-
OC(O)-R1 , -O-(C2-C6)alkyl-OC(=O)-R1, -NR1-(C2-C6)alkyl-OC(=O)-R2, -(C0- C6)alkyl-C(=0)-0R1, -0-(d-C6)alkyl-C(=0)-0R1, -NR1-(d-C6)alkyl-C(=O)- OR2, -(Co-C6)alkyl-C(=0)-R1, -0-(d-C6)alkyl-C(=0)-R1, -NR1-(d-C6)alkyl- C(=0)-R2, -(C0-C6)alkyl-NR1-C(=O)-OR2, -(C0-C6)alkyl-O-C(=O)-NR1R2, -(C0- C6)alkyl-NR1-C(=NR2)-NR3R4, -(C0-C6)alkyl-NR1-C(=O)-NR2R3, -0-(C2-
C6)alkyl-NR1-C(=O)-NR2R3, -NR1-(C2-C6)alkyl-NR2-C(=O)-NR3R4 and -(C0- C6)alkyl-NR1-C(=S)-NR2R3;
Any two radicals of Am (A1 and A2) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring; R1, R2, R3 and R4 are each independently hydrogen or an optionally substituted radical selected from the group of -(Ci-Ce)alkylhalo, -(Ci-Ce)alkyl, -(C1- Ce)alkylcyano, -(d-C7)cycloalkyl, -(C4-C io)alkylcycloalkyl, heteroaryl, -(C1- Ce)alkylheteroaryl, aryl, heterocycle and -(Ci-Ce)alkylaryl;
Any two radicals of R (R1, R2, R3 or R4) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
B1 and B2 are each independently selected from the group of hydrogen, halogen, - CN, -OH, -NO2, -CF3, -SH, -NH2 and an optionally substituted radical selected from the group of -(d-C6)alkyl, -(d-C6)alkylhalo, -(C3-C7)cycloalkyl, -(Ci- Ce)alkylcyano, -(Ci-C6)alkylheteroaryl, -(Ci-Ce)alkylaryl, aryl, heteroaryl, heterocycle, -(C0-C6)alkyl-OR5, -O-(C2-C6)alkyl-OR5, -NR5(C2-C6)alkyl-OR6, - (C3-C7)cycloalkyl-(Ci-C6)alkyl, -O-(C3-C7)cycloalkyl-(d-C6)alkyl, -NR5-(C3- C7)cycloalkyl-(Ci-C6)alkyl, -(Ci-C6)alkylhalo-OR5, -(Ci-C6)alkylhalo-NR5R6, - (C0-C6)alkyl-S-R5, -O-(C2-C6)alkyl-S-R5, -NR5-(C2-C6)alkyl-S-R6, -(C0-C6)alkyl- S(=O)-R5, -O-(Ci-C6)alkyl-S(=O)-R5, -NR5-(d-C6)alkyl-S(=O)-R6, -(C0- C6)alkyl-S(=O)2-R5, -O-(Ci-C6)alkyl-S(=O)2-R5, -NR5-(Ci-C6)alkyl-S(=O)2-R6, - (C0-C6)alkyl-NR5R6, -O-(C2-C6)alkyl-NR5R6, -NR5-(C2-C6)alkyl-NR6R7, -(C0-
C6)alkyl-S(=O)2NR5R6, -O-(Ci-C6)alkyl-S(=O)2NR5R6, -NR5-(d-C6)alkyl- S(=O)2NR6R7, -(C0-C6)alkyl-NR5-S(=O)2R6, -O-(C2-C6)alkyl-NR5-S(=O)2R6, - NR5-(C2-C6)alkyl-NR6-S(=O)2R7, -(C0-C6)alkyl-C(=O)-NR5R6, -O-(d-C6)alkyl- C(=O)-NR5R6, -NR5-(Ci-C6)alkyl-C(=O)-NR6R7, -(C0-C6)alkyl-NR5C(=O)-R6, - O-(C2-C6)alkyl-NR5C(=O)-R6, -NR5-(C2-C6)alkyl-NR6C(=O)-R7, -(C0-C6)alkyl-
OC(=O)-R5, -O-(C2-C6)alkyl-OC(=O)-R5, -NR5-(C2-C6)alkyl-OC(=O)-R6, -(C0- C6)alkyl-C(=O)-OR5, -O-(d-C6)alkyl-C(=O)-OR5, -NR5-(d-C6)alkyl-C(=O)- OR6, -(C0-C6)alkyl-C(=O)-R5, -O-(d-C6)alkyl-C(=O)-R5, -NR5-(d-C6)alkyl- C(=O)-R6, -(C0-C6)alkyl-NR5-C(=O)-OR6, -(C0-C6)alkyl-O-C(=O)-NR5R6, -(C0- C6)alkyl-NR5-C(=NR6)-NR7R8, -(C0-C6)alkyl-NR5-C(=O)-NR6R7, -0-(C2-
C6)alkyl-NR5-C(=O)-NR6R7, -NR5-(C2-C6)alkyl-NR6-C(=O)-NR7R8 and -(C0- C6)alkyl-NR5-C(=S)-NR6R7;
Any two radicals of Bn (B1 and B2) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring; R5, R6, R7 and R8 are each independently hydrogen or an optionally substituted radical selected from the group of -(Ci-Ce)alkylhalo, -(Ci-Ce)alkyl, -(C1- Ce)alkylcyano, -(d-C7)cycloalkyl, -(C4-C io)alkylcycloalkyl, heteroaryl, -(C1- C6)alkylheteroaryl, aryl, heterocycle and -(Ci-Ce)alkylaryl;
Any two radicals of R (R5, R6, R7 or R8) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring; provided that according to proviso (i):
Figure imgf000056_0001
and provided that according to proviso (iii): Formula (I) Am x2"χ1 can not be
Figure imgf000057_0001
; and provided that according to proviso (iv):
Formula (I) Am x2'*1 can not be
Figure imgf000057_0002
; and provided that according to proviso (v):
when X1 is O or S and X2,X3 and X4 are C then in Formula (I) HN ^B" can not
be HN ^ ^B- .
3. A compound according to claim 1 having the Formula (I-b),
Figure imgf000057_0003
a pharmaceutically acceptable acid or base addition salt thereof, a stereo chemically isomeric form thereof and an TV-oxide form thereof, wherein:
X1 is selected from the group of N, O and S and X2, X3 and X4 are each independently selected from the group of C, N, O, S and C=C representing a 5 or 6 membered heteroaryl ring which may further be substituted by 1 to 3 radicals Am;
m is an integer ranging from 1 to 3;
Am radicals are each independently selected from the group of hydrogen, halogen, -CN, -OH, -NO2, -CF3, -SH, -NH2 and an optionally substituted radical selected from the group of -(Ci-C6)alkyl, -(Ci-C6)alkylhalo, -(C3-C7)cycloalkyl, -(Ci- Ce)alkylcyano, -(Ci-C6)alkylheteroaryl, -(Ci-C6)alkylaryl, aryl, heteroaryl, heterocycle, -(C0-C6)alkyl-OR1, -O-(C2-C6)alkyl-OR1, -NR1(C2-C6)alkyl-OR2, - (C3-C7)cycloalkyl-(Ci-C6)alkyl, -O-(C3-C7)cycloalkyl-(Ci-C6)alkyl, -NR!-(C3- C7)cycloalkyl-(Ci-C6)alkyl, -(Ci-C6)alkylhalo-OR1, -(Ci-C6)alkylhalo-NR1R2, -
(Co-C6)alkyl-S-R1, -O-(C2-C6)alkyl-S-R1, -NR1-(C2-C6)alkyl-S-R2, -(C0-C6)alkyl- S(O)-R1, -O-(Ci-C6)alkyl-S(=O)-R1, -NR1-(d-C6)alkyl-S(=O)-R2, -(C0- C6)alkyl-S(=O)2-R1, -O-(Ci-C6)alkyl-S(=O)2-R1, -NR1-(Ci-C6)alkyl-S(=O)2-R2, - (C0-C6)alkyl-NR1R2, -O-(C2-C6)alkyl-NR1R2, -NR1-(C2-C6)alkyl-NR2R3, -(C0- C6)alkyl-S(=O)2NR1R2, -O-(Ci-C6)alkyl-S(=O)2NR1R2, -NR1-(d-C6)alkyl-
S(=O)2NR2R3, -(C0-C6)alkyl-NR1-S(=O)2R2, -O-(C2-C6)alkyl-NR1-S(=O)2R2, - NR1-(C2-C6)alkyl-NR2-S(=O)2R3, -(C0-C6)alkyl-C(=O)-NR1R2, -O-(d-C6)alkyl- C(=O)-NR1R2, -NR1-(Ci-C6)alkyl-C(=O)-NR2R3, -(C0-C6)alkyl-NR1C(=O)-R2, - O-(C2-C6)alkyl-NR1C(=O)-R2, -NR1-(C2-C6)alkyl-NR2C(=O)-R3, -(C0-C6)alkyl- OC(O)-R1, -O-(C2-C6)alkyl-OC(=O)-R1, -NR1-(C2-C6)alkyl-OC(=O)-R2, -(C0-
C6)alkyl-C(=O)-OR1, -O-(d-C6)alkyl-C(=O)-OR1, -NR1-(d-C6)alkyl-C(=O)- OR2, -(Co-C6)alkyl-C(=0)-R1, -O-(d-C6)alkyl-C(=O)-R1, -NR1-(d-C6)alkyl- C(=O)-R2, -(C0-C6)alkyl-NR1-C(=O)-OR2, -(C0-C6)alkyl-O-C(=O)-NR1R2, -(C0- C6)alkyl-NR1-C(=NR2)-NR3R4, -(C0-C6)alkyl-NR1-C(=O)-NR2R3, -0-(C2- C6)alkyl-NR1-C(=O)-NR2R3, -NR1-(C2-C6)alkyl-NR2-C(=O)-NR3R4 and -(C0-
C6)alkyl-NR1-C(=S)-NR2R3;
Any two radicals of Am (A1 and A2) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
R1, R2, R3 and R4 are each independently hydrogen or an optionally substituted radical selected from the group of -(Ci-C6)alkylhalo, -(Ci-Ce)alkyl, -(C1-
Ce)alkylcyano, -(C3-C7)cycloalkyl, -(C4-C io)alkylcycloalkyl, heteroaryl, -(C1- Ce)alkylheteroaryl, aryl, heterocycle and -(Ci-C6)alkylaryl;
Any two radicals of R (R1, R2, R3 or R4) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
B1 and B2 are each independently selected from the group of hydrogen, halogen, - CN, -OH, -NO2, -CF3, -SH, -NH2 and an optionally substituted radical selected from the group of -(Ci-C6)alkyl, -(Ci-C6)alkylhalo, -(C3-C7)cycloalkyl, -(Ci- Ce)alkylcyano, -(Ci-C6)alkylheteroaryl, -(Ci-C6)alkylaryl, aryl, heteroaryl, heterocycle, -(C0-C6)alkyl-OR5, -O-(C2-C6)alkyl-OR5, -NR5(C2-C6)alkyl-OR6, - (C3-C7)cycloalkyl-(Ci-C6)alkyl, -O-(C3-C7)cycloalkyl-(Ci-C6)alkyl, -NR5-(C3- C7)cycloalkyl-(Ci-C6)alkyl, -(Ci-C6)alkylhalo-OR5, -(Ci-C6)alkylhalo-NR5R6, -
(C0-C6)alkyl-S-R5, -O-(C2-C6)alkyl-S-R5, -NR5-(C2-C6)alkyl-S-R6, -(C0-C6)alkyl- S(=O)-R5, -O-(Ci-C6)alkyl-S(=O)-R5, -NR5-(d-C6)alkyl-S(=O)-R6, -(C0- C6)alkyl-S(=O)2-R5, -O-(Ci-C6)alkyl-S(=O)2-R5, -NR5-(Ci-C6)alkyl-S(=O)2-R6, - (C0-C6)alkyl-NR5R6, -O-(C2-C6)alkyl-NR5R6, -NR5-(C2-C6)alkyl-NR6R7, -(C0- C6)alkyl-S(=O)2NR5R6, -O-(Ci-C6)alkyl-S(=O)2NR5R6, -NR5-(d-C6)alkyl-
S(=O)2NR6R7, -(C0-C6)alkyl-NR5-S(=O)2R6, -O-(C2-C6)alkyl-NR5-S(=O)2R6, - NR5-(C2-C6)alkyl-NR6-S(=O)2R7, -(C0-C6)alkyl-C(=O)-NR5R6, -O-(d-C6)alkyl- C(=O)-NR5R6, -NR5-(Ci-C6)alkyl-C(=O)-NR6R7, -(C0-C6)alkyl-NR5C(=O)-R6, - O-(C2-C6)alkyl-NR5C(=O)-R6, -NR5-(C2-C6)alkyl-NR6C(=O)-R7, -(C0-C6)alkyl- OC(=O)-R5, -O-(C2-C6)alkyl-OC(=O)-R5, -NR5-(C2-C6)alkyl-OC(=O)-R6, -(C0-
C6)alkyl-C(=O)-OR5, -O-(d-C6)alkyl-C(=O)-OR5, -NR5-(d-C6)alkyl-C(=O)- OR6, -(Co-C6)alkyl-C(=0)-R5, -O-(d-C6)alkyl-C(=O)-R5, -NR5-(d-C6)alkyl- C(=O)-R6, -(C0-C6)alkyl-NR5-C(=O)-OR6, -(C0-C6)alkyl-O-C(=O)-NR5R6, -(C0- C6)alkyl-NR5-C(=NR6)-NR7R8, -(C0-C6)alkyl-NR5-C(=O)-NR6R7, -0-(C2- C6)alkyl-NR5-C(=O)-NR6R7, -NR5-(C2-C6)alkyl-NR6-C(=O)-NR7R8 and -(C0-
C6)alkyl-NR5-C(=S)-NR6R7;
Any two radicals of Bn (B1 and B2) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
R5, R6, R7 and R8 are each independently hydrogen or an optionally substituted radical selected from the group of -(C1-C6)alkylhalo, -(Ci-Ce)alkyl, -(C1-
Ce)alkylcyano, -(C3-C7)cycloalkyl, -(C4-C io)alkylcycloalkyl, heteroaryl, -(C1- Ce)alkylheteroaryl, aryl, heterocycle and -(Ci-C6)alkylaryl;
Any two radicals of R (R5, R6, R7 or R8) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring; provided that according to proviso (i): Formula (I) Am *2~x can not be
Figure imgf000060_0001
and provided that according to proviso (iii):
Formula
Figure imgf000060_0002
and provided that according to proviso (iv):
Formula (I) Am x2'χ1 can not be
Figure imgf000060_0003
.
4. A compound according to claim 1 having the Formula (I-c),
Figure imgf000060_0004
a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof and an TV-oxide form thereof, wherein:
X1 is selected from the group of N, O and S and X2, X3 and X4 are each independently selected from the group of C, N, O, S and C=C representing a 5 or 6 membered heteroaryl ring which may further be substituted by 1 to 3 radicals
Am;
m is an integer ranging from 1 to 3;
Am radicals are each independently selected from the group of hydrogen, halogen,
-CN, -OH, -NO2, -CF3, -SH, -NH2 and an optionally substituted radical selected from the group of -(d-C6)alkyl, -(Ci-C6)alkylhalo, -(C3-C7)cycloalkyl, -(Ci- Ce)alkylcyano, -(Ci-C6)alkylheteroaryl, -(Ci-C6)alkylaryl, aryl, heteroaryl, heterocycle, -(C0-C6)alkyl-OR1, -O-(C2-C6)alkyl-OR1, -NR1(C2-C6)alkyl-OR2, - (C3-C7)cycloalkyl-(Ci-C6)alkyl, -O-(C3-C7)cycloalkyl-(Ci-C6)alkyl, -NR^(C3- C7)cycloalkyl-(Ci-C6)alkyl, -(Ci-C6)alkylhalo-OR1, -(Ci-C6)alkylhalo-NR1R2, - (Co-C6)alkyl-S-R1, -O-(C2-C6)alkyl-S-R1, -NR1-(C2-C6)alkyl-S-R2, -(C0-C6)alkyl-
SC=O)-R1, -O-(Ci-C6)alkyl-S(=O)-R1, -NR1-(d-C6)alkyl-S(=O)-R2, -(C0- C6)alkyl-S(=O)2-R1, -O-(Ci-C6)alkyl-S(=O)2-R1, -NR1-(Ci-C6)alkyl-S(=O)2-R2, - (C0-C6)alkyl-NR1R2, -O-(C2-C6)alkyl-NR1R2, -NR1-(C2-C6)alkyl-NR2R3, -(C0- C6)alkyl-S(=O)2NR1R2, -O-(Ci-C6)alkyl-S(=O)2NR1R2, -NR1-(d-C6)alkyl- SC=O)2NR2R3, -(Co-C6)alkyl-NR1 -SC=O)2R2, -O-(C2-C6)alkyl-NR1-S(=O)2R2, -
NR1-(C2-C6)alkyl-NR2-S(=O)2R3, -(C0-C6)alkyl-C(=O)-NR1R2, -O-(d-C6)alkyl- CC=O)-NR1R2, -NR1-(Ci-C6)alkyl-C(=O)-NR2R3, -(C0-C6)alkyl-NR1C(=O)-R2, - O-(C2-C6)alkyl-NR1C(=O)-R2, -NR1-(C2-C6)alkyl-NR2C(=O)-R3, -(C0-C6)alkyl- OCC=O)-R1 , -O-(C2-C6)alkyl-OC(=O)-R1, -NR1-(C2-C6)alkyl-OC(=O)-R2, -(C0- C6)alkyl-C(=O)-OR1, -0-(d-C6)alkyl-C(=0)-0R1, -NR1-(d-C6)alkyl-C(=0)-
OR2, -(Co-C6)alkyl-C(=0)-R1, -O-(d-C6)alkyl-C(=O)-R1, -NR1-(d-C6)alkyl- C(=0)-R2, -(C0-C6)alkyl-NR1-C(=O)-OR2, -(C0-C6)alkyl-O-C(=O)-NR1R2, -(C0- C6)alkyl-NR1-C(=NR2)-NR3R4, -(C0-C6)alkyl-NR1-C(=O)-NR2R3, -0-(C2- C6)alkyl-NR1-C(=O)-NR2R3, -NR1-(C2-C6)alkyl-NR2-C(=O)-NR3R4 and -(C0- C6)alkyl-NR1-C(=S)-NR2R3;
Any two radicals of Am (A1 and A2) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
R1, R2, R3 and R4 are each independently hydrogen or an optionally substituted radical selected from the group of -(Ci-C6)alkylhalo, -(Ci-C6)alkyl, -(C1- Ce)alkylcyano, -(C3-C7)cycloalkyl, -(C4-C1 o)alkylcycloalkyl, heteroaryl, -(C1-
Ce)alkylheteroaryl, aryl, heterocycle and -(Ci-Ce)alkylaryl;
Any two radicals of R (R1, R2, R3 or R4) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
B1 is selected from the group of hydrogen, halogen, -CN, -OH, -NO2, -CF3, -SH, -
NH2 and an optionally substituted radical selected from the group of -(C1- C6)alkyl, -(Ci-C6)alkylhalo, -(C3-C7)cycloalkyl, -(d-C6)alkylcyano, -(Ci- C6)alkylheteroaryl, -(Ci-C6)alkylaryl, aryl, heteroaryl, heterocycle, -(Co-Ce)alkyl- OR5, -O-(C2-C6)alkyl-OR5, -NR5(C2-C6)alkyl-OR6, -(C3-C7)cycloalkyl-(Ci- C6)alkyl, -O-(C3-C7)cycloalkyl-(Ci-C6)alkyl, -NR5-(C3-C7)cycloalkyl-(Ci- C6)alkyl, -(Ci-C6)alkylhalo-OR5, -(Ci-C6)alkylhalo-NR5R6, -(C0-C6)alkyl-S-R5, - O-(C2-C6)alkyl-S-R5, -NR5-(C2-C6)alkyl-S-R6, -(C0-C6)alkyl-S(=O)-R5, -0-(Ci-
C6)alkyl-S(=O)-R5, -NR5-(d-C6)alkyl-S(=O)-R6, -(C0-C6)alkyl-S(=O)2-R5, -O- (Ci-C6)alkyl-S(=O)2-R5, -NR5-(Ci-C6)alkyl-S(=O)2-R6, -(C0-C6)alkyl-NR5R6, -O- (C2-C6)alkyl-NR5R6, -NR5-(C2-C6)alkyl-NR6R7, -(C0-C6)alkyl-S(=O)2NR5R6, -O- (Ci-C6)alkyl-S(=O)2NR5R6, -NR5-(Ci-C6)alkyl-S(=O)2NR6R7, -(Co-C6)alkyl-NR5- S(=O)2R6, -O-(C2-C6)alkyl-NR5-S(=O)2R6, -NR5-(C2-C6)alkyl-NR6-S(=O)2R7, -
(C0-C6)alkyl-C(=O)-NR5R6, -O-(d-C6)alkyl-C(=O)-NR5R6, -NR5-(d-C6)alkyl- C(=O)-NR6R7, -(C0-C6)alkyl-NR5C(=O)-R6, -O-(C2-C6)alkyl-NR5C(=O)-R6, - NR5-(C2-C6)alkyl-NR6C(=O)-R7, -(C0-C6)alkyl-OC(=O)-R5, -O-(C2-C6)alkyl- OC(=O)-R5, -NR5-(C2-C6)alkyl-OC(=O)-R6, -(C0-C6)alkyl-C(=O)-OR5, -0-(Ci- C6)alkyl-C(=O)-OR5, -NR5-(d-C6)alkyl-C(=O)-OR6, -(C0-C6)alkyl-C(=O)-R5, -
O-(Ci-C6)alkyl-C(=O)-R5, -NR5-(d-C6)alkyl-C(=O)-R6, -(C0-C6)alkyl-NR5- C(=O)-OR6, -(C0-C6)alkyl-O-C(=O)-NR5R6, -(C0-C6)alkyl-NR5-C(=NR6)-NR7R8, -(C0-C6)alkyl-NR5-C(=O)-NR6R7, -O-(C2-C6)alkyl-NR5-C(=O)-NR6R7, -NR5-(C2- C6)alkyl-NR6-C(=O)-NR7R8 and -(C0-C6)alkyl-NR5-C(=S)-NR6R7; R5, R6, R7 and R8 are each independently hydrogen or an optionally substituted radical selected from the group of -(Ci-C6)alkylhalo, -(Ci-Ce)alkyl, -(C1- Ce)alkylcyano, -(C3-C7)cycloalkyl, -(C4-C io)alkylcycloalkyl, heteroaryl, -(C1- Ce)alkylheteroaryl, aryl, heterocycle and -(Ci-C6)alkylaryl;
Any two radicals of R (R5, R6, R7 or R8) may be taken together to form an optionally substituted 3 to 10 membered carbocyclic or heterocyclic ring;
Z is selected from the group of O and NR9; and
R9 is hydrogen or an optionally substituted radical selected from the group of -
(Ci-C6)alkylhalo, -(d-C6)alkyl, -(d-C6)alkylcyano, -(C3-C7)cycloalkyl, -(C4- Cio)alkylcycloalkyl, heteroaryl, -(Ci-C6)alkylheteroaryl, aryl, heterocycle, -
C(=O)alkyl, -C(=O)-(C3-C7)cycloalkyl -C(=O)aryl, -C(=O)heteroaryl, - C(=O)heterocycle, -C(=O)-(d-C6)alkylcycloalkyl, -C(O)-(Ci-
C6)alkylheteroaryl and -(Ci-C6)alkylaryl.
5. A compound according to claims 1 to 4, which can exist as optical isomers, wherein said compound is either the racemic mixture or one or both of the individual optical isomers.
6. A compound according to claim 1, wherein said compound is selected from:
N-(3 ,4-dichlorophenyl)- lH-pyrrole-2-carboxamide
N-(3-Chlorophenyl)-lH-imidazole-2-carboxamide
N-(3-Methoxyphenyl)thiophene-2-carboxamide
5-Methyl-N-(4-phenoxyphenyl)furan-2-carboxamide
Furan-2-carboxylic acid {3-[2-(4-fluoro-phenyl)-2-oxo-ethoxy]-phenyl} -amide
N-(3 -Methoxyphenyl)picolinamide
N-(3 -Methoxyphenyl)-2-methylthiazo le-4-carboxamide
N-(3-Chlorophenyl)thiophene-2-carboxamide
5-Bromo-Λ/-(3-methoxyphenyl)furan-2-carboxamide
N-(3 -Chlorophenyl)pico linamide
N-(3-Methoxyphenyl)thiazole-2-carboxamide
N-(3-(2-(3-Methoxyphenyl)-2-oxoethoxy)phenyl)furan-2-carboxamide
N-(3-(2-Oxo-2-p-tolylethoxy)phenyl)furan-2-carboxamide
N-(3-(2-(4-Methoxyphenyl)-2-oxoethoxy)phenyl)furan-2-carboxamide
Λ/-(3-(l-Oxo-l-/?-tolylpropan-2-yloxy)phenyl)furan-2-carboxamide
N-(3 -(Trifluoromethoxy)phenyl)pico linamide
N-(3-(2-(3-Chlorophenyl)-2-oxoethoxy)phenyl)picolinamide
N-(3 -(3 -Phenylpropoxy)phenyl)pico linamide
N-(3-(2-(2-Methoxyphenyl)-2-oxoethoxy)phenyl)picolinamide
N-(3 -(2-(3 -Methoxyphenyl)-2-oxoethoxy)phenyl)pico linamide
N-(3-(2-(3-Fluorophenyl)-2-oxoethoxy)phenyl)pico linamide
N-(3-(2-(2-Chlorophenyl)-2-oxoethoxy)phenyl)picolinamide
N-(3 -Fluorophenyl)pico linamide
N-(3 -Methoxyphenyl)-5 -methylisoxazo le-3 -carboxamide
N-(4-Fluoro-3 -methoxyphenyl)pico linamide
Λ/-(3-Chlorophenyl)-lH-pyrrole-2-carboxamide
N-(3-(2-(2-Fluorophenyl)-2-oxoethoxy)phenyl)picolinamide
7V-(3-Methoxyphenyl)pyrimidine-4-carboxamide
6-Fluoro-Λ/-(4-fluoro-3-methoxyphenyl)pico linamide Λ/-(3-Chloro-4-(pyrimidin-2-yloxy)phenyl)picolinamide JV-(4-Fluoro-3 -methoxyphenyl)thiazo le-2-carboxamide and a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof and an JV-oxide form thereof.
7. A compound according to claim 1, wherein said compound is selected from:
Λ/-(3-Chloro-4-(pyrimidin-2-yloxy)phenyl)-2-methylthiazole-4-carboxamide Λ/-(3-Chloro-4-(pyrimidin-2-yloxy)phenyl)thiazo le-2-carboxamide N-(3 -Chloro-4-morpho linophenyl)pico linamide Λ/-(3-Chloro-4-(pyridin-2-yloxy)phenyl)picolinamide Λ/-(3-Chloro-4-(2,5-difluorophenoxy)phenyl)pico linamide JV-(3-Chloro-4-(2-chlorophenoxy)phenyl)pico linamide Λ/-(3-Chloro-4-(5-(trifluoromethyl)pyridin-2-yloxy)phenyl)pico linamide jV-(3-Chloro-4-(4-isobutyrylpiperazin- 1 -yl)phenyl)pico linamide Λ/-(3-Methoxy-4-(pyrimidin-2-yloxy)phenyl)pico linamide Λ/-(4-(Trifluoromethoxy)phenyl)pico linamide N-(3 -Chloro-4-(3 -chlorophenoxy)phenyl)pico linamide N-(3 -Chloro-4-(3 -fluorophenoxy)phenyl)pico linamide Λ/-(3-Chloro-4-(4-fluorophenoxy)phenyl)pico linamide N-(3-Chloro-4-(4-chlorophenoxy)phenyl)pico linamide N-(3-Chloro-4-(4-propionylpiperazin- 1 -yl)phenyl)pico linamide iV-(4-(4-Benzoylpiperazin- 1 -yl)-3-chlorophenyl)pico linamide JV-(3-Chloro-4-(4-cyanophenoxy)phenyl)pico linamide Λ/-(3-Chloro-4-(3-cyanopyridin-2-yloxy)phenyl)picolinamide N-(4-(4-Benzylpiperazin- 1 -yl)-3-chlorophenyl)pico linamide and a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof and an JV-oxide form thereof.
8. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claims 1 to 7 and a pharmaceutically acceptable carrier and/or excipient.
9. A method of treating or preventing a condition in a mammal, including a human, the treatment or prevention of which is affected or facilitated by the neuromodulatory effect of mGluR4 allosteric modulators, comprising administering to a mammal in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 8.
10. A method of treating or preventing a condition in a mammal, including a human, the treatment or prevention of which is affected or facilitated by the neuromodulatory effect of mGluR4 positive allosteric modulators, comprising administering to a mammal in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 8.
11. A method useful for treating or preventing central nervous system disorders selected from the group consisting of: addiction, tolerance or dependence, affective disorders, such as depression and anxiety, psychiatric disease such as psychotic disorders, attention-deficit/hyperactivity disorder and bipolar disorder; Parkinson's disease, memory impairment, Alzheimer's disease, dementia, delirium tremens, other forms of neurodegeneration, neurotoxicity, and ischemia, comprising administering to a mammalian patient in need of such treatment an effective amount of a compound/composition according to claims 1 to 8.
12. A method useful for treating or preventing central nervous system disorders selected from the group consisting of Parkinson's disease and movement disorders such as bradykinesia, rigidity, dystonia, drug-induced parkinsonism, dyskinesia, tardive dyskinesia, L-DOPA-induced dyskinesia, dopamine agonist-induced dyskinesia, hyperkinetic movement disorders, Gilles de Ia Tourette syndrome, resting tremor, action tremor, akinesia, akinetic-rigid syndrome, akathisia, athetosis, asterixis, tics, postural instability, postencephalitic parkinsonism, muscle rigidity, chorea and choreaform movements, spasticity, myoclonus, hemiballismus, progressive supranuclear palsy, restless legs syndrome, periodic limb movement disorder, comprising administering to a mammalian patient in need of such treatment an effective amount of a compound/composition according to claims 1 to 8.
13. A method useful for treating or preventing central nervous system disorders selected from the group consisting of cognitive disorders: delirium, substance- induced persisting delirium, dementia, dementia due to HIV disease, dementia due to Huntington's disease, dementia due to Parkinson's disease, Parkinsonian-ALS demential complex, dementia of the Alzheimer's type, substance-induced persisting dementia and mild cognitive impairment comprising administering to a mammalian patient in need of such treatment an effective amount of a compound/composition according to claims 1 to 8.
14. A method useful for treating affective disorders, anxiety, Agoraphobia, Generalized Anxiety Disorder (GAD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, Posttraumatic Stress Disorder (PTSD), Social Phobia, Other Phobias, Substance-Induced Anxiety Disorder, acute stress disorder comprising administering to a mammalian patient in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 8.
15. A method useful for treating or preventing central nervous system disorders selected from the group consisting of mood disorders: Bipolar Disorders (I & II), Cyclothymic Disorder, Depression, Dysthymic Disorder, Major Depressive Disorder, Substance-Induced Mood Disorder, comprising administering an effective amount of a compound/composition according to claims 1 to 8.
16. A method useful for treating or preventing neurological disorders selected from the group of neurodegeneration, neurotoxicity or ischemia such as stroke, spinal cord injury, cerebral hypoxia, intracranial hematoma, Parkinson's disease, memory impairment, Alzheimer's disease, dementia, delirium tremens comprising administering to a mammalian patient in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 8.
17. A method useful for treating or preventing inflammatory central nervous system disorders selected from multiple sclerosis forms such as benign multiple sclerosis, relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis, primary progressive multiple sclerosis, progressive-relapsing multiple sclerosis, comprising administering an effective amount of a compound/composition according to claims 1 to 8.
18. A method useful for treating migraine comprising administering an effective amount of a compound/composition according to claims 1 to 8.
19. A method useful for treating or preventing epilepsy and tremor, temporal lobe epilepsy, epilepsy secondary to another disease or injury e.g., chronic encephalitis, traumatic brain injury, stroke or ischemia comprising administering to a mammal in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 8.
20. A method useful for treating or preventing inflammation and/or neurodegeneration resulting from traumatic brain injury, stroke, ischemia, spinal cord injury, cerebral hypoxia or intracranial hematoma, comprising administering to a mammal in need of such treatment an effective amount of a compound/composition according to claims 1 to 8.
21. A method useful for treating or preventing sensory, motor or cognitive symptoms resulting from traumatic brain injury, stroke, ischemia, spinal cord injury, cerebral hypoxia or intracranial hematoma, comprising administering to a mammal in need of such treatment or prevention, an effective amount of a compound/composition according to claims 1 to 8.
22. A method useful for treating medulloblastomas comprising administering an effective amount of a compound/composition according to claims 1 to 8.
23. A method useful for treating or preventing inflammatory or neuropathic pain comprising administering to a mammalian patient in need of such treatment an effective amount of a compound/composition according to claims 1 to 8.
24. A method useful for treating, or preventing, ameliorating, controlling or reducing the risk of various metabolic disorders associated with glutamate dysfunction comprising administering to a mammalian patient in need of such treatment an effective amount of a compound/composition according to claims 1 to 8.
25. A method useful for treating or preventing type 2 diabetes comprising administering to a mammalian patient in need of such treatment an effective amount of a compound/composition according to claims 1 to 8.
26. A method useful for treating or preventing diseases or disorders of the retina, retinal degeneration or macular degeneration, comprising administering to a mammalian patient in need of such treatment an effective amount of a compound/composition according to claims 1 to 8.
27. A method useful for treating or preventing diseases or disorders of the gastrointestinal tract including gastro-esophageal reflux disease (GERD), lower esophageal sphincter diseases or disorders, diseases of gastrointestinal motility, colitis, Crohn's disease or irritable bowel syndrome (IBS), comprising administering to a mammalian patient in need of such treatment an effective amount of a compound/composition according to claims 1 to 8.
28. Use of a compound according to claims 1 to 7 in the manufacture of a medicament for a treatment or prevention as defined in any of claims 9 to 27.
29. Use of a compound according to claims 1 to 7 to prepare a tracer for imaging a metabotropic glutamate receptor.
30. Use of a compound according to claims 1 to 7 as a taste agent, flavour agent, flavour enhancing agent or a food or beverage additive.
PCT/EP2008/059043 2007-07-13 2008-07-10 Amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors WO2009010454A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US12/452,601 US20100137336A1 (en) 2007-07-13 2008-07-10 Novel amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
EP08775002A EP2181091A2 (en) 2007-07-13 2008-07-10 Amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
US13/135,069 US20110257182A1 (en) 2007-07-13 2011-06-25 Novel amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
US13/747,366 US8524726B2 (en) 2007-07-13 2013-01-22 Amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
US13/747,411 US20130137704A1 (en) 2007-07-13 2013-01-22 Novel amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0713686.4A GB0713686D0 (en) 2007-07-13 2007-07-13 New compounds 2
GB0713686.4 2007-07-13

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US12/452,601 A-371-Of-International US20100137336A1 (en) 2007-07-13 2008-07-10 Novel amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
US45260110A Continuation 2007-07-13 2010-01-11
US13/135,069 Continuation US20110257182A1 (en) 2007-07-13 2011-06-25 Novel amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors

Publications (2)

Publication Number Publication Date
WO2009010454A2 true WO2009010454A2 (en) 2009-01-22
WO2009010454A3 WO2009010454A3 (en) 2009-03-05

Family

ID=38461574

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/059043 WO2009010454A2 (en) 2007-07-13 2008-07-10 Amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors

Country Status (4)

Country Link
US (4) US20100137336A1 (en)
EP (1) EP2181091A2 (en)
GB (1) GB0713686D0 (en)
WO (1) WO2009010454A2 (en)

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011010222A1 (en) 2009-07-24 2011-01-27 Addex Pharma S.A. Novel pyrazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
WO2011050305A1 (en) * 2009-10-22 2011-04-28 Vanderbilt University Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
WO2011051478A1 (en) 2009-10-30 2011-05-05 Domain Therapeutics Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors
EP2334181A1 (en) * 2008-09-16 2011-06-22 Merck Sharp & Dohme Corp. Phthalimide derivative metabotropic glutamate r4 ligands
WO2011100607A1 (en) * 2010-02-11 2011-08-18 Vanderbilt University Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction
WO2011100614A1 (en) * 2010-02-11 2011-08-18 Vanderbilt University BENZISOXAZOLES AND AZABENZISOXAZOLES AS mgluR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION
US8173642B2 (en) 2005-10-25 2012-05-08 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
US8207164B2 (en) 2009-07-24 2012-06-26 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
US20120172359A1 (en) * 2010-07-13 2012-07-05 Novartis Ag Oxazine Derivatives and their Use in the Treatment of Neurological Disorders
EP2473055A1 (en) * 2009-09-04 2012-07-11 Vanderbilt University Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
EP2477631A1 (en) * 2009-09-17 2012-07-25 Vanderbilt University Substituted phenylamine carboxamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
CN102939006A (en) * 2010-05-12 2013-02-20 范德比尔特大学 Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8513282B2 (en) 2008-10-23 2013-08-20 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US8524897B2 (en) 2011-01-12 2013-09-03 Novartis Ag Crystalline oxazine derivative
EP2654428A1 (en) * 2010-12-22 2013-10-30 The Trustees of Columbia University in the City of New York Histone acetyltransferase modulators and usese thereof
US8637504B2 (en) 2008-06-13 2014-01-28 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
US8637508B2 (en) 2011-01-13 2014-01-28 Novartis Ag Heterocyclic derivatives and their use in the treatment of neurological disorders
US8653067B2 (en) 2007-04-24 2014-02-18 Shionogi & Co., Ltd. Pharmaceutical composition for treating Alzheimer's disease
WO2014012050A3 (en) * 2012-07-13 2014-03-20 Indiana University Research & Technology Corporation Compounds for treatment of spinal muscular atrophy
US8703785B2 (en) 2008-10-22 2014-04-22 Shionogi & Co., Ltd. 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity
WO2014117920A1 (en) 2013-02-04 2014-08-07 Merck Patent Gmbh Spiro-quinazolinone derivatives useful for the treatment of neurological diseases and conditions
CN103980265A (en) * 2014-05-14 2014-08-13 武汉工程大学 Synthetic technology for 3-phenyl-5-(thiophene-2-yl)-1,2,4-oxadiazole
WO2014121883A1 (en) 2013-02-07 2014-08-14 Merck Patent Gmbh Substituted acetylene derivatives and their use as positive allosteric modulators of mglur4
WO2014121885A1 (en) 2013-02-07 2014-08-14 Merck Patent Gmbh Substituted quinoxaline derivatives and their use as positive allosteric modulators of mglur4
US8841487B2 (en) 2010-07-16 2014-09-23 Abbvie Inc. Phosphine ligands for catalytic reactions
US8883779B2 (en) 2011-04-26 2014-11-11 Shinogi & Co., Ltd. Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them
US8884062B2 (en) 2007-04-24 2014-11-11 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
US8895737B2 (en) 2010-07-16 2014-11-25 Shashank Shekhar Process for preparing antiviral compounds
US8927721B2 (en) 2010-10-29 2015-01-06 Shionogi & Co., Ltd. Naphthyridine derivative
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
EP2853532A1 (en) 2013-09-28 2015-04-01 Instytut Farmakologii Polskiej Akademii Nauk 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
US8999980B2 (en) 2009-12-11 2015-04-07 Shionogi & Co., Ltd. Oxazine derivatives
US9018219B2 (en) 2010-10-29 2015-04-28 Shionogi & Co., Ltd. Fused aminodihydropyrimidine derivative
CN105121435A (en) * 2013-04-18 2015-12-02 安斯泰来制药有限公司 Heterocyclic acetic acid amide compound
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
WO2016030444A1 (en) 2014-08-27 2016-03-03 Prexton Therapeutics Sa Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
US9533982B2 (en) 2014-03-20 2017-01-03 Vanderbilt University Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators
US9540359B2 (en) 2012-10-24 2017-01-10 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity
US9550778B2 (en) 2014-10-03 2017-01-24 Vanderbilt University Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
WO2017032874A1 (en) 2015-08-27 2017-03-02 Prexton Therapeutics Sa Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
US9765091B2 (en) 2010-07-14 2017-09-19 Addex Pharma S.A. Tetrahydropyrazolo [3,4-b] azepine derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US9809532B2 (en) 2011-06-10 2017-11-07 The Trustees Of Columbia University In The City Of New York Uses of histone acetyltransferase activators
US9844542B2 (en) 2013-11-19 2017-12-19 Vanderbilt University Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mGluR5
KR101837957B1 (en) 2016-11-02 2018-03-13 한국과학기술연구원 Thiazole-2-carboxamides derivatives as mGluR5 antagonists
WO2019034059A1 (en) * 2017-08-14 2019-02-21 四川省中医药转化医学中心 Novel compound and application thereof in treating inflammation or inflammation-related diseases
WO2020021064A1 (en) 2018-07-26 2020-01-30 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
KR20200069687A (en) * 2018-12-07 2020-06-17 한국과학기술연구원 Novel phenoxy aromatic amide derivatives as protein kinase inhibitors
WO2023096304A1 (en) * 2021-11-24 2023-06-01 한양대학교 에리카산학협력단 Isoxazole derivative or pharmaceutically acceptable salt thereof and use thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338413B1 (en) 2012-03-07 2012-12-25 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
AU2018317403B2 (en) * 2017-08-16 2023-09-21 Vanderbilt University Indazole compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US20220363639A1 (en) * 2018-07-31 2022-11-17 The Trustees Of The University Of Pennsylvania Small molecules that sensitize hiv-1 infected cells to antibody dependent cellular cytotoxicity

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0816329A1 (en) * 1996-06-18 1998-01-07 Hoechst Aktiengesellschaft Benzoic acid derivatives, process for their preparation and their use for the treatment of diseases
WO2003011851A2 (en) * 2001-06-15 2003-02-13 F. Hoffman-La Roche Ag Aromatic hydroxamic acid derivatives useful as hdac inhibitors
WO2003093250A2 (en) * 2002-05-03 2003-11-13 Pharmacia & Upjohn Company Positive allosteric modulators of the nicotinic acetylcholine receptor
EP1394159A1 (en) * 2002-08-13 2004-03-03 Warner-Lambert Company LLC New thiophene derivatives, process for their preparation and pharmaceutical compositions containing them
WO2006074884A1 (en) * 2005-01-14 2006-07-20 F.Hoffmann-La Roche Ag Thiazole-4-carboxamide derivatives as mglur5 antagonists
WO2006094691A1 (en) * 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag PYRAZINE -2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS
WO2006094639A1 (en) * 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag Pyridine-2-carboxamide derivatives as mglur5 antagonists
WO2007001975A1 (en) * 2005-06-20 2007-01-04 Schering Corporation Piperidine derivatives useful as histamine h3 antagonists
WO2007072090A1 (en) * 2005-12-20 2007-06-28 Richter Gedeon Nyrt. Thienopyridine derivatives as modulators of metabotropic glutamate receptors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
DE19801646A1 (en) 1998-01-17 1999-07-22 Bayer Ag New bicyclic lactone glutamate receptor modulators for treating cerebral ischemia, cranial/brain trauma, pain or CNS-mediated spasms
AU2004226450A1 (en) 2003-03-26 2004-10-14 Merck & Co. Inc. Benzamide modulators of metabotropic glutamate receptors
US20060166972A1 (en) 2003-07-11 2006-07-27 Conn P J Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator
US7598259B2 (en) * 2004-06-15 2009-10-06 Schering Corporation mGluR1 antagonists as therapeutic agents

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0816329A1 (en) * 1996-06-18 1998-01-07 Hoechst Aktiengesellschaft Benzoic acid derivatives, process for their preparation and their use for the treatment of diseases
WO2003011851A2 (en) * 2001-06-15 2003-02-13 F. Hoffman-La Roche Ag Aromatic hydroxamic acid derivatives useful as hdac inhibitors
WO2003093250A2 (en) * 2002-05-03 2003-11-13 Pharmacia & Upjohn Company Positive allosteric modulators of the nicotinic acetylcholine receptor
EP1394159A1 (en) * 2002-08-13 2004-03-03 Warner-Lambert Company LLC New thiophene derivatives, process for their preparation and pharmaceutical compositions containing them
WO2006074884A1 (en) * 2005-01-14 2006-07-20 F.Hoffmann-La Roche Ag Thiazole-4-carboxamide derivatives as mglur5 antagonists
WO2006094691A1 (en) * 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag PYRAZINE -2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS
WO2006094639A1 (en) * 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag Pyridine-2-carboxamide derivatives as mglur5 antagonists
WO2007001975A1 (en) * 2005-06-20 2007-01-04 Schering Corporation Piperidine derivatives useful as histamine h3 antagonists
WO2007072090A1 (en) * 2005-12-20 2007-06-28 Richter Gedeon Nyrt. Thienopyridine derivatives as modulators of metabotropic glutamate receptors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
E.P. PAPADOPOULOS ET AL: "Reactions of Phenyl Isocyanate with some metal derivatives of pyrrole" JOURNAL OF ORGANIC CHEMISTRY, vol. 31, no. 1, 1966, pages 327-329, XP002508860 *
PALLE E. IVERSEN ET AL: "Reduction of some carboxylic acid derivatives of thiazole" ACTA CHIMICA SCANDINAVICA, vol. 21, no. 2, 1967, pages 389-396, XP002508861 *
YUICHI KANAOKA: "Photochemistry of The amide System-Synthetic Photochemistry with heterocyclic anilides" JOURNAL OF ORGANIC CHEMISTRY, vol. 40, no. 20, 1975, pages 3001-3003, XP002508862 *

Cited By (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546380B2 (en) 2005-10-25 2013-10-01 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
US8815851B2 (en) 2005-10-25 2014-08-26 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
US9029358B2 (en) 2005-10-25 2015-05-12 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
US8173642B2 (en) 2005-10-25 2012-05-08 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
US8633188B2 (en) 2005-10-25 2014-01-21 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
US8653067B2 (en) 2007-04-24 2014-02-18 Shionogi & Co., Ltd. Pharmaceutical composition for treating Alzheimer's disease
US8884062B2 (en) 2007-04-24 2014-11-11 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
US8895548B2 (en) 2007-04-24 2014-11-25 Shionogi & Co., Ltd. Pharmaceutical composition for treating alzheimer's disease
US9650371B2 (en) 2008-06-13 2017-05-16 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
US9273053B2 (en) 2008-06-13 2016-03-01 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having Beta secretase inhibitory activity
US8637504B2 (en) 2008-06-13 2014-01-28 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
EP2334181A4 (en) * 2008-09-16 2012-03-14 Merck Sharp & Dohme Phthalimide derivative metabotropic glutamate r4 ligands
EP2334181A1 (en) * 2008-09-16 2011-06-22 Merck Sharp & Dohme Corp. Phthalimide derivative metabotropic glutamate r4 ligands
US8703785B2 (en) 2008-10-22 2014-04-22 Shionogi & Co., Ltd. 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity
US8513282B2 (en) 2008-10-23 2013-08-20 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US8785640B2 (en) 2008-10-23 2014-07-22 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US8598205B2 (en) 2008-10-23 2013-12-03 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US8846658B2 (en) 2009-07-24 2014-09-30 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
US8207164B2 (en) 2009-07-24 2012-06-26 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
US8513252B2 (en) 2009-07-24 2013-08-20 Addex Pharma S.A. Pyrazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
WO2011010222A1 (en) 2009-07-24 2011-01-27 Addex Pharma S.A. Novel pyrazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
EP2473055A4 (en) * 2009-09-04 2013-02-13 Univ Vanderbilt Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
EP2473055A1 (en) * 2009-09-04 2012-07-11 Vanderbilt University Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8779157B2 (en) 2009-09-04 2014-07-15 Vanderbilt University MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
CN102740699A (en) * 2009-09-04 2012-10-17 范德比尔特大学 Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
EP2477631A1 (en) * 2009-09-17 2012-07-25 Vanderbilt University Substituted phenylamine carboxamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
US8569308B2 (en) 2009-09-17 2013-10-29 Vanderbilt University Substituted heteroarylamine carboxamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same
EP2477631A4 (en) * 2009-09-17 2013-05-08 Univ Vanderbilt Substituted phenylamine carboxamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
EP2477492A4 (en) * 2009-09-17 2013-05-01 Univ Vanderbilt Substituted heteroarylamine carboxamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
EP2477492A1 (en) * 2009-09-17 2012-07-25 Vanderbilt University Substituted heteroarylamine carboxamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
WO2011050305A1 (en) * 2009-10-22 2011-04-28 Vanderbilt University Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US9180192B2 (en) 2009-10-22 2015-11-10 Vanderbilt University mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
CN102665417A (en) * 2009-10-22 2012-09-12 范德比尔特大学 Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8962627B2 (en) 2009-10-30 2015-02-24 Prestwick Chemical, Inc. Oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors
WO2011051478A1 (en) 2009-10-30 2011-05-05 Domain Therapeutics Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
US11034647B2 (en) 2009-12-10 2021-06-15 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
US9656974B2 (en) 2009-12-11 2017-05-23 Shionogi & Co., Ltd. Oxazine derivatives
US8999980B2 (en) 2009-12-11 2015-04-07 Shionogi & Co., Ltd. Oxazine derivatives
US9290466B2 (en) 2009-12-11 2016-03-22 Shionogi & Co., Ltd. Oxazine derivatives
WO2011100614A1 (en) * 2010-02-11 2011-08-18 Vanderbilt University BENZISOXAZOLES AND AZABENZISOXAZOLES AS mgluR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION
US9108963B2 (en) 2010-02-11 2015-08-18 Vanderbilt University Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
WO2011100607A1 (en) * 2010-02-11 2011-08-18 Vanderbilt University Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction
US9163015B2 (en) 2010-02-11 2015-10-20 Vanderbilt University Pyrazolopyridine, pyrarolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
EP2568809A4 (en) * 2010-05-12 2013-11-06 Univ Vanderbilt Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
CN102939006A (en) * 2010-05-12 2013-02-20 范德比尔特大学 Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
EP2568809A1 (en) * 2010-05-12 2013-03-20 Vanderbilt University Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US9192603B2 (en) 2010-05-12 2015-11-24 Vanderbilt University Heterocyclic sulfone mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US20120172359A1 (en) * 2010-07-13 2012-07-05 Novartis Ag Oxazine Derivatives and their Use in the Treatment of Neurological Disorders
US9765091B2 (en) 2010-07-14 2017-09-19 Addex Pharma S.A. Tetrahydropyrazolo [3,4-b] azepine derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US9381508B2 (en) 2010-07-16 2016-07-05 Abbvie Inc. Phosphine ligands for catalytic reactions
US9266913B2 (en) 2010-07-16 2016-02-23 Abbvie Inc. Phosphine ligands for catalytic reactions
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
US9434698B2 (en) 2010-07-16 2016-09-06 Abbvie Inc. Process for preparing antiviral compounds
US9200021B2 (en) 2010-07-16 2015-12-01 Abbvie Inc. Phosphine ligands for catalytic reactions
US8895737B2 (en) 2010-07-16 2014-11-25 Shashank Shekhar Process for preparing antiviral compounds
US9732045B2 (en) 2010-07-16 2017-08-15 Abbvie Inc. Process for preparing antiviral compounds
US9669399B2 (en) 2010-07-16 2017-06-06 Abbvie Inc. Phosphine ligands for catalytic reactions
US8841487B2 (en) 2010-07-16 2014-09-23 Abbvie Inc. Phosphine ligands for catalytic reactions
US8927721B2 (en) 2010-10-29 2015-01-06 Shionogi & Co., Ltd. Naphthyridine derivative
US9018219B2 (en) 2010-10-29 2015-04-28 Shionogi & Co., Ltd. Fused aminodihydropyrimidine derivative
US9969677B2 (en) 2010-12-22 2018-05-15 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase modulators and uses thereof
EP3323813A1 (en) * 2010-12-22 2018-05-23 The Trustees of Columbia University in the City of New York Histone acetyltransferase modulators and uses thereof
EP2654428A1 (en) * 2010-12-22 2013-10-30 The Trustees of Columbia University in the City of New York Histone acetyltransferase modulators and usese thereof
JP2014501763A (en) * 2010-12-22 2014-01-23 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Histone acetyltransferase modulators and uses thereof
EP2654428A4 (en) * 2010-12-22 2014-08-27 Univ Columbia Histone acetyltransferase modulators and usese thereof
US8524897B2 (en) 2011-01-12 2013-09-03 Novartis Ag Crystalline oxazine derivative
US10301296B2 (en) 2011-01-13 2019-05-28 Novartis Ag Heterocyclic derivatives and their use in the treatment of neurological disorders
US10683287B2 (en) 2011-01-13 2020-06-16 Novartis Ag Heterocyclic derivatives and their use in the treatment of neurological disorders
US8865712B2 (en) 2011-01-13 2014-10-21 Novartis Ag Heterocyclic derivatives and their use in the treatment of neurological disorders
US9550758B2 (en) 2011-01-13 2017-01-24 Novartis Ag Heterocyclic derivatives and their use in the treatment of neurological disorders
US10035794B2 (en) 2011-01-13 2018-07-31 Novartis Ag Heterocyclic derivatives and their use in the treatment of neurological disorders
US8637508B2 (en) 2011-01-13 2014-01-28 Novartis Ag Heterocyclic derivatives and their use in the treatment of neurological disorders
US8883779B2 (en) 2011-04-26 2014-11-11 Shinogi & Co., Ltd. Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them
US9809532B2 (en) 2011-06-10 2017-11-07 The Trustees Of Columbia University In The City Of New York Uses of histone acetyltransferase activators
US9212209B2 (en) 2012-07-13 2015-12-15 Indiana University Research And Technology Corporation Screening methods for spinal muscular atrophy
WO2014012050A3 (en) * 2012-07-13 2014-03-20 Indiana University Research & Technology Corporation Compounds for treatment of spinal muscular atrophy
US9758513B2 (en) 2012-10-24 2017-09-12 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity
US9540359B2 (en) 2012-10-24 2017-01-10 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity
WO2014117920A1 (en) 2013-02-04 2014-08-07 Merck Patent Gmbh Spiro-quinazolinone derivatives useful for the treatment of neurological diseases and conditions
WO2014121883A1 (en) 2013-02-07 2014-08-14 Merck Patent Gmbh Substituted acetylene derivatives and their use as positive allosteric modulators of mglur4
WO2014121885A1 (en) 2013-02-07 2014-08-14 Merck Patent Gmbh Substituted quinoxaline derivatives and their use as positive allosteric modulators of mglur4
AU2014254768B2 (en) * 2013-04-18 2017-10-05 Astellas Pharma Inc. Heterocyclic acetic acid amide compound
CN105121435A (en) * 2013-04-18 2015-12-02 安斯泰来制药有限公司 Heterocyclic acetic acid amide compound
EP2987793A4 (en) * 2013-04-18 2016-09-07 Astellas Pharma Inc Heterocyclic acetic acid amide compound
EP2853532A1 (en) 2013-09-28 2015-04-01 Instytut Farmakologii Polskiej Akademii Nauk 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
US9844542B2 (en) 2013-11-19 2017-12-19 Vanderbilt University Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mGluR5
US9533982B2 (en) 2014-03-20 2017-01-03 Vanderbilt University Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators
CN103980265A (en) * 2014-05-14 2014-08-13 武汉工程大学 Synthetic technology for 3-phenyl-5-(thiophene-2-yl)-1,2,4-oxadiazole
WO2016030444A1 (en) 2014-08-27 2016-03-03 Prexton Therapeutics Sa Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
EP3502115A1 (en) 2014-08-27 2019-06-26 Prexton Therapeutics SA Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
US10442818B2 (en) 2014-08-27 2019-10-15 Prexton Therapeutics Sa Chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
EP3696183A1 (en) 2014-08-27 2020-08-19 Prexton Therapeutics SA Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
US9550778B2 (en) 2014-10-03 2017-01-24 Vanderbilt University Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
WO2017032874A1 (en) 2015-08-27 2017-03-02 Prexton Therapeutics Sa Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
US10532057B2 (en) 2015-08-27 2020-01-14 Prexton Therapeutics Sa Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
EP3696182A1 (en) 2015-08-27 2020-08-19 Prexton Therapeutics SA Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
KR101837957B1 (en) 2016-11-02 2018-03-13 한국과학기술연구원 Thiazole-2-carboxamides derivatives as mGluR5 antagonists
WO2019034059A1 (en) * 2017-08-14 2019-02-21 四川省中医药转化医学中心 Novel compound and application thereof in treating inflammation or inflammation-related diseases
US11618738B2 (en) 2017-08-14 2023-04-04 Sichuan Center For Translational Medicine Of Traditional Chinese Medicine Compound and application thereof in treating inflammation or inflammation-related diseases
WO2020021064A1 (en) 2018-07-26 2020-01-30 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4
KR20200069687A (en) * 2018-12-07 2020-06-17 한국과학기술연구원 Novel phenoxy aromatic amide derivatives as protein kinase inhibitors
KR102218861B1 (en) * 2018-12-07 2021-02-24 한국과학기술연구원 Novel phenoxy aromatic amide derivatives as protein kinase inhibitors
WO2023096304A1 (en) * 2021-11-24 2023-06-01 한양대학교 에리카산학협력단 Isoxazole derivative or pharmaceutically acceptable salt thereof and use thereof

Also Published As

Publication number Publication date
GB0713686D0 (en) 2007-08-22
US20130131092A1 (en) 2013-05-23
US20110257182A1 (en) 2011-10-20
US20130137704A1 (en) 2013-05-30
EP2181091A2 (en) 2010-05-05
WO2009010454A3 (en) 2009-03-05
US8524726B2 (en) 2013-09-03
US20100137336A1 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
US8524726B2 (en) Amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
US8524718B2 (en) Heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
CA2686651C (en) Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
US8697744B2 (en) Substituted 5,6-dihydro-4H-thiazolo[4,5-E]indazoles and their use as positive allosteric modulators of metabotropic glutamate receptors
JP6319436B2 (en) 2-acylaminothiazole derivatives or salts thereof
EP2376486B1 (en) Novel thiazoles derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
AU2019234858A1 (en) Amino-benzoisothiazole and amino-benzoisothiadiazole amide compounds
EP2456769B1 (en) Novel pyrazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
US7135472B2 (en) 3-Heterocyclic benzylamide derivatives as potassium channel openers
JPWO2005113550A1 (en) Aminopyrimidine derivatives and their pharmaceutical use
US20130267499A1 (en) NOVEL TETRAHYDROPYRAZOLO [3,4-b] AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
GB2455111A (en) Metabotropic glutamate receptor (mGluR4) modulators having 5- or 6-membered N-heteroaryl ring substituted by both N-cyclylamino &amp; 5-membered N-heteroaryl ring
US8604033B2 (en) Preparation of 4-amino-thiazoles and 3-amino-1,2,4-thiadiazoles and their use as allosteric modulators of metabotropic glutamate receptors
CN104080766A (en) Sulphamide derivative having an adamantyl group and a pharmaceutically acceptable salt thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08775002

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12452601

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008775002

Country of ref document: EP